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ABSTRACT 
Previous publications from this laboratory demonstrated that administration of leukemia 
inhibitory factor (LIF) (125 µg/kg) to young, male Sprague-Dawley rats at 6, 24, and 48 h after 
middle cerebral artery occlusion (MCAO) reduced infract volume, improved sensimotor skills, and 
alleviated damage to white matter at 72 h after the injury. In vitro studies using cultured 
oligodendrocytes (OLs) showed that LIF (200 ng/ml) also protects against 24 h of oxygen-glucose 
deprivation through activation of Akt signaling and upregulation of the antioxidant enzymes 
peroxiredoxin IV and metallothionein III. Other groups have demonstrated that LIF reduces 
neurodegeneration in animal models of disease, but the neuroprotective mechanisms of LIF 
during permanent ischemia have not yet been examined. The overall hypothesis to be tested in 
this project is whether LIF exerts similar protective mechanisms against neurons during ischemia 
through increased antioxidant enzyme expression in neurons. 
 In the first set of experiments, superoxide dismutase (SOD) activity was significantly 
increased in the ipsilateral hemisphere of LIF-treated rats compared to rats that received PBS 
treatment at 72 h after MCAO. Western blot and immunohistochemical analysis revealed that 
SOD3 was upregulated in brain tissue and induced specifically in cortical neurons tissue at this 
time point. Neurons that expressed high levels of SOD3 at 72 h after MCAO also showed high 
levels of phosphorylated Akt (Ser473). LIF (200 ng/ml) reduced necrotic and apoptotic cell death 
against 24 h of OGD as measured by lactate dehydrogenase (LDH) release and caspase-3 
activation. Quantitative real-time PCR analysis showed that LIF treatment upregulated SOD3 
gene expression in vitro during OGD. Treatment with 10 µM Akt Inhibitor IV and transfection with 
xii 
 
SOD3 siRNA counteracted the neuroprotective effects of LIF in vitro, showing that upregulation 
of SOD3 and activation of Akt signaling are necessary for LIF-mediated neuroprotection.  
Several transcription factors that regulated Akt-inducible genes were previously identified 
by this lab, including myeloid zinc finger-1 (MZF-1) and specificity protein-1 (Sp1). The goal of the 
second set of experiments was to determine whether LIF exerted protective actions through MZF-
1 and Sp1. According to analysis with Genomatix, MZF-1 and Sp1 have multiple binding sites in 
the promoter for the rat SOD3 gene. Western blot analysis showed that there was a trend towards 
increased MZF-1 protein expression in the brains of LIF-treated rats that approached significance.  
Immunohistochemical analysis and quantitative real-time PCR showed a significant in vitro 
upregulation in MZF-1 expression among LIF-treated neurons compared to PBS-treated neurons. 
Sp1 gene expression was not changed by LIF treatment, but there was a trend towards increased 
protein expression. In addition, there was a significant correlation between Sp1 and MZF-1 among 
brain samples from LIF-treated rats but not PBS-treated or sham rats at 72 h after MCAO. 
Immunohistochemical analysis revealed that Sp1 and MZF-1 co-localized with neuronal nuclei 
and SOD3 at 72 h after MCAO. Neurons that were transfected with MZF-1 or Sp1 siRNA following 
isolation did not show a significant decrease in LDH release after 24 h OGD that was observed 
among neurons transfected with scrambled siRNA. These data demonstrate that Sp1 and MZF-
1 are involved with the neuroprotective signaling of LIF under ischemia.  
This laboratory has demonstrated that LIF activates transcription of protective genes and 
increases the activity of transcription factors through modulation of intracellular signaling. 
However, the upstream signaling mechanisms of LIF during ischemia had not previously been 
investigated. Previous investigators found that the LIF-specific subunit of the heterodimeric LIF 
receptor (LIFR) is induced by CNS injury. Western blot analysis was used to determine whether 
LIFR was induced in the brain and the spleen, which plays a role in the peripheral immune 
response, after MCAO. According to these results, LIF treatment significantly upregulates LIF in 
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the brain compared to PBS treatment or sham injury at 72 h after MCAO.  Genomatix analysis of 
the LIFR promoter region revealed a binding site for Sp1, which is one of the transcription factors 
responsible for neuroprotection by LIF. At this same time point, splenic LIFR expression is 
significantly reduced after MCAO compared to sham injury. LIF treatment did not significantly 
increase LIFR expression, but did significantly increase spleen size compared to PBS treatment 
at 72 h after MCAO. Although there was a trend towards increased LIFR expression in the spleen 
from 24 h to 72 h after MCAO, this increase was not statistically significant. However, there was 
a significant positive correlation between spleen weight and LIFR expression among rats 
euthanized 24-72 h after MCAO/sham injury. In addition, there was a significant negative 
correlation between LIFR expression in the brain and the spleen weight, thus showing that LIFR 
is upregulated following the splenic response.  
According to findings from other groups, JAK1 has been shown to associate with the 
heterodimeric LIF receptor (LIFR/gp130) and directly activate PI3K/Akt signaling. To test whether 
JAK1 contributes neuroprotection during ischemia, cultured neurons were treated with several 
concentrations (2.5-50 nM) of GLPG0634, a JAK1-specific inhibitor prior to 24 h of OGD. With the 
exception of the 2.5 nM concentration, all concentrations of GLPG0634 significantly decreased 
LDH release compared to DMSO treatment, with the 5 nM concentration having the most potent 
effect on reducing cytotoxicity.  However, the 5 nM concentration had no significant did not 
significantly reduce LDH release compared to DMSO treatment under 24 h of normoxic 
conditions. These results indicate that JAK1 activity is primarily detrimental to neurons during 
ischemia. Although it is possible that LIF signaling activates JAK1, it is unlikely that JAK1 is 
responsible for LIF-mediated neuroprotection during ischemia.  
The results of these experiments allowed us to determine several molecular mechanisms 
for LIF-mediated neuroprotection. LIF, which binds to its heterodimeric receptor, activates Akt 
signaling during ischemia. The transcription factors Sp1 and MZF-1, which are located 
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downstream of Akt, bind to the promoter of the SOD3 gene. In addition, Sp1 also regulates the 
LIFR gene. SOD3 upregulation increases total SOD activity, which decreases apoptotic and 
necrotic cell death during apoptosis. Due to its ability to promote antioxidant expression and 
survival signaling in multiple neural cell types, LIF shows promise as a novel treatment for 
permanent focal cerebral ischemia.  
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CHAPTER ONE 
INTRODUCTION 
Stroke Overview  
Stroke as a Worldwide Healthcare Problem 
A cerebrovascular accident, commonly known as a stroke, occurs when the blood supply 
of the brain becomes disrupted due to a blocked or ruptured vessel. Stroke contributes to the 
fifth leading cause of death in the United States overall and among individuals age 15-59 
worldwide. Among individuals older than 60 years of age, stroke is the second leading cause of 
death worldwide. Although many stroke cases are not fatal, resulting brain damage may lead to 
permanent disabilities in motor skills and cognitive function (2015a). In addition to the mortalities 
and morbidities resulting from stroke, treatment of stroke patients imposes a significant financial 
burden on the U.S. healthcare system. In 2008, $65 billion of direct and indirect healthcare costs 
may be attributed to stroke-related injuries (Demaerschalk, Hwang et al. 2010). Notable 
advances have occurred in regards to the prevention and treatment of strokes over the past two 
decades, which contributed to lower age-standardized stroke mortality. Nonetheless, the rapid 
aging of the U.S. population will almost certainly lead to a higher incidence of stroke in the near 
future (Feigin, Forouzanfar et al. 2014). 
Risk Factors for Stroke 
Factors that render patients more susceptible to stroke may be divided into two 
categories: factors that may be controlled by lifestyle choices and factors that are out of the 
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patient’s control. Age is arguably the most important contributing factor towards stroke risk, since 
the risk of stroke doubles for individuals every decade past the age of 55. Certain racial groups 
such as African-Americans are more prone to strokes due to high prevalence of hypertension 
among these individuals. In addition, women are more susceptible to stroke-related mortality 
compared to men. Although these factors cannot be controlled by patients, lifestyle choices such 
as smoking, alcoholism, inactivity, and poor diet may lead to hypertension, obesity, diabetes, 
and other cardiovascular complications. Individuals with these heath conditions have a much 
greater risk of having a stroke compared to those who maintain healthier lifestyle choices.  
Types of Stroke  
Ischemic strokes comprise 85% of all stroke cases. These strokes occur when a cerebral 
blood vessel becomes occluded by an on-site clot (thrombotic) or an embolus that forms 
elsewhere in the body (embolic). Hemorrhagic strokes make up the other 15% of stroke cases 
and occur when a blood vessel ruptures due to weak spot (aneurysm) or other trauma. In 10% 
of all stroke cases, the ruptured vessel is located within the brain. This event triggers an 
intracranial hemorrhage (ICH). When the ruptured vessel is located between the brain and the 
meninges, a subarachnoid hemorrhage (SAH) occurs. SAH events comprise 3% of all stroke 
cases. In the instance that an ischemic stroke is too short lived for significant brain damage to 
occur, the stroke is classified as a transient ischemic attack (TIA) or mini-stroke. Approximately 
33% of individuals who have experienced a TIA will have a major ischemic stroke within the 
year(Association 2015a, Association 2015b). This project will focus on the pathogenesis and 
treatment of ischemic stroke.  
Animal Models of Ischemic Stroke 
Several in vivo models may be used to recapitulate the effects of cerebral ischemia. Due 
to their relatively low cost and variability between subjects, rodent models using the house mouse 
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and Norway rat are widely used in mammalian models of ischemic stroke. However, higher 
mammals with gyrencephalic brains, which include the miniature pig, sheep, and several primate 
species, are also used in models of stroke (Bacigaluppi, Comi et al. 2010). For the purpose of 
this introduction, the focus will remain on rodent models of ischemic stroke.   
In models of global ischemia, which often occurs following cardiac arrest, both 
hemispheres of the brain become ischemic. Global ischemia may be induced using ventricular 
fibrillation, bilateral occlusion of the common carotid arteries, or an inflatable neck cuff. Focal 
cerebral ischemia (FCI) reduces perfusion of one hemisphere via occlusion of a single vessel. In 
most cases, the blocked vessel in question is the middle cerebral artery, which becomes blocked 
in the majority of human stroke cases (Mohr, Lazar et al. 1992, Traystman 2003). This laboratory 
utilizes the proximal middle cerebral artery occlusion (MCAO) model, where a 40 mm filament is 
advanced to the origin of the MCA via the external carotid artery (Koizumi, Nakazawa et al. 1985, 
Longa, Weinstein et al. 1989). Other models involving blockage of the MCA include the distal 
MCAO procedure, where the portion of the MCA near the rhinal fissure is occluded in order to 
avoid blockage of collateral vessels (Robinson and Coyle 1980, Kuraoka, Furuta et al. 2009). 
Electrocoagulation and photothrombosis are used to induce clotting on site within the MCA 
(Kobatake, Sako et al. 1984, Yao, Ibayashi et al. 1996). Finally, the injection of clot fragments 
into the common carotid artery may also be used to block the origin of the MCA. However, this 
model is disadvantageous due to the high variability in the infarct size/location following clot 
injection (Kaneko, Nakamura et al. 1985, Traystman 2003).  
Current Treatments for Ischemic Stroke 
Thrombolytic Therapy 
In 1996, tissue-type plasminogen activator (tPA) was approved by the FDA (Zivin 2009). 
Currently, it remains the only FDA-approved treatment for ischemic stroke patients. While 
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intravenous tPA therapy may be effective at dissolving clots if administered within 3-4.5 hours 
following the onset of stroke, many patients are not able to receive tPA within this time window 
(Hacke, Kaste et al. 2008). In other instances, patients have preexisting conditions that are 
contraindicated with tPA therapy such as advanced age (≥ 80 years), diabetes mellitus, 
hypertension, or are recipients of anticoagulant/antiplatelet drugs (Frank, Grotta et al. 2013). 
Thrombolytic therapy also carries the risk of triggering an ICH by increasing levels of matrix 
metalloproteinases (MMPs) 2 and 9 and subsequently weakening the blood-brain barrier (BBB) 
(The NINDS t-PA Stroke Study Group 1997, Foerch, Rosidi et al. 2013).     
Cellular Treatment 
 
Although tPA is the only FDA-approved drug for the treatment of ischemic stroke, cellular 
therapies have shown promise in preclinical models as well as clinical trials. Postmitotic 
immature neurons derived from human teratocarcinomas were effective at reducing brain 
damage in rats following distal MCAO. These promising results led to a nonrandomized phase I 
trial where the cells were administered intracranially following basal ganglia stroke. Patients 
administered these cells in phase I trials showed little to no adverse effects. Moreover, these 
cells increased metabolic activity in the infarct as indicated by fluorodeoxyglucose-positron 
emission tomography scans. Although phase II trials revealed no significant difference in motor 
improvement using the European Stroke Scale motor score, treatment was associated with 
improvement as measured by the Action Research Arm Test (Rosado-de-Castro, Pimentel-
Coelho et al. 2013).  
Among preclinical rodent studies, neural stem cells (NSCs) contributed to brain repair 
through several mechanisms. These cells, which are derived from neurogenesis sites in the 
subventricular and subgranular zones, facilitate tissue repair by proliferating and differentiating 
into neurons and glia. Preclinical studies indicate that NSCs confer neuroprotection through the 
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release of neurotropic and anti-inflammatory factors as well.  Cell populations from the bone 
marrow, umbilical cord blood, and autologous peripheral blood have also been reported as 
cerebroprotective by several groups. These cells are currently undergoing several independent 
clinical trials. Although these therapies contain mesenchymal stem cells, cells isolated from 
autologous peripheral and umbilical cord blood also contain a large fraction of mononuclear cells, 
which consist of monocytes/macrophages, lymphocytes, and neutrophils. Similar to NSCs, these 
cell populations have been shown to exert protective effects via released factors that activate 
survival signaling. This laboratory determined through preclinical rodent studies that HUCB 
treatment after stroke increases PI3K/Akt signaling and induces the expression of antioxidant 
enzymes (Rowe, Leonardo et al. 2010, Rowe, Leonardo et al. 2012). The cerebroprotective 
potential of cellular therapies lies in their ability to turn on pro-survival signaling in neural cells 
via paracrine mechanisms. However, one major obstacle to overcome in regards to cellular 
therapies is standardization of treatment, since heterogeneous cell populations may vary in 
efficacy.  
Other Therapies 
Several clinical trials examined whether commonly-prescribed therapeutics may serve as 
alternative treatments for stroke.  Drugs commonly prescribed for hypertension, such as 
angiotensin receptor blockers, diuretics, and calcium channel blockers have shown to be 
cerebroprotective in animal models of ischemic and hemorrhagic stroke(Maniskas, Roberts et 
al. 2015, Wijkman 2015). These classes of drugs, which stimulate production of angiotensin II, 
may promote the recruitment of collateral vessels to the ischemic core.  Although angiotensin II 
confers pro-hypertensive effects via systemic activation of AT1 receptors, these neuroprotective 
benefits primarily occur through AT2, which is induced in the cerebral microcirculation following 
ischemia (Fournier, Messerli et al. 2004). Diuretics also reduce brain damage by counteracting 
cerebral edema. For instance, combination therapy with conivaptan, a vasopressin receptor 
6 
 
antgonist, and hypertonic saline reduced post-stroke inflammation as well as edema (Decker, 
Collier et al. 2016). Agonists for peroxisome proliferator-activated receptors (PPARs), which are 
normally used for the treatment of type 2 diabetes mellitus/metabolic syndrome, have also shown 
potential in animal as well as human models of stroke.  In a rat model of transient FCI, 
administration of the PPAR-γ receptor agonist pioglitazone upregulated expression of antioxidant 
enzymes in the brain and improved neurological scoring compared to vehicle treatment 
(Shimazu, Inoue et al. 2005). Clinical research also suggests that pioglitazone treatment may 
help prevent reoccurring strokes in diabetes patients (Wilcox, Bousser et al. 2007). 
Unfortunately, pre-clinical results demonstrated that pioglitazone was ineffective at providing 
neuroprotection against permanent FCI.  
Phases of Stroke Pathophysiology 
Acute Excitotoxic Injury 
Although neural cell death during stroke is commonly associated with energy failure and 
low levels of oxygen, resulting brain damage occurs during two distinct phases of cellular 
damage. The acute cytotoxicity phase, which occurs minutes to hours after the onset of stroke, 
results in the death of cells within the ischemic core.  Reduced generation of ATP due to low 
glucose and oxygen levels leads to difficulties in maintaining neuronal membrane potential. As 
a result, rates of neuronal depolarization and subsequent glutamatergic transmission increase 
rapidly. The release of glutamate from injured cells and reduced glutamate uptake by astrocytes 
causes further depolarization, activation of NMDA receptors, and influx of Na+ and Ca2+ into 
neurons. Higher intracellular Ca2+ may trigger neuronal death through mitochondrial dysfunction, 
calpain activation, and caspase cleavage (Rothstein, Dykes-Hoberg et al. 1996, Bano and 
Nicotera 2007). This phase occurs immediately following the onset of stroke and may be targeted 
by thrombolytic therapy.  
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Delayed Neuroinflammation 
Approximately 18 h after the onset of stroke, dying cells release compounds such as 
ATP, CX3CL1, or other danger-associated molecular patterns, which activate microglia, the 
resident macrophage-like immune cells in the brain (Streit, Graeber et al. 1988, Davalos, 
Grutzendler et al. 2005, Marsh, Williams-Karnesky et al. 2009, Patel, Ritzel et al. 2013). Once 
activated, microglia damage the BBB via the release of pro-inflammatory cytokines and MMPs 
(Clark, Krekoski et al. 1997). Increased permeability of the BBB contributes to cerebral edema, 
and renders cells in the parenchyma vulnerable to invading peripheral immune cells. These 
immune cells infiltrate the brain approximately 48 h after FCI, and include 
monocytes/macrophages, lymphocytes, and neutrophils (Akopov, Simonian et al. 1996, Barone 
and Feuerstein 1999, Vendrame, Cassady et al. 2004). Although certain populations of these 
immune cells, such as anti-inflammatory macrophages/microglia, may play a crucial role in 
phagocytosis and tissue repair, pro-inflammatory leukocytes perpetuate further damage in the 
area surrounding the ischemic core (penumbra). In addition, peripheral B and T lymphocytes that 
are exposed to central nervous system (CNS)-specific antigens may contribute towards the post-
stroke adaptive immune response by antibody secretion or direct cytotoxicity (Hurn, 
Subramanian et al. 2007, Iadecola and Anrather 2011). This secondary phase continues until 
approximately 96 h after the onset of stroke, when the infarct reaches its maximum volume 
(Leonardo, Hall et al. 2010, Leonardo, Seifert et al. 2012). 
Role of the Spleen   
Of the peripheral immune cell populations that infiltrate the brain after stroke, a 
substantial portion of them originate in the spleen. After stroke, elevated levels of norepinephrine 
and epinephrine mediate splenic contraction through the activation of α and β-adrenoreceptors 
in the white pulp, where splenic leukocytes reside (Myers, Norris et al. 1981, Ajmo Jr, Collier et 
al. 2009). These leukocyte are released into the peripheral circulation, although the secretion of 
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pro-inflammatory mediators causes these cells to migrate towards the injured hemisphere and 
amplify the inflammatory response in the brain. Previous studies revealed inverse relationships 
between post-stroke spleen weights and infract volumes in addition to spleen weights and splenic 
CD8+ cytotoxic T-cell count. These findings show that greater splenic atrophy is the result of 
more infiltrating immune cells, which mediate delayed neurodegeneration (Vendrame, Gemma 
et al. 2005, Seifert, Hall et al. 2012). Although microglia are directly stimulated by dying cells 
within the ischemic core, some studies demonstrate that peripheral immune cells, specifically 
migrating splenocytes, may be crucial for full microglial activation (Chopp, Zhang et al. 1994, 
Ajmo Jr., Vernon et al. 2008). Rats that underwent splenectomy 2 weeks prior to permanent 
MCAO had significantly smaller infarct volumes than those that received a sham splenectomy 
procedure (Ajmo Jr., Vernon et al. 2008). Published works from this laboratory demonstrate that 
administration of interferon gamma (IFNγ), a pro-inflammatory cytokine produced by activated,  
T lymphocytes, and natural killer (NK) cells, counteracted the protective effect of the splenectomy 
(Schoenborn and Wilson 2007, Ajmo, Vernon et al. 2008). IFNγ signaling is implicated in the 
development of pro-inflammatory macrophages/microglia. These data suggest that IFNγ triggers 
the first step in the delayed post-stroke inflammatory response (Mosser and Edwards 2008, 
Seifert, Collier et al. 2014). 
 Oxidative Stress 
Production of Reactive Oxygen Species  
Oxidative stress is characterized by the excess production of reactive oxygen species 
(ROS), which may cause irreversible damage to cellular components. Although neural cell 
damage during stroke is partially triggered by hypoxia, oxidative stress plays an instrumental role 
during both phases of stroke pathophysiology. The increase in intracellular Ca2+ triggered by 
glutamatergic activity activates calmodulin, which is responsible for neuronal nitric oxide (nNOS) 
activity. Although nitric oxide is not directly neurotoxic, it may react with superoxide anions to 
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form peroxynitrite, an extremely toxic reactive nitrogen species (Dawson, Dawson et al. 1991, 
Dawson, Dawson et al. 1993). Protein Kinase C, which may be activated by Ca2+ and 
diacylglycerol, increases activity of NAPDH oxidase, which generates additional ROS (Noh and 
Koh 2000). During the secondary wave of neuroinflammation, ROS are produced by activated 
microglia/peripheral immune cells. Activated microglia and peripheral macrophages generate 
nitric oxide via inducible nitric oxide synthase (iNOS) (Merrill, Ignarro et al. 1993). Invading 
neutrophils contribute to oxidative damage in the brain via myeloperoxidase, an enzyme 
responsible for producing hypochloric acid, a strong oxidant (Beray-Berthat, Croci et al. 2003). 
Generation of ROS may cause cellular necrosis by damaging mitochondria and activating pro-
apoptotic signaling. Astrocytes facilitate endogenous protection of vulnerable cells, mainly 
neurons and white matter-forming oligodendrocytes, by increasing activity of antioxidant 
enzymes. Since oxidative stress is a key factor behind neural cell death at both time points, 
decreasing ROS remains a popular alternative for treating ischemic stroke (Terasaki, Liu et al. 
2014). 
Failure of Exogenous Antioxidants 
Despite the role of oxidative stress in neural cell damage during stroke, the performance 
of exogenous antioxidants in clinical trials has been inconsistent. Some pro-antioxidant drugs 
have yielded positive results in clinical trials. Ebselen, a glutathione peroxidase (GPx) mimetic 
that improved outcomes after transient FCI in rodents, was used in a double blind clinical trial for 
acute ischemic stroke patients. According to the results of the study, patients that received oral 
ebselen within 24 of stroke onset showed improvement on the Glasgow Outcome Scale at 1 
month after injury compare to patients who received the placebo. Unfortunately, there was no 
significant improvement at 3 months post-stroke (Dawson, Masayasu et al. 1995, Yamaguchi, 
Sano et al. 1998).  
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Unfortunately, clinical trials for “free radical scavengers” have yielded more negative 
results compared to successful treatments. Arguably the most notable failed trial was for α-(2, -
disulfophenyl)-N-tertbutylnitrone, also known as NXY-059. NXY-059 is a nitrone compound that 
prevents the formation of peroxynitrite by mimicking NO. This drug performed extremely well in 
rodent and primate models of FCI, and produced significant improvements on the Rankin scale 
compared to placebo during its initial phase III clinical trial (SAINT I). However, NXY-059 
produced no significant improvement compared to placebo in an expanded phase III trial (SAINT 
II). 
 Several reasons were given as to why NXY-059 failed in the expanded study. For 
instance, the drug used in the SAINT II trial may have been older than the lot used in the SAINT 
I trial. As a result, this older lot may have undergone oxidation prior to administration, rendering 
the drug less effective. Secondly, NXY-059 induces vasodilation of cerebral vessels, but does 
not directly promote survival of neural cells. Pharmacokinetic issues, such as the short half-life 
of the drug and its inability to easily cross the BBB may have also contributed to its lack of efficacy 
(Strid, Borga et al. 2002, Lees, Zivin et al. 2006, Shuaib, Lees et al. 2007). In order to confer 
longer lasting neuroprotection during ischemic stroke, researchers have begun focusing on 
therapeutics that enhance the activity the brain’s endogenous antioxidant enzymes.  
Endogenous Antioxidant Protection 
Glutathione Metabolism 
Under physiological and pathophysiological conditions, several enzymes are responsible 
for regulating redox balance in neurons. Some of these enzymes product neurons from oxidative 
stress by maintaining adequate levels of the antioxidant glutathione (GSH). GSH, an oligopeptide 
containing a cysteine residue, acts as a nucleophile by donating electrons to break the disulfide 
bonds of oxidized proteins. Once reduced, these proteins are unable to react with other cellular 
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components and cause further damage. Oxidized glutathione molecules will form disulfide bonds 
with each other until they are converted to reduced GSH by glutathione reductase (Kidd 1997, 
Pompella, Visvikis et al. 2003).  GSH may also reduce the accumulation of pro-oxidant xenobiotic 
agents via the glutathione-S-transferase-dependent conjugation (Friling, Bensimon et al. 1990). 
Although GSH is low in neurons, astrocytes may protect neurons by synthesizing and secreting 
high levels of GSH in vitro. In addition, neuronal glutathione synthesis is largely dependent upon 
the release of a cysteine-glycine dipeptide from astrocytes (Raps, Lai et al. 1989, Dringen, 
Pfeiffer et al. 1999). 
In addition to its endogenous antioxidant capabilities, GSH serves as a cofactor for the 
GPx family of enzymes. GPx enzymes contain the amino acid selenocysteine, which contains a 
selenium in the space normally occupied by sulfur. Although debate has occurred regarding the 
function of selenocysteine vs cysteine, studies suggest that the higher reactivity of selenium 
allows selenoproteins to scavenge peroxides more efficiently (Brigelius-Flohe 1999, Saccoccia, 
Angelucci et al. 2014).  Some members of the GPx family that are expressed in mammalian 
tissues include classical GPx, gastrointestinal GPx, plasma GPx, and phospholipid 
hydroperoxide GPx. All GPx enzymes possess the ability to catalyze the breakdown of organic 
hydroperoxides, but some isoforms such as plasma GPx are able to reduce more complex 
hydroperoxides. Phospholipid hydroperoxide GPx and classical GPx are highly stable in brain 
tissue, and preclinical studies show that upregulation of GPx may occur in response to oxidative 
damage in animal models of neurodegeneration, including Parkinson’s Disease (PD) and 
Alzheimer’s Disease (AD) (Aksenov, Tucker et al. 1998, Lindenau, Noack et al. 1998, Schulz, 
Lindenau et al. 2000). GPx activity is also neuroprotective in animal models of stroke.  In rodent 
models of transient MCAO, overexpression of GPx enzymes as well as treatment with a GPx 
mimetic (ebselen) aided in protection against oxidative injury (Dawson, Masayasu et al. 1995, 
Weisbrot-Lefkowitz, Reuhl et al. 1998, Ishibashi, Prokopenko et al. 2002).  
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Peroxirexodins 
Peroxiredoxin (Prdx) family enzymes, or “thiol-specific antioxidants,” were initially 
identified due to their ability to reduce oxidized proteins in the presence of dithiothreitol, which 
reduced molecular O2 to form several ROS species (Chae, Kim et al. 1993). Similar to GPx, Prdx 
enzymes are able to form disulfide linkages following oxidation, and return to their active form 
following reduction by an additional enzyme (thioredoxin) (Rhee, Kang et al. 2001). During each 
redox cycle, Prdx enzymes catabolize the conversion of H2O2 into H2O and O2. However, a study 
by Bryk et al. indicated that Prdx isoforms in bacteria have the capacity to scavenge peroxynitrite 
(ONOO-) (Bryk, Griffin et al. 2000).  Six Prdx isoforms are expressed in mammals; the cytosolic 
isoforms Prdx1, Prdx2, and Prdx6; the mitochondrial isoform Prdx3; the secreted isoform Prdx4; 
and Prdx5, which is localized in multiple organelles (Rhee, Woo et al. 2012). In brain tissue, 
Prdx2-5 are expressed by neurons, while Prdx1, 4, and 6 are localized to glial cells (Goemaere 
and Knoops 2012). As previously mentioned, Prdx4, the isoform expressed by multiple neural 
cell types, is one of the antioxidant enzymes upregulated by HUCB cell therapy after permanent 
MCAO(Rowe, Leonardo et al. 2010, Rowe, Leonardo et al. 2012). Currently, the role of Prdx 
enzymes in neural cell protection remains controversial. Studies from this laboratory as well as 
other groups identify pro-survival mechanism for Prdx 2, 4, and 5 during in vivo and in vitro 
ischemia.  Shichita et al. demonstrated that antibodies against Prdx 1, 2, 5, and 6 decreased 
infarct volume and decreased the release of IL-23 from macrophages after transient MCAO. This 
paradoxical role for Prdx enzymes in stroke pathology may be explained by several factors. The 
protective role for Prdx4-5 during stroke was demonstrated using rodent models of permanent 
MCAO, suggesting that differences between permanent and transient FCI pathology may 
determine whether Prdx enzymes contribute to neuroprotection vs. neuroinflammation. In 
addition, the time point at which the anti-Prdx antibodies are administered may determine 
whether or not blocking their activity is neuroprotective. The studies showing the neuroprotective 
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role of Prdx2 were performed in vitro, meaning that this isoform may only be neuroprotective in 
the absence of invading leukocytes (Vendrame, Gemma et al. 2005, Boulos, Meloni et al. 2007, 
Rowe, Leonardo et al. 2010, Rowe, Leonardo et al. 2012, Shichita, Hasegawa et al. 2012, Rowe, 
Collier et al. 2014).  
Catalase  
Catalase, a normal component of cellular peroxisomes, is responsible for converting 
H2O2 into water and molecular oxygen. Catalase is ubiquitously expressed by neurons and glia 
of the CNS, and is among the most efficient enzymes found in nature (Vainshtein, Melik-
Adamyan et al. 1981, Moreno, Mugnaini et al. 1995).  A study looking at the antioxidant enzymes 
in human patients with neurodegenerative diseases demonstrated that patients who had 
experienced an ischemic stroke or had PD showed lower levels of catalase activity in the brain 
(Rosario de la Torre, Casado et al. 1996). As a result, increasing catalase activity has been 
examined as a potential therapeutic strategy for ischemic stroke. Neurons in the striatum that 
overexpress catalase are less susceptible to damage following transient MCAO (Gu, Zhao et al. 
2004). Two independent groups demonstrated that injecting catalase conjugated to polyethylene 
glycol reduces total infarct size as well as BBB dysfunction after transient MCAO (Liu, Beckman 
et al. 1989, Armstead, Mirro et al. 1992). However, both of these studies showed that conjugated 
catalase is most efficacious when administered in conjunction with a polyethylene glycol-
conjugated form of another antioxidant, superoxide dismutase.  
Superoxide Dismutase   
SOD isoforms  
Superoxide dismutase (SOD) family enzymes are responsible for converting superoxide 
(O2-) anions to H2O2 and H2O. Mammalian cells express three isoforms of SOD: SOD1, SOD2, 
and SOD3. SOD1, alternatively known as copper/zinc-dependent SOD (Cu/Zn-dependent SOD) 
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is a 32 kDa homodimeric enzyme that is ubiquitously expressed and localized in the cytosol. 
SOD2, or manganese-dependent SOD, is an 88 kDa homotetrameric enzyme that is localized in 
the mitochondria. Similar to SOD1, SOD2 exhibits a ubiquitous pattern of expression. SOD3, or 
extracellular SOD, is also dependent upon copper and zinc and contains a signaling peptide 
sequence for localization to the endoplasmic reticulum and eventual secretion into the 
extracellular environment.  SOD3 exists as a homotetramer of 135 kDa in humans and mice, but 
it is primarily dimeric in rats (Carlsson, Marklund et al. 1996, Zelko, Mariani et al. 2002). In 
contrast to the ubiquitous expression of SOD1 and SOD2, levels of SOD3 expression vary 
greatly between organs. Under physiological conditions, SOD3 mRNA levels are highest in the 
heart, lung, and pancreas, but low in brain tissue. Fukui et al. showed that neuronal populations 
have the capacity to induce SOD3 following FCI, indicating that SOD3 activity may be 
neuroprotective despite its low basal expression (Fukui, Ookawara et al. 2002).  
SOD enzymes as stroke targets  
Since oxidative stress is a pathological hallmark of neurodegeneration, SOD dysfunction 
is implicated in diseases characterized by neuronal loss. Mutations in SOD1 contribute to the 
development of familial amyotrophic lateral sclerosis (ALS), and multiple studies suggest that 
reduced SOD2 activity may be associated with AD and PD. However, preclinical studies 
demonstrate that increased activity of all three SOD enzymes may reduce brain damage after 
FCI.  As previously mentioned, treatment with polyethylene glycol-conjugated catalase and SOD 
effectively reduced ischemic brain damage. EUK-134, a selenium -manganese complex that acts 
as a mimetic for SOD and catalase, decreased brain damage when administered 3 h after stroke, 
a comparable time point to administration of tPA (Baker, Marcus et al. 1998). Since H2O2 is a 
product of the reduction of O2-, combination therapy with both enzymes would allow for 
scavenging of both ROS and better protection against ischemic damage.  
15 
 
Targeting SOD enzyme expression has also shown considerable success in animal 
models of stroke.  Davis et al. showed that delivery of the SOD1 gene using herpes simplex viral 
vectors protected mice against striatal damage induced by transient MCAO compared to the 
vector alone (Davis, Zhao et al. 2007). Unfortunately, the neuroprotective effect of SOD1 
overexpression appears to be limited to models of cerebral ischemia/reperfusion injury, since 
SOD1 overexpressing mice did not show a significant decrease in infarct volume compared to 
wild-type mice after permanent MCAO. The authors of the latter study suggest that the protective 
effect of SOD1 overexpression is minimal due to high basal levels of SOD1 in the brain tissue of 
wild-type mice (Chan, Kamii et al. 1993). Several independent groups reported that SOD2 
knockout mice show greater susceptibility to oxidative stress after permanent and transient 
MCAO (Mikawa, Li et al. 1995, Murakami, Kondo et al. 1998, Kim, Kondo et al. 2002). Increasing 
SOD3 is also an effective strategy in protecting against oxidative damage in models of ischemic 
stroke.  Sheng et al. demonstrated that mice that overexpress the SOD3 gene have smaller 
infarct volumes compared to wild-type mice (Sheng, Brady et al. 1999).  The effectiveness of 
SOD3 overexpression as neuroprotective strategy stems from its low levels of basal expression 
in the brain. While SOD1 and SOD2 are highly expressed under basal conditions, SOD3 is only 
induced in neurons during injury (Fukui, Ookawara et al. 2002). Therefore, the difference in 
antioxidant capacity between SOD3 transgenic mice and wild-type mice might be greater than 
the difference between SOD1/SOD2 transgenic mice and wild-type mice.  
Transcription Factors  
Upregulation of Protective Genes  
     During the HUCB studies from this laboratory, emphasis was not only placed on 
identifying protective genes that were induced by the cells, but also transcription factors (TFs) 
that might be involved in regulating expression of protective genes. Using the software program 
Genomatix, this laboratory analyzed the promoter regions of eight genes induced by HUCB cell 
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therapy to identify possible transcription factors implicated in oligoprotective gene upregulation. 
According to Genomatix analysis, several common TFs had binding sites in the promoters of all 
8 genes, while several more were found in 7 out of the 8 genes. Moreover, the pro-survival effects 
of HUCB cells, in addition to expression of Prdx4, were determined to be dependent upon 
PI3K/Akt activation in cultured oligodendrocytes (Rowe, Leonardo et al. 2010, Rowe, Leonardo 
et al. 2012). Further investigation revealed that several of the identified TFs are activated by 
PI3K/Akt signaling; these factors including myeloid zinc finger-1 (MZF-1) and specificity protein 
1 (Sp1) (Pore, Liu et al. 2004, Moeenrezakhanlou, Shephard et al. 2008).  
Myeloid Zinc Finger-1 
Hromas et al. first identified MZF-1 as a member of the Kruppel TF family that regulates 
hematopoietic development (Hromas, Collins et al. 1991). MZF-1 consists of 13 C2H2 zin fingers 
that make up two separate DNA-binding domains. Each binding domain recognizes a separate 
consensus sequence containing several consecutive guanine resides (Morris, Hromas et al. 
1994). Similar to other zinc finger TFs, MZF-1 regulates genes containing GC-rich promoters 
lacking TATA and CAAT boxes (Mudduluru, Vajkoczy et al. 2010). Currently, there are few 
known regulatory mechanisms of MZF-1. Moeenrezakhanlou et al. showed that the pro-survival 
PI3K/Akt signaling pathway induces MZF-1 in myeloid cells. This study showed that the 
regulation of MZF-1 by Akt was controlled at the level of expression, but a recent report by Eguchi 
et al. indicates that MZF-1 may also contain phosphorylation sites (Moeenrezakhanlou, 
Shephard et al. 2008, Eguchi, Prince et al. 2015).  
Although MZF-1 has not been extensively characterized in brain tissue, several studies 
show that MZF-1 is involved with the regulation of genes that are implicated in stroke pathology. 
Luo et al. showed that fibroblast growth factor-2 (FGF-2), a neuroprotective trophic factor, is 
induced in astrocytes following treatment with apomorphine, a dopamine receptor agonist. 
Furthermore, increased transcription of the FGF-2 gene was shown to be dependent upon MZF-
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1 activity (Alzheimer and Werner 2002, Luo, Zhang et al. 2009). Cystathionine-β-synthase and 
cystathionine-γ-lyase, two enzymes involved with hydrogen sulfide (H2S) synthesis, are 
positively regulated by MZF-1. Although the role of H2S in mediating ischemic damage is 
controversial, Wen et al. reported that H2S reduces hippocampal neuron damage and cognitive 
deficits after stroke in an Akt-dependent manner (Wen, Qi et al. 2014). MZF-1 also suppresses 
transcription of genes that may be detrimental during ischemia. Expression of MMP-2, a 
gelatinase that mediates the breakdown of the BBB, is decreased in cervical cancer cells 
following overexpression of MZF-1 (Clark, Krekoski et al. 1997, Tsai, Hwang et al. 2012). Of 
particular interest to this project is the ability of MZF-1 to control expression of antioxidant 
enzymes. In addition to Prdx4, MZF-1 regulates the expression of Prdx1 in lung cancer cells and 
SOD3 in the same tissue under physiological conditions (Zelko and Folz 2003, Kim, Bogner et 
al. 2008).  
Specificity Protein 1  
Sp1, alternatively known as stimulating protein 1, is a ubiquitously expressed zinc finger 
transcription factor. Sp1 was first discovered as a regulator of the Simian virus 40 and AIDS 
retrovirus early promoters (Dynan and Tjian 1983, Jones, Kadonaga et al. 1986). Further 
characterization by other groups revealed that it contains two DNA-binding domains with 
molecular weights of 105 and 95 kDa binds to a 5’-GGGGCGGGGC consensus sequence. 
Genes regulated by Sp1 usually contain GC-rich promoter sequences and may or may not 
contain a TATA box. Pugh and Tijan reported that Sp1 cannot function as the sole activator for 
TATA-less genes in Drosophila. Emani et al. published a later study showing that in the presence 
of human transcription tactor IID, Sp1 may initiate transcription of genes lacking the TATA box 
(Briggs, Kadonaga et al. 1986, Pugh and Tjian 1990, Emami, Smale et al. 1998). In addition to 
transcription factor IID, several other mechanisms regulate the DNA-binding activity of Sp1. Sp1 
contains several post-translational modifications that facilitate its interaction with gene 
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promoters. For instance, acetylation by the histone actetyltransferases p300 and p300/CREB 
binding protein-associated factor enhance its interaction with the promoter of transforming 
growth factor β type II receptor (Huang, Zhao et al. 2005). PI3K/Akt signaling increases the 
activity of Sp1 by two independent mechanisms. Akt phosphorylates Sp1 and induces its protein 
expression (Pore, Liu et al. 2004, Amodio, Di Martino et al. 2012).   
Sp1 plays several known roles in controlling gene expression in brain tissue. Zawia et al. 
determined that Sp1 regulates the expression of genes involved in brain development, including 
myelin basic protein and proteolipid protein, and its regulatory activity may be altered by heavy 
metal toxicity (Zawia, Sharan et al. 1998). Moreover, the transcriptional activity of Sp1 is 
dysregulated in several neurodegenerative diseases. Some of these studies demonstrate that 
Sp1 activity is primarily neuroprotective. Dunah et al. showed that the DNA-binding activity Sp1, 
in addition to transcription factor IID subunit 4, is decreased by aggregated huntingtin in a mouse 
model of Huntington’s disease (HD) (Dunah, Jeong et al. 2002). Hypoxia-inducible factor-1α 
confers neuroprotection against prion diseases by upregulating Sp1 (Jeong and Park 2012). 
However, other groups found that Sp1 transcriptional activity is upregulated in models of HD 
(Qiu, Norflus et al. 2006).  In addition, Citron et al. showed that Sp1 contributes to AD pathology 
through regulation of amyloid precursor protein and tau (Citron, Dennis et al. 2008). In spite of 
these conflicting roles in other neurodegenerative diseases, research points to a neuroprotective 
role for Sp1 during cerebral ischemia. Yeh et al. showed that neurons will upregulate Sp1 in vitro 
as a protective mechanism against oxygen glucose deprivation (OGD). Histone deacetylase 
inhibitors, including valproic acid and trichostatin A protect neurons against in vitro oxidative 
damage. This pro-antioxidant effect of Sp1 activity stems from its ability to induce transcription 
of enzymes that break down ROS, including SOD3.  (Ryu, Lee et al. 2003a, Ryu, Lee et al. 
2003b, Lee, Kosaras et al. 2006, Marinova, Ren et al. 2009).  
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Leukemia Inhibitory Factor  
Discovery of LIF  
Leukemia inhibitory factor (LIF) is a cytokine in the interleukin-6 (IL-6) family that was 
initially identified based on its ability to induce terminal differentiation of a myeloid leukemia cell 
line. Medium that had been pre-conditioned with Krebs-II ascites tumor cells was used to purify 
LIF and cloning was achieved using cDNA from a mouse T lymphocyte library. Cloning studies 
revealed that LIF consisted of a single polypeptide chain containing four α-helices that was 
glycosylated. LIF was also shown to facilitate maturation of macrophages. Despite its inhibitory 
effects on the self-renewal on leukemia cells, LIF has a crucial role in maintaining the 
pluripotence of embryonic stem cells.  (Gearing, Gough et al. 1987, Gough, Gearing et al. 1988, 
Hilton, Nicola et al. 1988, Metcalf 2003).  
LIF signaling  
LIF confers its effects via activation of its heterodimeric receptor: the low-affinity LIF 
receptor (LIFR) subunit and the high-affinity glycoprotein 130 (gp130) subunit, which is shared 
by all IL-6 family cytokine receptors (Gearing, Thut et al. 1991). Both receptor subunits dimerize 
upon LIF binding, and Janus kinases (JAKs) that associate with both receptor subunits undergo 
self-phosphorylation. Three main signaling pathways may be subsequently activated:  
Ras/MAPK/ERK, PI3K/Akt, and JAK/STAT signaling (Boulton, Stahl et al. 1994, Stahl, Boulton 
et al. 1994, Stahl, Farruggella et al. 1995, Oh, Fujio et al. 1998). The precise consequences of 
each signaling pathway differ between cell types, but one of the ways in which LIF exerts long-
lasting effects is through changes in gene expression. In several ES cell populations, Ras/MAPK 
signaling upregulates genes involved in proliferation, JAK/STAT controls genes that regulate 
self-renewal, and PI3K/Akt signaling induces pro-survival genes (Graf, Casanova et al. 2011, 
Majumder, Banerjee et al. 2012)  
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Clinical Trials  
Although LIF has not yet been used to treat brain damage, it has been tested for the 
treatment of other conditions under the trade name of Emfilermin. For instance, LIF was used in 
clinical trials for the treatment of chemotherapy-induced peripheral neuropathy, infertility, and 
several types of cancer, including non-small cell lung carcinoma. Unfortunately, none of these 
trials yielded successful results. However, these studies reported a very low incidence of adverse 
effects in response to LIF treatment, indicating that it would be a safe therapeutic option for other 
diseases (Gunawardana, Basser et al. 2003, Davis, Kiers et al. 2005, Brinsden, Alam et al. 
2009).  
LIF in the Nervous System Development 
LIF exerts pleiotropic effects on the body due to the wide distribution of its receptors, but 
it exerts several important functions as a neurokine in the peripheral and central nervous 
systems. According to Murphy et al., treatment of mouse neural crest cells triggered the 
development of sensory neurons in vitro (Murphy, Reid et al. 1991). LIF also induces the 
development of neurons from precursor cells in the spinal cord (Richards, Kilpatrick et al. 1992), 
and induced neurogenesis in vitro when combined with ciliary neurotrophic factor (CTNF), 
another IL-6 family neurokine (Galli, Pagano et al. 2000). However, LIF exerts anti-neurogenic 
effects by inhibiting the terminal differentiation of murine olfactory receptor neurons (Moon, Yoo 
et al. 2002). The reason for this inhibitory effect on neurogenesis in the olfactory bulb is explained 
by its effects on embryonic self-renewal. LIF increases NSC populations and enhances self-
renewal by inhibiting differentiation, which allows NSCs to aid in neural repair during injury (Bauer 
and Patterson 2006). Using a gene microarray, Wright et al. demonstrated that these anti-
differentiation effects on NSC populations following LIF treatment occurred due to changes in 
the expression of over 200 genes (Wright, Li et al. 2003).  
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 LIF regulates the development of several glial cell populations in addition to neurons. LIF 
enhances proliferation of oligodendrocyte progenitor cells and increased the population of 
mature oligodendrocytes in the hippocampus during cuprizone-induced demyelination 
(Deverman and Patterson 2012). LIF, in conjunction with bone morphogenetic protein 2 causes 
NSCs to differentiate into astrocytes (Yoshida, Satoh et al. 1993, Nakashima, Yanagisawa et al. 
1999). However, the study by Koblar et al. shows that LIF knockout mice show only a partial 
reduction in hippocampal astrocytes, while LIFR knockout mice show a complete deficiency 
(Koblar, Turnley et al. 1998). Other IL-6 family neurokines, such as CNTF and neuropoetin, exert 
similar downstream effects to LIF since they also signal through gp130 and LIFR (Ip, Nye et al. 
1992) (Derouet, Rousseau et al. 2004). These studies that the presence of the low-affinity LIF 
receptor is more important for the development of certain neural cell populations compared to 
LIF alone (Li, Sendtner et al. 1995, Koblar, Turnley et al. 1998).  
Treatment of Neurodegenerative Disease 
Under pathophysiological conditions, LIF is upregulated endogenously and released by 
several cells of the nervous system. Brain endothelial cells release LIF to promote the 
differentiation of astrocytes, which also secrete LIF to promote neuroprotective signaling 
(Banner, Moayeri et al. 1997, Mi, Haeberle et al. 2001, Moidunny, Vinet et al. 2012). Pericytes, 
which help comprise the BBB, have been tested as a therapeutic for myocardial infarction based 
on their ability to promote cardioprotection via secretion of LIF (Chen, Okada et al. 2013). NSC 
populations upregulate LIF mRNA following stimulation with IFNγ, which is produced by T 
lymphocytes and NK cells after stroke. This secretion of LIF promotes brain repair by acting on 
neural cells and by triggering proliferation of other NSCs (Yilmaz, Arumugam et al. 2006, Laterza, 
Merlini et al. 2013). Neurons also increase expression of LIF in response to injury. Getchell et al. 
showed that olfactory receptor neurons upregulate LIF mRNA following targeted ablation, which 
may promote survival in an autocrine manner (Getchell, Shah et al. 2002).  
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Animal models of neurodegeneration show that LIF enhances survival of neural cells and 
promote regeneration of damaged tissue. Anzari et al. revealed LIF decreased the degradation 
of motor neurons in the G93A SOD1 mouse model of familial ALS and reduced white matter 
damage after spinal cord injury (Azari, Galle et al. 2001, Azari, Lopes et al. 2003, Azari, Profyris 
et al. 2006).Due to its pro-survival effects on oligodendrocytes, LIF has been explored as a 
therapeutic for demyelinating diseases, most notably multiple sclerosis (Butzkueven, Zhang et 
al. 2002, Butzkueven, Emery et al. 2006, Slaets, Dumont et al. 2008, Laterza, Merlini et al. 2013).  
The ability of LIF to rescue gray and white matter from damage makes it a promising 
candidate for preclinical stroke studies, in which preventing neuronal and oligodendrocyte loss 
is crucial. Suzuki et al. showed that LIF activates its three main signaling pathways (MAPK, 
PI3K/Akt, and JAK/STAT) to promote neuroprotection after FCI (Suzuki, Yamashita et al. 2005). 
LIF treatment alone and in conjunction with fibroblast growth factor-2 increased the activity of 
antioxidant enzymes, including GPx and SOD isoforms, and reduced oxidative damage when 
administered after MCAO (Huang, Li et al. 2012). This laboratory performed more extensive 
studies regarding the ability of LIF to protect white matter during permanent FCI in the rat. Not 
only did LIF promote oligodendrocyte survival in vivo and in vitro via the Akt-dependent 
upregulation of Prdx4, but LIF treatment also reduced the infarct volume and improved motor 
function 72 h after MCAO (Rowe, Collier et al. 2014).  
Immunomodulation by LIF  
Although LIF belongs to the same family as IL-6, which is commonly associated with 
inflammation, LIF primarily confers anti-inflammatory and pro-regulatory effects. Metcalfe et al. 
reported that LIF signaling was associated with greater immune tolerance following 
transplantation. This phenomenon may be explained by the role of LIF in suppressing the 
immune response(Metcalfe, Watson et al. 2005).   
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During the maturation of naïve T lymphocytes, the balance between IL-6 and LIF 
determines whether the immature cells will develop into CD4+ IL-17+ helper T (Th17) or CD4+ 
forkhead box transcription factor P3 (FOXP3)+ regulatory T (Treg) lymphocytes. Th17 cells 
require IL-6, interleukin-1 (IL-1), and transforming growth factor-β for maturation, and are 
distinguished by their ability to secrete interleukin-17 (IL-17). Th17 cells are often active at sites 
of inflammation in autoimmune diseases such as multiple sclerosis (MS) or rheumatoid arthritis. 
In the absence of IL-6, the naïve lymphocytes will mature into CD4+ Tregs (Furuzawa-
Carballeda, Vargas-Rojas et al. 2007, Kimura and Kishimoto 2010). Gao et al. reported that LIF 
induces the development of Tregs and inhibits Th17 maturation by increasing the expression of 
FOXP3. Mature Tregs will maintain immunotolerance by releasing LIF and favoring the 
development of other Treg populations. By contrast, IL-6 quenches LIF signaling by 
downregulating LIFR mRNA and activating the E3 ubiquitin ligase MARCH-7, which targets LIFR 
for degradation (Gao, Thompson et al. 2009). Cao et al. reported similar findings, in which LIF 
not only induced Treg differentiation, but suppressed IL-6-mediated Th17 development through 
upregulation of suppressor of cytokine signaling-3 (Cao, Yang et al. 2011). The ability of LIF to 
suppress the immune response renders it a promising therapeutic for neuroinflammatory 
diseases. Although LIF was initially explored as a treatment for MS based on its ability to promote 
oligodendrocyte survival and remyelination, recent studies have focused more on its ability to 
suppress autoimmunity by increasing Treg populations (Butzkueven, Zhang et al. 2002, 
Butzkueven, Emery et al. 2006, Slaets, Dumont et al. 2008, Janssens, Van den Haute et al. 
2015, Metcalfe, Strom et al. 2015).  
Dysregulation of the balance between Th17 and Treg populations may be induced by 
ischemic stroke. Th17 cells are among the populations that mediate tissue damage, and, and 
several groups have reported a higher Th17/Treg ratio after stroke and TIA (Li, Wang et al. 2013, 
Swardfager, Winer et al. 2013, Hu, Zheng et al. 2014). By contrast, depletion of Tregs prior to 
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stroke decreased levels of the anti-inflammatory cytokine IL-10, increased the severity of brain 
damage and worsened overall outcome after permanent MCAO (Liesz, Suri-Payer et al. 2009, 
Liesz, Zhou et al. 2013). Other reports show that higher Treg numbers may be detrimental after 
stroke, since Treg activity is associated with post-stroke immunosuppression (Offner, 
Subramanian et al. 2006). However, controlled administration of LIF could be used to merely 
restore the Th17/Treg balance rather than induce complete immunosuppression.  
In addition to its effects on Th17 and Treg populations, LIF exerts beneficial signaling on 
macrophages that could potentially decrease delayed brain damage after stroke. While activated 
macrophages/microglia potentiate tissue damage via the release of pro-inflammatory mediators, 
IL-6 family cytokines (LIF, IL-6, IL-11, oncostatin M) polarize macrophages/microglia towards an 
anti-inflammatory phenotype. These cells are primarily phagocytic, assist in tissue repair, and 
release IL-10 and TGF-β (Duluc, Delneste et al. 2007, Janssens, Slaets et al. 2015). Considering 
pro-inflammatory macrophages and T lymphocytes are among the splenocyte populations that 
contribute to brain damage during stroke, LIF may also reduce brain damage by attenuating 
splenic response.  
LIF as a Neuroprotective Stroke Therapeutic  
This laboratory has previously explored the role of LIF in decreasing white matter damage 
by inducing antioxidant enzymes as well as the targeting the immune response generated by the 
spleen after stroke. However, the role of LIF in protecting gray matter and mediating the splenic 
response has not been thoroughly explored.  LIF-mediated oligoprotection and upregulation of 
Prdx4 occurs primarily via Akt signaling, which increases the activity of TFs that modulate 
antioxidant expression. By identifying protective signaling mechanisms induced in neurons, we 
may further evaluate LIF as a stroke therapeutic. Furthermore, determining whether LIF plays a 
role in the splenic response may open the door for LIF-based stroke immunotherapies. The 
following set of experiments discussed in this dissertation will be used to determine whether: 1) 
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LIF protects neurons during ischemia by upregulating SOD3, 2) MZF-1 and Sp1 confer 
neuroprotection downstream of LIF by regulating SOD3 transcription, and 3) LIF treatment 
enhances sensitivity to subsequent LIF signaling in the brain and spleen via LIFR/JAK dependent 
mechanisms.  
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CHAPTER 2 
LEUKEMIA INHIBITORY FACTOR PROTECTS NEURONS FROM ISCHEMIC DAMAGE VIA 
UPREGULATION OF SUPEROXIDE DISMUTASE 3 
Note to Reader 
The contents of this chapter have previously been published in Molecular Neurobiology 
(Davis, Collier et al. 2016). Permission to use said material has been obtained from the publisher. 
Stephanie Davis was the main author on this manuscript. Lisa A. Collier, Dr. Hilary A. Seifert, Dr. 
Christopher C. Leonardo, and Dr. Craig T. Amjo Jr. assisted with experimentation and editing of 
the manuscript and all are listed as co-authors on the published manuscript. This project was 
overseen by Dr. Keith R. Pennypacker, who is the corresponding author on the published 
manuscript.  
Abstract 
Leukemia inhibitory factor (LIF) has been shown to protect oligodendrocytes from 
ischemia by upregulating endogenous antioxidants. The goal of this study was to determine 
whether LIF protects neurons during stroke by upregulating superoxide dismutase 3 (SOD3). 
Animals were administered PBS or 125 µg/kg LIF at 6, 24, and 48 h after middle cerebral artery 
occlusion or sham surgery. Neuron were isolated from rat pups on embryonic day 18 and used 
between 7-15 days in culture. Cells were treated with LIF and/or 10 µM Akt inhibitor IV with PBS 
and 0.1% DMSO acting as vehicle controls. Neurons transfected with scrambled or SOD3 siRNA 
were subjected to 24 h ischemia after PBS or LIF treatment. LIF significantly increased 
superoxide dismutase activity and SOD3 expression in ipsilateral brain tissue compared to PBS. 
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Following 24 h ischemia, LIF reduced cell death and increased SOD3 mRNA in vitro compared 
to PBS. Adding Akt inhibitor IV with LIF counteracted the decrease in cell death. Partially 
silencing expression of SOD3 using siRNA prior to LIF treatment counteracted the protective 
effect of LIF alone PBS treatment. These results indicate that LIF protects neurons in vivo and 
in vitro via upregulation of SOD3.  
Key Words 
 Stroke, Neuroprotection, Superoxide Dismutase, Oxidative Stress 
Introduction 
Reactive oxygen species (ROS) play an instrumental role in both the acute and delayed 
phases of neuronal death during focal cerebral ischemia (FCI). During the early phase of 
ischemia, energy failure leads to membrane depolarization (Calabresi, Pisani et al. 1995), 
calcium influx, and activation of pro-oxidant enzymes such as neuronal nitric oxide (NO) 
synthase (Dawson, Dawson et al. 1991 ) and nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase (Brennan, Won Suh et al. 2009). These enzymes generate ROS, such as 
peroxynitrite and superoxide, which damage cellular components and trigger neuronal death 
(Bonfoco, Krainc et al. 1995). A second wave of neuronal death occurs during the period of 
delayed neuroinflammation, which may continue hours to days after the initial injury (Dirnagl, 
Iadecola et al. 1999). Activation of microglia exacerbates oxidative damage to neurons via 
inducible NO synthase activation (Merrill, Ignarro et al. 1993). Furthermore, matrix 
metalloproteinases derived from activated microglia compromise blood-brain barrier (BBB) 
function by disrupting tight junctions (Gasche, Copin et al. 2001, McColl, Rothwell et al. 2008 
Leonardo, 2010 #94). Increased BBB permeability allows for the invasion of peripheral 
lymphocytes, monocytes/macrophages, and neutrophils (Offner, Subramanian et al. 2006). 
Accumulation of immune cells in the brain damages already degenerating neurons in the 
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penumbra (Rosell, Ortega-Aznar et al. 2006). Since the therapeutic window for tissue 
plasminogen activator, the only FDA-approved drug for ischemic stroke, ranges from 3 to 4.5 
hours after stroke,  it cannot target this delayed phase of neuronal death (Hacke, Kaste et al. 
2008).  Consequently, the need for novel stroke therapeutics that will protect vulnerable neurons 
from oxidative stress remains high.  
While small molecule scavengers of ROS have demonstrated limited efficacy in clinical 
trials (Shuaib, Lees et al. 2007), overexpressing endogenous antioxidant enzymes may be more 
effective than administering exogenous agents. These enzymes include those in the superoxide 
dismutase (SOD) family, which react with excess superoxide to form hydrogen peroxide and 
water.   Three SOD isoforms have been identified in mammals (Scandalios 1993, Zelko, Mariani 
et al. 2002) Moreover, decreased activity of SOD enzymes yields deleterious effects on nervous 
system function. The G93A mutation in SOD1, a ubiquitously expressed cytoplasmic enzyme, is 
associated with familial amyotrophic lateral sclerosis (ALS) (Wiedau-Pazos, Goto et al. 1996, 
Yim, Kang et al. 1996, Boillée, Yamanaka et al. 2006). Dysfunction of SOD2, which regulates 
ROS production in the mitochondria (Melov, Coskun et al. 1999), is implicated in the 
development of conditions such as AD (Wiener, Perry et al. 2007, Massaad, Washington et al. 
2009, Belluzzi, Bisaglia et al. 2012) and PD (Belluzzi, Bisaglia et al. 2012). SOD3, the 
extracellular isoform with the lowest expression in neural cells (Folz and Crapo 1994), opposes 
the negative effects of hypertension in the brain by increasing NO bioavailability and regulating 
cerebral blood flow (Demchenko, Oury et al. 2002).   
Several murine studies have implicated the neuroprotective role of SOD enzymes 
following FCI. Delivery of the SOD1 gene via herpes simplex virus protects mice against cerebral 
ischemia/reperfusion injury (Davis, Zhao et al. 2007). SOD2 homozygous knockout mice had 
greater infarct volumes after transient FCI compared to their wild-type counterparts (Mikawa, Li 
et al. 1995). Conversely, mice overexpressing SOD3 showed resistance to neural cell damage 
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following transient FCI (Sheng, Brady et al. 1999).  Nonetheless, information regarding the role 
of SOD3 in protecting neurons remains limited.  
Few studies focus on exogenous agents that upregulate expression of these enzymes. 
Previous data from this lab demonstrates the therapeutic potential of upregulating endogenous 
antioxidant enzymes as a protective strategy against stroke. Specifically, the Akt-dependent 
upregulation of the antioxidant enzyme peroxiredoxin IV (Prdx4) contributes to human umbilical 
cord blood (HUCB) cell-mediated protection of oligodendrocytes (Rowe, Leonardo et al. 2010, 
Rowe, Leonardo et al. 2012). This lab has chosen to focus on released factors such as leukemia 
inhibitory factor (LIF), which provide neural cell protection while avoiding cellular treatment 
(Neuhoff, Moers et al. 2007, Rowe, Leonardo et al. 2010).  
Leukemia inhibitory factor (LIF), an anti-inflammatory cytokine in the interleukin-6 family, 
(Metcalfe, Watson et al. 2005) binds to a heterodimeric receptor consisting of the LIF receptor 
(LIFR)  and glycoprotein 130 (gp130) subunits. Upon binding, several downstream signaling 
pathways are activated including the MAPK (Boulton, Stahl et al. 1994), PI3K/Akt  (Oh, Fujio et 
al. 1998), and JAK/STAT pathway (Stahl, Boulton et al. 1994, Stahl, Farruggella et al. 1995). 
These signaling cascades, especially the PI3K/Akt pathway, play an instrumental role in the pro-
survival and neurotrophic effects of LIF (Alonzi, Middleton et al. 2001).  
LIF has shown promising results as a therapeutic in several animal models of 
neurodegenerative disease. Administration of LIF reduces demyelination in the experimental 
autoimmune encephalomyelitis model of multiple sclerosis (Butzkueven, Zhang et al. 2002) and 
a murine model of spinal cord injury (Azari, Profyris et al. 2006). In addition, LIF reduced 
degeneration of motor neurons in the SOD1 G93A murine model of familial ALS (Azari, Galle et 
al. 2001). Recently, we showed that LIF decreases infarct volume, improves functional recovery, 
and upregulates Prdx4 in oligodendrocytes after ischemia (Rowe, Collier et al. 2014). Although 
LIF is released by several cell types during brain injury (Banner, Moayeri et al. 1997, Chen, 
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Okada et al. 2013, Laterza, Merlini et al. 2013), its potential as a stroke therapeutic has not yet 
been determined.  
The ability of LIF to activate protective pathways and reduce neural cell damage in 
several animal models of disease makes it a prime candidate for targeting delayed neuronal 
death after stroke. The goal of this study is to identify the molecular mechanisms by which LIF 
exerts neuroprotection after permanent FCI. This lab tested the hypothesis that LIF increases 
neuronal survival after stroke by upregulating SOD enzyme expression and activity.  
Materials and Methods 
Animal care 
All animal procedures were conducted in agreement with the NIH Guide for the Care and 
Use of Laboratory Animals. Experimental protocols were approved by the Institutional Animal 
Care and Use Committee at the University of South Florida. Power analysis was conducted prior 
to experiments to determine the minimum number of animals required to detect significant 
effects. Sprague–Dawley rats were purchased from Harlan Labs (Indianapolis, IN, USA), 
maintained on a 12 h light–dark cycle (07:00–19:00 h) in a climate-controlled room, and allowed 
access to food and water ad libitum. Neurons for in vitro experiments were taken from embryonic 
day 18 (E18) rat pups obtained from timed pregnant dams. Young, male rats weighing 300 to 
350 g were used for in vivo experiments. 
 
Permanent Middle Cerebral Artery Occlusion (MCAO) and Administration of LIF 
Induction of FCI was achieved using the permanent MCAO model as previously 
described (Ajmo, Vernon et al. 2006). Briefly, an incision was made near the sternum and blunt 
dissection was used to expose the common carotid artery.  After ligating and cutting the external 
carotid artery, a 40 mm monofilament was introduced and fed through the internal carotid artery. 
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The monofilament was advanced to the base of the middle cerebral artery. The monofilament 
was secured and the wound was closed using polypropylene sutures. Laser Doppler (Moore Lab 
Instruments, Farmington, CT) was used to confirm the reduction in cerebral blood flow. Animals 
experiencing less than a 60% reduction in CBF were excluded from analysis. For the sham 
MCAO procedure, the common carotid artery was exposed without subsequent occlusion of the 
middle cerebral artery.  Animals were administered recombinant human LIF (ProSpec, Ness 
Ziona, Israel) (125 μg/kg) or vehicle control (PBS pH 7.4) intravenously at 6, 24, and 48 h post-
MCAO. Rats were euthanized 24, 48, and 72 h post-MCAO for immunohistochemistry or 
biochemical analysis. The number of subjects in each treatment group were as follows 24 h PBS: 
n =3; 24 h LIF: n =5; 48 h PBS: n =4; 48 h LIF: n =4; 72 h PBS: n =12; 72 h LIF: n =10.  
Histochemical Analysis 
Tissue sections were prepared for histochemical analysis as previously described (Ajmo 
Jr., Vernon et al. 2008). Following euthanization, animals were perfused transcardially with 
normal saline followed by 4% paraformaldehyde in PBS (pH 7.4). Brains were removed and 
incubated in 4% paraformaldehyde followed by 20% and 30% sucrose solutions. Brains were cut 
into 30 µm sections including bregma -1.7 mm through +3.3 mm. 3, 3-diaminobenzidine (DAB) 
immunohistochemisty was performed as previously described (Hall, Guyer et al. 2009). This 
procedure was also performed as previously described (Rowe, Leonardo et al. 2010) on 18 mm 
glass coverslips containing primary cortical rat neurons. The following antibodies were used for 
immunological detection: mouse α-SOD3 (1:250; Novus Biologicals, Littleton, CO), rabbit α-
phospho-Akt (Ser473) (1:50; Cell Signaling, Danvers, MA) (Rowe, Leonardo et al. 2012) and 
rabbit α-active caspase-3 (1:1000; Sigma-Aldrich, St. Louis, MO) (Rowe, Leonardo et al. 2012). 
Biotinylated secondary antibodies (1:300; Vector Laboratories, Burlingame, CA) were used in 
conjunction with their complimentary primary counterparts.  
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Fluorescent immunohistochemistry was performed on brain tissue sections as previously 
described (Rowe et al., 2010) using rabbit α-microtubule-associated protein 2 (MAP2) (1:200; 
EMD Millipore, Billerica, MA) and mouse α-SOD3 (1:250; Novus Biologicals) (Wang, Harrell et 
al. 2014) antibodies. Tissue sections were also double-labeled with mouse α-SOD3 (1:250; 
Novus Biologicals) and rabbit anti-phospho-Akt (Ser473) (1:50; Cell Signaling) or rabbit-α-LIFR 
(1:200; Santa Cruz Biotechnology, Dallas, TX) (Butzkueven, Zhang et al. 2002) and rabbit α-
MAP2 (1:200; EMD Millipore) (Justice, Yuan et al. 2008) antibodies. AlexaFluor® 488 and 594 
secondary antibodies (1:1000; Life Technologies, Carlsbad, CA) were used for fluorescent 
visualization and slides were mounted using VECTASHIELD® medium containing 4', 6-
diamidino-2-phenylindole (DAPI) (Vector Labs). Images were captured using a Zeiss AxioCam 
color camera attached to a Zeiss AxioSkop2 microscope (Dublin, CA) interfaced with OpenLab 
imaging software (Boston, MA).  
Western Blot Analysis 
Brain tissue was homogenized in whole cell lysis buffer and protein concentrations were 
measured using a Bradford Assay (Bio-Rad, Hercules, CA). Samples were prepared and run on 
SDS-PAGE gels (10% for SOD3, 12% for SOD2 and 15% for SOD1). Nitrocellulose membranes 
were blocked in 5% nonfat milk in TBS + 0.1% Tween (TBST)  for 1h at 25˚C and probed with 
the following primary antibodies overnight at 4˚C: mouse α-SOD3 (1:500; Novus Biologicals) 
(Wang, Harrell et al. 2014), rabbit α-SOD1 (1:500; Abcam, San Francisco, CA) (Marengo, De 
Ciusis et al. 2010) or rabbit α-SOD2 (1:500; Novus Biologicals) (Chen, Lin et al. 2014).   
Membranes were then probed with AlexaFluor® 488 goat α-rabbit IgG (1:250) or AlexaFluor® 
488 goat α-mouse IgG1 (1:250) for 1h at 25˚C and visualized using a Typhoon 9410 Imager  (GE 
Healthcare Life Sciences, Marlborough, MA). Membranes were also probed with mouse α-β-
actin (1:5000; Novus Biologicals) (Lee, Kan et al. 2012) antibodies. All protein bands of interest 
were normalized to β-actin bands to act as a loading control.  
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SOD Inhibition Assay 
Prior to assay, brain tissue samples were diluted in an equal volume of dilution buffer to 
lower detergent concentrations. Percent inhibition of SOD activity was measured according to 
the manufacturer’s protocol (K-Assay, Seattle, WA). Absorbance was measured at 450 nm using 
a µQuant microplate spectrophotometer (Biotek, Winooski, VT) and KC Junior software (BioTek). 
The following equation was used to calculate % inhibition:  
[(A Blank 1 – A Blank3) - (A Sample-A Blank 2)] / (A Blank 1- A Blank 3) * 100% 
Average % Inhibition rates for each set of sample dilutions were graphed using the nonlinear 
regression function. The slope of the linear portion of each standard curve was used to calculate 
the IC50 for each sample. The IC50 and protein concentrations of samples were used to calculate 
units of SOD activity per mg protein lysate (U/mg).   
Cortical Neuronal Cultures 
Rat primary cortical neurons were isolated as previously described (Katnik, Guerrero et 
al. 2006). Cells were counted using the Trypan Blue exclusion method and seeded at a density 
of 800,000 cells/ well into 12 well plates coated with 0.1 mg/ml poly-L-lysine solution. Neurobasal 
complete media containing B-27 supplement and 1.25 mM glutamine (Life Technologies) was 
changed 24 h after seeding and subsequent media changes occurred on a weekly basis. 
Neurons were used between 7 and 15 days in vitro.  
In vitro Ischemia 
Oxygen glucose deprivation (OGD) was performed as previously described to induce in vitro 
ischemia (Hall, Guyer et al. 2009). Cells were given a fresh media change: 1 ml DMEM with 4.5 
g/L D-glucose and sodium pyruvate per well for control cells and 1 ml DMEM without D-glucose 
or sodium pyruvate for cells subjected to OGD. Neurons were treated with either 50 ng/ml, 200 
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ng/ml, or 1000 ng/ml LIF. Sterile filtered PBS was used as a vehicle control for LIF. In another 
experiment, neurons were treated with PBS or 200 ng/ml LIF in the presence or absence of 10 
μM Insolution™ Akt Inhibitor IV (EMD Millipore). This inhibitor blocks the ATP binding site of a 
kinase located upstream of Akt and downsteam of PI3K. DMSO (0.1%) was used as vehicle 
control for Akt Inhibitor IV. Following treatment with LIF and Akt Inhibitor IV, neurons were placed 
in an airtight chamber. This chamber was flushed with a gas mixture containing 94% N2, 5% 
CO2, and 1% O2 (Airgas, Tampa, FL) for 15 min prior to sealing the chamber for 24 h. Following 
the 24 h incubation, cells were removed from the chamber and supernatants were collected to 
measure the release of lactate dehydrogenase (LDH). Cells were washed twice with PBS, 
pelleted via centrifugation, and snap-frozen. Pellets were stored at -80°C for further biochemical 
analyses.   
LDH Assay  
Neuronal death was quantified by measuring the release of LDH as previously described 
(Hall, Guyer et al. 2009) using a colorimetric assay kit (Takara Biosciences, Madison, WI). Cell 
supernatant samples were diluted 1:4 in fresh medium prior to assay to avoid obtaining 
absorbance readings beyond the linear threshold. Absorbance was read at 490 nm using a 
µQuant microplate spectrophotometer (BioTek) and KC Junior software (BioTek). To quantify 
approximate levels of neuronal death, a standard curve was created as previously described 
(Hall, Guyer et al. 2009) by lysing known quantities of neurons with 2% Triton-X-100 and 
measuring LDH release .  
Gene Silencing 
Silencing expression of SOD3 in cortical neurons was achieved via transfection with 
siRNA. This procedure was performed according to manufacturer’s protocol using a 
Nucleofector™ 2b Device and the Amaxa™ Basic Nucleofector™ Kit for primary mammalian 
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neurons (Lonza, Allendale, NJ). Scrambled (Control-A) and siRNA sequences directed against 
the rat SOD3 gene were purchased from Santa Cruz Biotechnology. Freshly isolated cortical 
neurons were transfected with either scrambled or SOD3 siRNA using protocol G-013. Cells 
were removed from cuvettes and seeded into 12 well plates containing pre-equilibrated DMEM 
complete medium. Media was changed to Neurobasal Complete 24 h after seeding. Suppression 
of SOD3 expression was confirmed using quantitative reverse transcriptase PCR (qRT- PCR).  
Two-Step qRT- PCR 
Two-step qRT- PCR was performed as previously described with minor modifications 
(Rowe, Leonardo et al. 2010). AffinityScript® Master Mixes for reverse-transcriptase and qPCR 
reactions were obtained from Agilent Technologies (Santa Clara, CA).  Synthesis of cDNA was 
performed per manufacturer’s instructions in a Mastercycler Gradient thermal cycler (Eppendorf, 
Hauppauge, NY). Reaction components were at 25˚C for 5 min to allow primers to anneal, 42˚C 
for 30 min to allow cDNA synthesis, and 95˚C for 5 min to quench the reaction. Concentration 
and quality of newly synthesized cDNA was determined using a NanoDrop ND-1000 
spectrophotometer (Thermo-Fisher Scientific, Waltham, MA). Primer sequences for rat SOD3 
and GAPDH genes were obtained from Qiagen (Valencia, CA). The qPCR reaction was 
performed according to manufacturer’s instructions using the Chromo4 DNA Engine thermal 
cycler and Opticon™ 3.1 Software (Bio-Rad) with the following steps: 15 min at 95˚C to heat the 
reaction mixture, 30 s at 95 ˚C to denature strands, 30 s at 55˚C to allow primers to anneal, and 
30 s at 72˚C for strand elongation. This denaturing-annealing-elongation cycle was repeated 40 
times. Following the qPCR reaction, melt temperature curve analysis was performed to detect 
the presence of primer-dimers in the reaction mixture. Cycle threshold values were determined 
by setting the threshold to a value where all samples were in the amplification phase.  
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Data Analysis 
All DAB immunohistochemical images were uniformly sharpened and converted to black 
and white using Jasc Paint Shop Pro 9 (Eden Prairie, MN).  Optical density measurements for 
western blot bands and histochemical staining was performed using ImageJ 1.49 (NIH, 
Bethesda, MD) and. All statistical tests were performed using Graphpad Prism 4.0 (La Jolla, CA) 
software and all data are expressed as the mean ± SEM. A Pearson-D’Agostino test was used 
to determine normality among data sets. Unless stated otherwise, experiments were analyzed 
via a one-way ANOVA followed by Fisher’s Protected Least Significant Difference post hoc test. 
Data with significantly different variances between treatment groups or a non-Gaussian 
distribution was analyzed via a Kruskal-Wallis H test. Mann-Whitney U Tests were used to 
determine significance between pairs and a Bonferroni correction was applied to the p value 
based on the number of individual comparisons made. Statistical significance was determined 
using an alpha value set at p = 0.05. All p values reported are one-tailed.  
Results 
LIF increases total SOD activity and SOD3 expression 72 h post-MCAO 
Total SOD activity was measured in brain lysates from rats euthanized 24, 48, or 72 h 
after MCAO or sham surgery. Mean SOD activities were normalized to the mean activity in 
samples from 72 h sham-operated rats. Ipsilateral tissue samples from all MCAO rats 
demonstrated a time-dependent increase in SOD activity from 24 to 72 h, while activities in 
contralateral samples remained stable throughout this period. SOD activities were significantly 
altered among treatment groups at 72 h post-MCAO (H (3) =13.29; p = 0.004). SOD activity was 
significantly higher in LIF-treated ipsilateral tissue compared to PBS-treated ipsilateral tissue (U 
= 1.00; p = 0.0237). In addition, there was a trend towards increased SOD activity in the PBS 
and LIF ipsilateral samples compared to their contralateral counterparts (Fig. 2.1a).  
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Western blotting was used to determine protein expression of SOD1, SOD2, and SOD3 
in brain tissue from rats euthanized 72 h post-MCAO. At 72h post-MCAO, SOD1 was only 
significantly induced in contralateral tissue from LIF treated rats (p = 0.0051, F4,10 = 7.321). 
Contralateral SOD1 expression from LIF-treated rats was significantly higher than that of 
ipsilateral tissue from PBS-injected rats (p = 0.0026) and ipsilateral tissue from the same 
treatment group (p = 0.0004; Fig. 2.1b). There were no significant differences in SOD2 
expression between tissue samples at this time point (H (4) = 8.400; p = 0.0780), but there was 
trend toward decreased SOD2 expression in ipsilateral tissue from LIF-treated rats compared to 
other samples (Fig. 2.1c). SOD3 expression was significantly higher in ipsilateral tissue from LIF-
treated rats (p = 0.0021, F4,10  = 9.271) compared to ipsilateral tissue from PBS-treated rats (p = 
0.0111) and sham-treated rats (p = 0.008; Fig. 2.1d). SOD3 expression remained relatively 
constant between the sham and contralateral samples.  
Immunohistochemistry was used to visualize SOD3 expression within the intact cortical 
tissue. Representative images show several SOD3-positive cells in the ipsilateral cortex of PBS-
treated rats. However, these SOD3-positive cells appeared dysmorphic (black arrows) and many 
cells were surrounded by noticeable tissue lesions. By contrast, stained ipsilateral tissue from 
LIF-treated rats revealed SOD3-positive cells that retained a common triangular morphology 
compared to those found in PBS-treated rats. These cells were arranged in an orderly fashion 
and less tissue damage was observed in the LIF-treated rat brains. Contralateral cortical staining 
from both treatment groups did not reveal noticeable SOD3 staining (Fig. 2.2a). Quantitative 
analysis of cortical staining revealed induction of SOD3 in the ipsilateral cortex following LIF 
treatment (p < 0.0001, F3,15  = 24.38). Among PBS-treated rats, elevated levels of SOD3 were 
observed in the ipsilateral cortex compared to the contralateral cortex (p = 0.0111). However, 
LIF treatment yielded significantly higher SOD3 expression in the ipsilateral cortex compared to 
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PBS treatment (p = 0.0048). Levels of SOD3 staining were normalized to sham tissue to account 
for baseline SOD3 expression in the ipsilateral cortex (Fig. 2.2b). 
SOD3 is induced in cortical neurons following LIF treatment  
To determine whether LIF exerts positive neurotrophic effects on cortical neurons, brain 
tissue sections and cultured neurons were labeled with antibodies against LIFR and MAP2. 
Staining revealed localization of LIFR in neurons of the cerebral cortex (Fig. 2.3a). Cultured 
cortical neurons also expressed basal LIFR levels under physiological in vitro conditions (Fig. 
2.3b). Tissue sections from LIF-treated animals that were euthanized 24 h and 72 h post-MCAO 
were double-labeled with SOD3 and MAP2 antibodies. MAP2-positive neurons were observed 
at 24 and 72 h after MCAO (Figs. 2.3c, 2.3d). Likewise, SOD3-positive cells were also visualized 
at these time points (Figs. 2.3e, 2.3f).  DAPI was used to indicate the presence of cell nuclei at 
both time points (Figs. 2.3g, 2.3h). Co-localization of SOD3 and MAP2 was observed at 24 h and 
72 h after MCAO, indicating the presence of SOD3-positive neurons at both time points (Figs. 
2.3i, 2.3j).  
To determine whether this increase in neuronal SOD3  occurred in conjunction with  Akt 
activation, tissue sections from LIF-treated rats euthanized at 24 h and 72 h after MCAO were 
double-labeled with antibodies against SOD3 and Akt phosphorylated on residue Ser473 
(phospho-Akt). Several cells stained positive for phospho-Akt at 24 h and 72 h post-MCAO (Figs. 
2.4a, 2.4b). Likewise, SOD3 positive cells were also visualized at both time points (Figs. 2.4c, 
2.4d). Cell nuclei were labeled using DAPI at 24 and 72 h post-MCAO (Figs. 2.4e, 2.4f) Cells 
staining positive for phospho-Akt and SOD3 were observed at 24 h and 72 h post-MCAO (Figs. 
2.4g, 2.4h).  
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LIF protects neurons from in vitro ischemic damage  
This laboratory previously demonstrated that 200 ng/ml LIF protects oligodendrocytes 
during OGD(Rowe, Collier et al. 2014). A similar concentration response experiment was 
performed to determine whether this concentration of LIF confers neuroprotection against in vitro 
ischemia. Subjecting neurons to 24 h OGD and treating with LIF yielded a significant change in 
LDH release (H (7) =25.74; p = 0.0006) Treating cells with 200 ng/ml LIF significantly decreased 
LDH release compared to PBS-treated neurons that were subjected to the same 24 h OGD 
exposure (U = 7.000; p = 0.0256; Fig. 2.5a). To confirm the results of the LDH assay, neuronal 
cultures were subjected to the same conditions and treatments but were subsequently labeled 
with antibodies generated against activated caspase-3. Representative images show levels of 
active caspase-3 in neurons following 24 h normoxia, 24 h OGD + PBS, or 24 h OGD + 200 
ng/ml LIF (Fig. 2.5b). Immunohistochemical analysis revealed significant changes in caspase-3 
activation triggered by OGD exposure and LIF treatment (p = 0.0003, F2,9  = 23.57). Caspase-3 
immunoreactivity was significantly higher after 24 h OGD + PBS compared to 24 h normoxia (p 
= 0.0003) while LIF treatment reduced caspase-3 activation during OGD compared to PBS 
treatment (p = 0.0128; Fig. 2.5c).  
Neuroprotective Effects of LIF are dependent upon Akt activity  
To determine whether the protective effects of LIF are dependent upon Akt activity, 
neurons were treated with PBS + 0.1% DMSO, 200 ng/ml LIF + 0.1% DMSO, PBS + 10 μM Akt 
Inhibitor IV, or 200 ng/ml LIF + 10 μM Akt Inhibitor IV prior to OGD.  LIF and Akt IV treatment 
both exerted significant effects on LDH release following 4 h OGD (H (3) = 17.55; p = 0.0005). 
Treatment with 200 ng LIF significantly reduced LDH release compared to PBS (U = 15.00; p = 
0.0012). Co-incubating cells with 10 μM Akt Inhibitor IV and LIF yielded significantly higher levels 
of LDH compared to neurons treated with  LIF alone (U = 19.00; p = 0.0024; Fig. 2.6a). To 
determine whether this decrease in neuronal death correlated with higher expression of SOD3 
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in vitro, representative coverslips subjected to 24 h normoxia or 24 h OGD with DMSO + PBS, 
DMSO + LIF, Akt Inhibitor IV + PBS, or Akt Inhibitor IV + LIF treatment were stained with 
antibodies directed against phospho-Akt or SOD3. Neurons incubated under normoxia revealed 
low basal levels of phospho-Akt and SOD3 (Figs. 2.6b, 2.6c). Cells treated with DMSO + PBS 
followed by 24 h OGD yielded higher levels of phospho-Akt and SOD3 compared to normoxic 
cells.  (Figs. 2.6d, 2.6e). However, neurons that were treated with DMSO + LIF prior to OGD 
showed high levels of phospho-Akt and SOD3 while returning to the healthy morphology seen in 
normoxic cells (Figs. 2.6f, 2.6g). Treatment with Akt Inhibitor IV + PBS prior to OGD decreased 
phospho-Akt compared to the neurons treated with DMSO + PBS (Fig. 2.6h), but SOD3 levels 
did not change (Fig. 2.6i). Co-incubation with LIF and Akt Inhibitor IV lowered phospho-Akt and 
SOD3 staining compared to neurons treated with DMSO + LIF (Figs. 2.6j, 2.6k).  
Neuroprotection against OGD by LIF is dependent upon increased SOD3 
Expression  
Transfection with siRNA and treatment with LIF prior to 24 h OGD significantly altered 
levels of SOD3 mRNA in primary cortical neurons (p < 0.0001, F3,17 = 17.51). LIF significantly 
increased SOD3 mRNA compared to PBS treatment in cells transfected with scrambled siRNA 
(p = 0.0023). Transfection with SOD3 siRNA significantly downregulated expression of SOD3 
compared to scrambled siRNA (p = 0.0165). Transfection with SOD3 siRNA prior to LIF treatment 
significantly decreased SOD3 expression compared to scrambled siRNA+ PBS cells (p = 0.0212) 
and siRNA + LIF cells (p = 0.0005; Fig. 2.7a). LIF and siRNA treatment yielded an overall trend 
towards altered LDH release following 24 h OGD (p = 0.1701, F3,8 = 2.165). However, LIF 
treatment significantly reduced LDH release among neurons transfected with scrambled siRNA 
(p < 0.05; Bonferroni method; Fig. 2.7b).  Representative images show levels of active caspase-
3 among treatment groups (Fig. 2.7c). Treatment with LIF and SOD3 siRNA significantly altered 
caspase-3 activation following OGD (p = 0.0002, F3,13 = 14.50).  LIF significantly reduced 
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caspase-3 activation following OGD compared to PBS treatment among scrambled siRNA-
transfected cells (p = 0.0104). SOD3 siRNA + PBS treatment prior to OGD significantly increased 
activation of caspase-3 compared to scrambled siRNA + PBS treatment (p = 0.0003). LIF 
significantly lowered caspase-3 activation compared to PBS among SOD3 siRNA-transfected 
cells (p = 0.0214). However, SOD3 knockdown prevented LIF from reducing caspase-3 
activation compared to scrambled siRNA + PBS cells (Fig. 2.7d).  
Discussion 
SOD3, unlike SOD1 and SOD2, is not highly expressed by neural cells under normal 
physiological conditions (Folz and Crapo 1994, Chan 2001). Nonetheless, several distinct 
neuronal populations will upregulate SOD3 following FCI, including cortical and striatal neurons 
(Fukui, Ookawara et al. 2002).  These data demonstrate that LIF treatment further increases 
SOD3 in neurons following ischemic injury.  At 72 h post-MCAO, antibodies against SOD3 
detected three Western blot bands corresponding to the monomer (40 kDa), dimer (80 kDa), and 
tetramer (140 kDa) of SOD3. Wild-type SOD3 is expressed as a dimer in rats, compared to the 
tetrameric human and murine isoforms, a single point mutation of the Asp residue at position 24 
may yield a tetrameric SOD3 isoform (Carlsson, Marklund et al. 1996). This mutant isoform may 
correspond to the smaller, high molecular weight band at 140 kDa. These findings were further 
confirmed by measuring SOD3 immunoreactivity in the cerebral cortex. Immunohistochemical 
analysis revealed higher levels of SOD3 in the ipsilateral tissue of sham rats compared to the 
ipsilateral cortex of PBS-treated rats. The higher level of staining is most likely due to the higher 
number of viable neural cells in the cortex after sham operation compared to MCAO. Cells 
expressing SOD3 after LIF treatment had a morphology resembling pyramidal neurons, and 
double-labeling tissue with MAP2 and SOD3 antibodies confirmed neuronal localization of 
SOD3.  
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Western blotting and histochemical analysis revealed that SOD3 was upregulated in the 
ipsilateral, but not contralateral hemisphere at 72 h post-MCAO. The absence of LIF-mediated 
cellular protection under normoxia reflects previous findings with cultured oligodendrocytes 
(Rowe, Collier et al. 2014). Decreased LDH release from cultured oligodendrocytes following LIF 
treatment was not observed under normoxia, but LIF significantly reduced LDH release during 
OGD (Rowe, Collier et al. 2014). Although LIF is transported into the brain via an ATP-dependent 
carrier (Pan, Kastin et al. 2000), Pan et al. demonstrated that LIF transport increases following 
neuronal injury (Pan, Cain et al. 2006). Breakdown of the BBB following permanent FCI (Kastrup, 
Engelhorn et al. 1999) could allow LIF to reach the ipsilateral hemisphere via paracellular 
transport. In addition, negative feedback mechanisms that regulate PI3K/Akt signaling under 
physiological conditions are compromised under FCI (Omori, Jin et al. 2002). Finally, minimal 
levels of cellular death under normoxia may account for the lack of significant LIF-mediated 
neuroprotection under normoxic conditions. Despite the overall increase in SOD activity, neither 
SOD1 nor SOD2 expression was significantly altered from the ipsilateral tissue of PBS-treated 
rats. The trend towards decreased SOD2 expression in the ipsilateral hemisphere of LIF-treated 
rats is most likely due to increased activation of Akt. Previous findings show that Akt may 
downregulate SOD2 expression via inactivation of the transcription factor FoxO3 (Li, Chiu et al. 
2006, Laatikainen, Incoronato et al. 2011, Du, Yu et al. 2013). Significantly higher levels of SOD1 
at 72 h post-MCAO were observed after LIF treatment, but only in contralateral tissue. This 
finding reflects studies where LIF treatment ameliorates the ALS-like symptoms seen in G93A 
mice (Azari, Galle et al. 2001, Azari, Profyris et al. 2006). Although western blotting did not show 
increased SOD1 in the ipsilateral tissue of LIF-treated rats, ischemic conditions may cause SOD1 
to aggregate. These insoluble aggregates would not be detected in the portion of lysates used 
for western blot analysis (Chen, Guan et al. 2012). 
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 The answer to the difference between the efficacies of LIF under normoxia vs ischemia 
may lie in the regulation of LIFR/gp130.  Immunohistochemical detection of LIFR in neurons 
incubated under normoxia showed that LIF could hypothetically trigger protective signaling in the 
absence of ischemia.  Moreover, oligodendrocytes express LIFR under basal conditions 
(Butzkueven, Zhang et al. 2002). Future studies may be needed to further explain how LIF signal 
transduction is regulated in neurons. Several groups reported that the termination of LIF signaling 
is facilitated via the phosphorylation of both receptor subunits (Gibson, Schiemann et al. 2000, 
Radtke, Wüller et al. 2010). Our immunohistochemical staining reveals high levels of nuclear 
LIFR in the absence of LIF signaling. Nuclear LIFR was previously seen under physiological 
conditions in several cell types, including neurons of the dorsal root ganglion. However, injury to 
the dorsal root ganglion caused LIFR to translocate from the nucleus to the cytoplasm (1999, 
Gardiner, Cafferty et al. 2002). Endocytosis of LIFR and gp130 have been previously reported 
by multiple independent groups (Gerhartz, Dittrich et al. 1994, Thiel, Behrmann et al. 1999, 
Blanchard, Duplomb et al. 2000).  While the internalization of LIFR may precede its degradation, 
it is also possible that the majority of LIFR remains in the nucleus until stimulation with LIF 
promotes its trafficking to the cell membrane.   
The increase in SOD3 mRNA and decrease in LDH release/caspase-3 activation 
following LIF treatment indicates that upregulation of SOD3 is responsible for LIF’s protective 
effects protection against OGD. Furthermore, LIF-treated neurons that were previously 
transfected with SOD3 siRNA showed no significant difference in LDH release and caspase-3 
activation compared to PBS-treated neurons transfected with scrambled siRNA. These results 
indicate that LIF primarily protects neurons against ischemic oxidative damage via SOD3 
upregulation. LIF and siRNA treatment yielded a significant overall change among treatment 
groups when caspase-3 activation was measured, but not LDH. This discrepancy between these 
results could be due to several factors. LDH release corresponds to the rate of necrosis (Chan, 
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Moriwaki et al. 2013) while caspase-3 cleavage corresponds to apoptosis. Previous research 
indicates that neurons undergo both processes during FCI (Choi 1996, Broughton, Reutens et 
al. 2009). Caspase-3 activation may be detected prior to LDH release, indicating that staining 
will identify cells with intact membranes that are beginning to undergo programmed death 
(Shioiri, Muroi et al. 2009). Moreover, the larger increase in caspase-3 activation may be due to 
the inhibitory effect of SOD3 and active Akt on caspase-3-mediated apoptosis (Gao, Ordas et al. 
2008, Laatikainen, Incoronato et al. 2011).   
Previous data from this lab indicated that injection of LIF improved several outcomes 
including infarct size, white matter damage, and functional motor skills at 72 h after permanent 
FCI. In vitro experiments using cultured oligodendrocytes and Prdx4 antibodies confirmed that 
the ability of LIF to reduce oxidative damage to white matter during stroke is primarily dependent 
upon its upregulation of Prdx4 through PI3K/Akt signaling (Rowe, Collier et al. 2014). Prdx4, not 
unlike SOD3, may be secreted into the extracellular environment to scavenge ROS (Okado-
Matsumoto, Matsumoto et al. 2000, Sasagawa, Matsuki et al. 2001). By neutralizing extracellular 
ROS, enzymes such as SOD3 and Prdx4 may protect other cells in the parenchyma by 
preventing further intracellular damage. LIF-mediated upregulation of SOD3 and Prdx4 in the 
brain may help regulate redox balance after FCI. Since hydrogen peroxide and water are 
products of SOD-catalyzed reactions, higher SOD3 expression could potentially lead to excess 
peroxidation of cellular components. Peroxiredoxin family enzymes catalyze the breakdown of 
hydrogen peroxide to water and oxygen (Kang, Chae et al. 1998, Rhee, Kang et al. 2001, 
Lehtonen, Svensk et al. 2004). Therefore, increased Prxd4 expression following LIF treatment 
would prevent the buildup of hydrogen peroxide generated from excess SOD activity.  
 Although results from in vitro experiments indicate that the neuroprotective effects of LIF 
are attenuated following siRNA-mediated knockdown of SOD3, this does not necessarily mean 
that SOD3 upregulation is the only mechanism of in vivo neuroprotection. Unfortunately, there 
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are no selective SOD3 inhibitors that could be administered following MCAO. Due to the lack of 
tissue-specific knockout rats available, obtaining a neuron-specific SOD3 knockout rat strain for 
these experiments would be difficult. To demonstrate that induction of Prdx4 was necessary for 
in vitro oligoprotection, this laboratory used neutralizing antibodies to block Prdx4 activity prior 
to OGD (Rowe, Collier et al. 2014). It is likely that the improvement in sensimotor skills and 
smaller infarct volume after LIF treatment may be attributed to protective mechanisms other than 
Prdx4 induction. This lab has shown that LIF confers protection in multiple neural cell types 
during ischemia. Moreover, systemic LIF administration may result in additional protection that 
is independent of its effects on cell survival. For instance, LIF plays a crucial role in the 
development of regulatory T lymphocytes and anti-inflammatory macrophages/microglia 
(Metcalfe 2011, Janssens, Slaets et al. 2015). As a result, LIF may reduce neurodegeneration 
triggered by the release of inflammatory splenocytes after stroke. Further investigation will be 
necessary to determine whether its primary neuroprotective mechanism in vivo is dependent 
upon SOD3.  
This laboratory previously measured infarct volume after LIF treatment using Fluoro-Jade 
staining due to its ability to specifically label dying neurons (Schmued, Albertson et al. 1997, 
Rowe, Collier et al. 2014). Although a lower number of viable neurons in the infarct and penumbra 
could contribute to a significant reduction in the total area of Fluoro-Jade-positive tissue, the 
improvement in motor skills among LIF-treated rats indicated that LIF reduced neuronal 
degradation in addition to protecting oligodendrocytes in vivo (Gardiner, Cafferty et al. 2002).  
Previous studies indicate that LIF mRNA levels are approximately thirty times higher in 
astrocytes 6 h after cortical brain injury compared to pre-injury levels. Microglia were also found 
to have elevated levels of LIF mRNA at this same time point (Banner, Moayeri et al. 1997). This 
upregulation of LIF transcript following injury to the gray matter indicates that LIF may serve as 
an endogenous protective factor against neuronal injury. However, the magnitude of damage 
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observed after our model permanent FCI indicates that endogenous LIF release is not sufficient 
to rescue neurons in the penumbra. These data indicate that damage may be reduced via 
exogenous supplementation of LIF following injury.  
Further studies will be needed to determine the mechanism of LIF-mediated upregulation of 
SOD3 in neurons. Our group and others have demonstrated that LIF controls the expression of 
protective genes at the transcriptional level (Rowe, Collier et al. 2014, Umoh, Walker et al. 2014).  
Therefore, LIF may be activating transcription factors downstream of Akt. The reduced infarct 
size and improved motor skills observed after LIF treatment   in previous studies suggest that it 
may exert pro-survival effects independent of antioxidant enzymes (Rowe, Collier et al. 2014). 
Nevertheless, the ability to induce protective antioxidant enzymes makes LIF a promising 
treatment that will protect neural cells against immediate and delayed damage following ischemic 
stroke.  
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Figure 2.1. LIF increases SOD activity and SOD3 Expression. (a) Total SOD activity was 
measured in brain lysates from PBS and LIF-treated rats euthanized 24, 48, or 72 h post-MCAO. 
LIF ipsilateral samples had significantly higher SOD activity compared to PBS-treated ipsilateral 
samples at 72 h post-MCAO (*p<0.05). Mean activities were normalized to SOD activity in brains 
from sham rats. n ≥ 5 samples per group.  (b) At 72 h after MCAO, SOD1 expression was 
significantly increased in contralateral tissue of LIF-treated rats, compared to ipsilateral tissue 
from PBS-treated rat (*p<0.01)  and ipsilateral tissue from the same treatment group (#p<0.001). 
SOD1 bands were observed at approximately 18 kDa. (c) There was a trend towards decreased 
SOD2 expression in the ipsilateral samples from the LIF group; however, this decrease was not 
significant. SOD2 bands were observed at approximately 25 kDa. (d) Ipsilateral samples from 
LIF-treated rats showed a corresponding increase in SOD3 expression compared to PBS 
(*p<0.05) and sham (#p<0.01) ipsilateral samples. Three bands corresponding to SOD3 were 
observed in all samples at approximately 50, 80, and 130 kDa. n = 3 samples per group. Ips: 
ipsilateral; Contra: contralateral. 
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Figure 2.2. LIF upregulates SOD3 in the Ipsilateral Cortex. (a) Representative images of 
cortical tissue from PBS rats show higher levels of SOD3 staining compared to contralateral 
tissue from the same group. However, these cells appeared dysmorphic and unhealthy.  LIF 
treatment increased SOD3 expression in the ipsilateral cerebral cortex while visibly reducing 
damage to SOD3-positive cells and surrounding tissue. (b) After normalizing to sham SOD3 
levels, immunohistochemical quantification revealed significantly higher levels of staining in 
ipsilateral tissue compared to contralateral tissue in PBS-treated rats (*p<0.05). LIF treatment 
further raised SOD3 in the ipsilateral tissue compared to PBS (#p<0.01). n = 5 per treatment 
group. Scale bars = 50 μm. Ips: ipsilateral; Contra: contralateral.  
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Figure 2.3. Cortical Neurons Express SOD3 after LIF Treatment. (a) Co-labeling tissue with 
MAP2 (green) and LIFR (red) antibodies revealed localization of LIFR in the neuronal somata. 
LIFR was concentrated primarily in the cytoplasm and perinuclear region. (b) Cultures of cortical 
neurons also showed LIFR staining in the cell bodies. Following LIF treatment, neurons stained 
positive for MAP2 at (c) 24 h and (d) 72 h post-MCAO. SOD3 immunoreactivity was observed in 
the brains of LIF-treated rats at (e) 24 and (f) 72 h after MCAO (g, h). DAPI was used to stain for 
cell nuclei. (i, j) Co-localization with the neuronal marker MAP2 indicates that SOD3 is expressed 
by neurons in vivo following LIF treatment. Scale bars = 20 µm.  
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Figure 2.4. SOD3 co-localizes with Phospho-Akt (Ser473). Levels of phospho-Akt (Ser473) 
increased from (a) 24 h to (b) 72 h after MCAO, which corresponded with increased SOD3 
staining over this same time period (c, d). DAPI was used to stain for cell nuclei (e, f). The number 
of cells staining positive for phospho-Akt (Ser473) and SOD3 increased from (g) 24 h to (h) 72 h 
post-MCAO. Arrows indicate representative cells. Scale bars = 20 μm. P-Akt: phospho-Akt 
(Ser473).  
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Figure 2.5. LIF treatment protects neurons in vitro against OGD. (a) Following 24 h OGD, 
200 ng/ml LIF significantly reduced cell death compared to PBS treatment (#p<0.05). n ≥ 3 per 
treatment group. (b) Images show neurons stained with α-active caspase-3 antibodies after 24 
h normoxia, 24 h OGD + PBS and 24 h OGD + 200 ng/ml LIF. Arrows identify representative 
cells. (c) Neurons treated with PBS prior to OGD had significantly higher levels of active caspase-
3 (*p<0.001) compared to the 24 h normoxia group. LIF treatment prior to 24 h OGD decreased 
caspase-3 activation compared to PBS (#p<0.05). Arrows identify representative cells. n = 4 per 
treatment group. Scale bar = 50 µm. Norm = 24 h Normoxia.  
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Figure 2.6. In vitro neuroprotection by LIF is dependent upon Akt activity. (a) LIF treatment 
significantly lowered neuronal death during OGD compared to PBS (*p<0.001). Akt IV reverses 
the neuroprotective effect of LIF treatment alone (#p<0.01) n = 12 per treatment group. 
Representative images show (b) p-Akt and (c) SOD3 immunoreactivity in neurons under 
normoxia.  DMSO + PBS treatment before 24 h OGD increased (d) p-Akt and (e) SOD3 levels 
compared to 24 h normoxia. (f) Phospho-Akt (Ser473) and (g) SOD3 levels were highest in cells 
treated with DMSO + LIF before OGD. Addition of Akt IV + PBS prior to OGD caused (h) a 
minimal decrease in phospho-Akt (Ser473) and (i) no change to SOD3 levels compared to the 
DMSO + PBS group. Co-incubation with Akt Inhibitor IV + LIF prior to OGD prevented the LIF-
induced increase in (j) phospho-Akt (Ser473) and (k) SOD3 expression. Arrows identify 
representative cells. P-Akt = phospho-Akt (Ser473); Akt IV = Akt Inhibitor IV.  Scale bar = 25 µm. 
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Figure 2.7. LIF Increases Cell Survival by Upregulating SOD3. (a) LIF treatment prior to 24 
h OGD increased SOD3 mRNA among neurons transfected with scrambled siRNA (*p<0.01). 
SOD3 siRNA treatment + PBS prior to OGD significantly decreased SOD3 mRNA compared to 
scrambled siRNA + PBS (#p<0.05). SOD3 siRNA + LIF reduced SOD3 mRNA compared to 
scrambled siRNA + LIF (^p<0.001) and scrambled siRNA + PBS. n ≥ 4 per treatment group. (b) 
LDH release was significantly lower in scrambled siRNA-transfected cells treated with LIF 
compared to their PBS-treated counterparts (*p<0.05) while LIF treatment did not reduce LDH 
release in SOD3 siRNA-transfected cells compared to SOD3 siRNA + PBS cells. n =3 per 
treatment group. (c) Representative cells show levels of active caspase-3 among treatment 
groups. (d) Active caspase-3 immunoreactivity was significantly reduced by LIF treatment in 
neurons transfected with scrambled siRNA compared to Scr + PBS cells (*p<0.05).  Transfection 
with SOD3 siRNA + PBS treatment significantly increased caspase-3 activation compared to Scr 
+ PBS treatment (#p<0.001). SOD3 siRNA + LIF cells had significantly lower levels of active 
caspase-3 compared to SOD3 siRNA + PBS cells (^p<0.05), but not Scr + PBS cells. n ≥ 3 per 
treatment group. Scr = scrambled siRNA. Scale bar = 50 µm.  
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CHAPTER 3: 
NEUROPROTECTIVE ACTIONS OF LEUKEMIA INHIBITORY FACTOR ARE DEPENDENT 
UPON MYELOID ZINC FINGER-1 AND SPECIFICITY PROTEIN 1 
Note to Reader 
Some of the data showing SOD3 mRNA expression was previously published by Davis 
et al. (Davis, Collier et al. 2016) as well as in Chapter 2 of this discussion. Stephanie Davis was 
the main author on this section of the manuscript. However, assistance with experimentation and 
editing was provided by Lisa A. Collier, Jawad A. Fazal, Dr. Christopher C. Leonardo, and Dr. 
Craig T. Ajmo Jr. This project was overseen by Dr. Keith R. Pennypacker.   
Abstract 
 This lab previously demonstrated that leukemia inhibitory factor (LIF) protects neurons 
and oligodendrocytes (OLs) during stroke via the upregulation of antioxidant enzymes. The 
hypothesis of this study was to determine whether LIF exerts its neuroprotective effects through 
activation of the transcription factors myeloid zinc finger-1 (MZF-1) and specificity protein 1 
(Sp1). The promoter region of the rat superoxide dismutase 3 (SOD3) gene was examined for 
MZF-1 and Sp1 binding sites using Genomatix software. Stroke was induced via middle cerebral 
artery occlusion and animals were administered PBS or 125 µg/kg LIF at 6, 24, and 48 h after 
the injury. Cortical neurons isolated from E18 embryonic rat pups were transfected with 
scrambled, MZF-1, or Sp1 siRNA were subjected to 24 h ischemia after PBS or LIF treatment. 
Genomatix identified four MZF-1 sites and two Sp1 sites in the SOD3 promoter. There was a 
trend towards MZF-1 upregulation in brain the brains of LIF-treated rats compared to PBS-
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treated rats at 72 h post-MCAO and significantly higher levels of MZF-1 mRNA after LIF 
treatment in primary cortical neurons. Moreover, neurons that expressed higher levels of MZF-1 
after LIF treatment had upregulated SOD3 as well. There was trend towards higher Sp1 
expression after LIF treatment in brain tissue and no change in Sp1 mRNA among primary 
neurons. However, there was a significant correlation between MZF-1 and Sp1 levels in the 
brains of LIF-treated rats and nuclear localization of Sp1 and MZF-1 in neuronal tissue. At 72 h 
after MCAO. At this time point, co-localization of SOD3 and MZF-1/Sp1 was observed in the 
cerebral cortex of LIF-treated rats. Finally, knockdown of Sp1 and MZF-1 using siRNA 
counteracted the neuroprotective effects of LIF in vitro. These data demonstrate that LIF-
mediated neuroprotection is dependent upon Sp1 and MZF-1, and LIF increases MZF-1 gene 
expression. 
Introduction 
According to the National Center for Health Statistics, ischemic stroke remains the fifth 
leading cause of death in the United States as well as a major cause of adult disability (Talwalkar, 
Uddin et al. 2015).  Treatment with thrombolytic agents, such as tissue plasminogen activator, 
may be effective in curbing neurological damage during the early phases of stroke pathology 
(Hacke, Kaste et al. 2008). Cellular damage in the first few hours following focal cerebral 
ischemia (FCI) may be attributed to increased transmission of glutamate and the Ca2+-
dependent activation of apoptotic signaling and pro-oxidant enzymes (Dawson, Dawson et al. 
1991, Brennan, Won Suh et al. 2009). 
 Although thrombolytic therapy may decrease excitotoxicity during this period, it is 
ineffective at treating the symptoms of delayed neuroinflammation, which occurs hours to days 
after the onset of stroke (Dirnagl, Iadecola et al. 1999). During this period, the survival of cells 
within the penumbra, the area surrounding the ischemic core, is compromised by several factors. 
Dying cells in the ischemic core release factors such as high-mobility group box 1 (HMGB1) 
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(Faraco, Fossati et al. 2007) and ATP(Davalos, Grutzendler et al. 2005), which contribute to the 
activation of microglia. Activated microglia release pro-inflammatory cytokines and matrix 
metalloproteinases that increase blood-brain barrier permeability (Gasche, Copin et al. 2001, 
McColl, Rothwell et al. 2008, Leonardo, Hall et al. 2010, Taylor and Sansing 2013). Peripheral 
leukocyte populations infiltrate the parenchyma and further damage cells in the parenchyma by 
releasing reactive oxygen species (ROS) and other inflammatory mediators (Offner, 
Subramanian et al. 2006).  
In order to maximize cell survival during this phase of stroke pathophysiology, several 
groups have focused on therapies that upregulate protective genes in neural cells.  For instance, 
this laboratory demonstrated that human umbilical cord blood (HUCB) cells upregulate genes 
involved with survival signaling after focal cerebral ischemia. These protective genes that are 
induced by HUCBs, increase the survival of oligodendrocytes (OLs). Among these genes 
induced by HUCB treatment were the antioxidant enzymes metallothionein III (Mt3) and 
peroxiredoxin IV (Prdx4) (Rowe, Leonardo et al. 2010, Rowe, Leonardo et al. 2012). Prdx4 gene 
expression was also elevated in OLs after treatment with leukemia inhibitory factor, an anti-
inflammatory cytokine that confers cellular protection in an Akt-dependent manner (Rowe, Collier 
et al. 2014). Furthermore, this laboratory identified common transcription factors (TFs) with 
putative binding sites in the promoter regions the genes induced by HUCB cells, including of Mt3 
and Prdx4. Among these TFs were myeloid zinc finger-1 (MZF-1) and specificity protein 1 (Sp1) 
(Rowe, Leonardo et al. 2010). 
MZF-1 belongs to the Kruppel family of TFs and is highly expressed by cells of myeloid 
origin (Hromas, Collins et al. 1991). Although previously implicated in hematopoietic 
development, MZF-1 modulates expression of several genes that play a role in stroke 
pathogenesis/recovery (Morris, Davis et al. 1995, Hromas, Davis et al. 1996).  Apomorphine 
stimulates upregulation of fibroblast growth factor-2, a neuroprotective factor, in astrocytes 
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through MZF-1 activity (Luo, Zhang et al. 2009). MZF-1 binding sites were identified in the 
promoter region for peroxiredoxin I, a member of the peroxiredoxin family that is highly expressed 
by OLs (Mizusawa, Ishii et al. 2000, Kim, Bogner et al. 2008).  In addition, levels of MMP-2, a 
gelatinase released by activated microglia during stroke, were significantly decreased by 
overexpressing MZF-1 in the SiHa cervical cancer line(Tsai, Hwang et al. 2012).  Studies indicate 
that the activity of MZF-1 is regulated via its protein expression. For instance, calcitriol regulates 
CD11b and CD14 expression in mononuclear cells by upregulating MZF-1 protein levels in a 
PI3K-dependent manner (Moeenrezakhanlou, Shephard et al. 2008). Granulocyte/macrophage 
colony stimulating factor (GM-CSF), a cytokine implicated in leukocyte maturation, increases 
neuronal survival through PI3K/Akt activation (Takahashi, Hayashi et al. 2006, Schabitz, Kruger 
et al. 2007). In addition, GM-CSF has also been shown to increase levels of MZF-1(Hui, Guo et 
al. 1995).  
Specificity protein 1, a ubiquitously expressed zinc finger protein, has also been shown 
to confer protection against ischemic and oxidative damage by several independent groups. 
Upregulation of Sp1 and Sp3 was observed in primary cortical neurons subjected to in vitro 
glutathione depletion (Ryu, Lee et al. 2003). During myocardial and hepatic ischemia, Sp1 
enhances the response to cellular injury by increasing the gene expression of ectonucleoside-
triphosphate-diphosphohydrolase-1, the enzyme that converts ATP to adenosine (Eltzschig, 
Köhler et al. 2009, Hart, Gorzolla et al. 2010). This enzyme is also implicated in restoring cerebral 
perfusion during ischemic stroke; animals that were administered the soluble form of this enzyme 
3 h after transient stroke demonstrated a significant reduction in infarct volume (Belayev, 
Khoutorova et al. 2003). Yeh et al. determined that Sp1 activity is triggered by increased levels 
of hydrogen peroxide during stroke. Moreover, administration of the Sp1-specific inhibitors 
mythramycin A or WP631 following middle cerebral artery occlusion (MCAO) exacerbated 
ischemic injury compared to MCAO alone(Yeh, Yang et al. 2011).  
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MZF-1 and Sp1 share a common role in the regulation of superoxide dismutase (SOD) 
3, a secreted antioxidant enzyme (Zelko and Folz 2003, Zelko and Folz 2004). Although basal 
expression of SOD3 remains highest in vascular smooth muscle, blood, and lung tissue, cortical 
neurons increase the gene expression of SOD3 as an endogenous defense mechanism against 
ischemia. This laboratory previously discovered an essential role for the upregulation of SOD3 
in leukemia inhibitory factor (LIF)-mediated neuroprotection after MCAO (Davis, Collier et al. 
2016). Although quantitative PCR data from this study indicated that LIF increases expression 
of SOD3 at the transcriptional level, the specific TFs that regulate its expression downstream of 
LIF signaling are currently unknown. Considering the roles of MZF-1 and Sp1 in HUCB-mediated 
oligoprotection and regulation of SOD3 in other tissues, they may be responsible for inducing 
SOD3 in neurons after LIF treatment. This study will test the hypothesis that MZF-1 and Sp1 are 
essential for the LIF-mediated neuroprotection, which leads to the elevated expression for 
antioxidant enzymes.   
Materials and Methods 
Animal Care  
Animal procedures were performed according to the NIH Guide for the Care and Use of 
Laboratory Animals and pre-approved by the Institutional Animal Care and Use Committee at 
the University of South Florida. The minimum number of animals needed for each study was 
determined using power analysis. All procedures were performed on Sprague–Dawley rats were 
purchased from Envigo (Indianapolis, IN, USA). Animals were maintained on a 12 h light–dark 
cycle (07:00–19:00 h) in a climate-controlled room, and allowed access to food and water ad 
libitum. In vivo procedures were performed on young, male rats weighing between 300 and 350 
g. Cultured neurons were isolated from taken from embryonic day 18 (E18) fetal rat pups.  
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Middle Cerebral Artery Occlusion 
The middle cerebral artery occlusion (MCAO) method was used to induce permanent focal 
cerebral ischemia as previously described (Ajmo, Vernon et al. 2006). Briefly, the external carotid 
artery was exposed, ligated, and cut prior to introducing a 40 mm monofilament. The 
monofilament was fed through the cut external carotid artery and advanced through the internal 
carotid artery until the end of the filament blocked the origin of the middle cerebral artery. 
Subsequent reduction in cerebral blood flow was confirmed using Laser Doppler (Moore Lab 
Instruments, Farmington, CT). Only animals with a ≥ 60% reduction in cerebral perfusion were 
included in the study. Animals subjected to the sham MCAO procedure only underwent exposure 
of the common carotid artery without cutting the external carotid or occluding the MCA. 
Drug administration  
Recombinant human LIF (ProSpec, Ness Ziona, Israel) (125 μg/kg) or PBS (pH 7.4) were 
injected intravenously at 6, 24, and 48 h post-MCAO as previously described. Rats were 
euthanized at 72 h post-MCAO via intraperitoneal injection of ketamine/xylazine (75 mg/kg and 
7.5 mg/kg) as previously described (Seifert, Hall et al. 2012). Animals used for 
immunohistochemical analysis were perfused with normal saline followed by 4% 
paraformaldehyde in phosphate buffer. Animals used for biochemical analysis were only 
perfused with saline.  
Tissue Homogenization  
To obtain whole cell extracts, frozen tissue was homogenized in whole cell lysis buffer 
containing the following: 50 mM Tris pH 8, 150 mM NaCl, 0.1% SDS, 1% IGEPAL, 1 mM PMSF, 
and a Complete Mini protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN). . Briefly, 
tissue was disrupted using a handheld electric homogenizer and allowed to incubate on ice for 
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20 min. Tissue lysates were vortexed and pipetted to break up nuclei. Protein concentrations 
were estimated using a Bradford Protein Assay (Bio-Rad, Hercules, CA).  
Primary Neuronal Culture 
Primary cortical neurons were isolated and cultured as described previously (Katnik, 
Guerrero et al. 2006). Briefly, brains were removed from E18 fetal rat pups, cortices were 
separated from the midbrain and hindbrain, and meninges were removed. Cortices were 
dissociated by a combination of mechanical disruption and incubation in trypsin/EDTA solution 
at 37 °C. Cells were suspended in DMEM complete medium, washed 2x, counted, and plated 
onto glass coverslips pre-coated with poly-L-lysine. At 24 h following isolation, DMEM complete 
was removed and cells were incubated in Neurobasal medium containing L-glutamine and B-27 
serum-free supplement. Cells were treated with 2 µM cytosine-β-D-arabinofuranoside at 5 days 
post-isolation to suppress proliferation of glial cells.  
Oxygen Glucose Deprivation 
In vitro ischemia was achieved via oxygen-glucose deprivation (OGD) as previously 
described (Hall, Guyer et al. 2009). Media was aspirated, and 1 ml DMEM without D-glucose or 
sodium pyruvate was added to each well. Cells were treated with 200 ng/ml or sterile filtered 
PBS as a vehicle control. Neurons were placed in a humidified airtight chamber that was flushed 
with 94% N2, 5% CO2, and 1% O2 (Airgas, Tampa, FL) for 15 min. After 15 min, the chamber 
was sealed.  Once cells were removed from the chamber, supernatants were collected for 
assessment of cytotoxity. Cells were washed twice with PBS and either fixed for 10 min in 4% 
paraformaldehyde in phosphate buffer or pelleted via centrifugation and snap-frozen. Fixed cells 
were used for immunocytochemical staining and cell pellets were stored at -80°C.  
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Lactate Dehydrogenase Assay 
Measurement of LDH in the cellular supernatant was performed as previously described 
using a colorimetric assay (Takara Biosciences, Madison, WI). Supernatant samples from cells 
subjected to OGD were diluted 1:4 in fresh cellular medium prior to assay to avoid saturation. 
Absorbance readings were measured using a µQuant microplate spectrophotometer (BioTek, 
Winooski, VT) at 490 nm. LDH readings from separate experiments were normalized to a control 
group (OGD + PBS) to account for differences in the baseline response between batches of 
cells.  
Promoter Analysis 
Identification of transcription factor (TF) binding sites was performed as previously 
described using Genomatix Software (Munich, Germany). The sequences for the rat (Rattus 
norvegicus) SOD3 gene was used in the search query and a table was generated for all TF sites. 
Consensus sites for the TFs in the table were aligned with the rat SOD3 promoter sequence to 
identify their locations.  
siRNA-mediated Gene Silencing 
Primary cortical neurons were isolated and transfected as previously described with 
siRNA using the Nucleofector™ 2b Device and the Amaxa™ Basic Nucleofector™ Kit for primary 
mammalian neurons (Lonza, Allendale, NJ). Scrambled (Control-A) and siRNA sequences 
(MZF-1 and Sp1) were purchased from Santa Cruz Biotechnology. Transfection with 300-400 
nM siRNA was achieved using the Nucleofector™ protocol G-013. Following transfection, 
neurons were seeded into 12 well plates containing poly-L-lysine coated coverslips and pre-
equilibrated DMEM complete medium. Downregulation of target genes was confirmed using 
quantitative PCR (qRT- PCR).  
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Isolation of Total RNA 
Total RNA was isolated from cortical neurons as previously described using the Qiagen 
RNeasy Mini Kit protocol (Velencia, CA). RNA samples were immediately converted to cDNA or 
stored at -80°C.  
2-step qRT-PCR 
Two-step  quantitative real-time PCR (qRT- PCR) was performed as previously described 
(Davis, Collier et al. 2016) (Rowe, Leonardo et al. 2010). AffinityScript® Master Mix components 
for cDNA synthesis and qPCR reactions were purchased from Agilent Technologies (Santa 
Clara, CA).  The reverse-transcriptase reaction was performed according to the kit protocol using 
a Mastercycler Gradient thermal cycler (Eppendorf, Hauppauge, NY). Reaction components 
were incubated at 25˚C for 5 min to allow for primer annealing, 42˚C for 30 min to allow for cDNA 
synthesis, and finally 95˚C for 5 min to stop the reaction. A Nanodrop ND-1000 
spectrophotometer (Thermo-Fisher Scientific, Waltham, MA) was used to assess the quality and 
measure the concentration of cDNA samples. All primers (MZF-1, SOD3, GAPDH, 18s rRNA) 
were obtained from Qiagen. The qPCR reaction was performed according to kit protocol using 
Opticon™ 3.1 Software attached to a Chromo4 DNA ENGINE thermal cycler (Bio-Rad). The 
reaction was carried out at the following steps: 15 min at 95˚C to heat reaction components and 
activate Taq polymerase, 30 s at 95 ˚C for denaturation, 30 s at 55˚C for annealing, and 30 s at 
72˚C for elongating strands. After 40 cycles of denaturation-annealing-elongation, a melt 
temperature curve was measured. Cycle threshold values from the gene of interest and 
housekeeping genes (GAPDH, 18s rRNA) were used to calculate the relative change in gene 
expression. 
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Immunohistochemical Analysis 
Fluorescent immunohistochemistry was performed on brain tissue sections using a 
previously described protocol (Hall, Guyer et al. 2009). The following antibodies were used: 
rabbit α-Sp1 (1:1000; Novus Biologicals, Littleton, CO), rabbit α-MZF-1 (1:500; Abcam, San 
Francisco, CA), and mouse-α-neuronal nuclear antigen (NeuN) (1:500; EMD Millipore, Billerica, 
MA) antibodies. AlexaFluor® 488 and 594 secondary antibodies (1:1000; Life Technologies, 
Carlsbad, CA) were used for visualizing antigens. Coverslips were mounted onto slides using 
VECTASHIELD® medium containing 4', 6-diamidino-2-phenylindole (DAPI) (Vector Labs, 
Burlingame, CA). Images were captured using a Zeiss AxioCam color camera attached to a 
Zeiss AxioSkop2 microscope (Thornwood, NY) interfaced with ZEN 2 Imaging Software.   
Western Blot Analysis 
Western blotting was used for semi-quantitative measurement of protein expression 
using a previously described protocol. Briefly, whole cell or nuclear lysates from brain tissue were 
run on 10% SDS-PAGE gels and transferred to nitrocellulose membranes. Membranes were 
blocked in 5% milk dissolved in TBST) and probed with the following antibodies: rabbit α-MZF-1 
(1:250; Abcam) and rabbit α-Sp1 (1:1000; Novus Biologicals). Membranes were incubated in 
AlexaFluor® 488 goat α-rabbit IgG (1:250; Life Technologies) for visualization of protein bands. 
Membranes were imaged using a Typhoon 9410 Imager (GE Healthcare Life Sciences, 
Marlborough, MA). To normalize for loading, membranes containing whole cell extracts were re-
probed with mouse α-β-actin (1:5000; Novus Biologicals) and AlexaFluor® 488 goat α-mouse 
IgG1 (1:250; Life Technologies).  
Data analysis 
Images were minimally processed in a uniform matter across treatment groups and were 
analyzed using ImageJ software (NIH, Bethesda, MD). Statistical analysis was for experiments 
containing two groups was performed using an independent student’s t-test and a one-way 
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ANOVA was used for those containing three or more groups. Outliers were detected using the 
interquartile method as previously described (Rousseeuw and Hubert 2011) and omitted. 
Fisher’s Protected Least Significant Difference post hoc test was used to detect prior to statistical 
analyses individual differences between groups. A p value of 0.05 or less was considered 
significant. All p values reported are one-tailed.  
Results 
 MZF-1 and Sp1 Sites were identified in the Rat SOD3 Promoter 
Within the SOD3 promoter, four MZF-1 sites and two Sp1 sites were identified. All MZF-
1 sites contained ten nucleotides with a core sequence of four consecutive guanines (GGGG). 
The Sp1 sites contained 14 nucleotides with a core sequence of three guanines followed by 
another nucleotide (GGGX). Interestingly, the third MZF-1 site and the first Sp-1 sites covered 
nucleotides 73-80, indicating that these sites overlap with each other. Sequences for all MZF-1 
and Sp1 sites may be found in Table 1, while approximate locations in the SOD3 promoter may 
be found in Fig. 3.1.  
LIF Upregulates MZF-1 in Cortical Neurons  
Western blotting was used to determine the protein expression of MZF-1 in the brains of 
rats that were euthanized 72 h after MCAO. At this time point, MCAO and LIF administration 
resulted in an overall difference in MZF-1 expression (p = 0.0434; F4,14 = 3.266). The ipsilateral 
tissue of PBS-treated rats had significantly higher levels of MZF-1 compared to the contralateral 
tissue (p = 0.0201) but not compared to tissue from sham rats (p = 0.2042).  There clear trend 
towards increased expression of MZF-1 in the ipsilateral tissue from the MCAO + LIF rats 
compared to sham-operated rats (p = 0.0848) and the contralateral tissue of the same group (p 
= 0.0557). (Fig. 3.2a). To examine the neuron-specific change in MZF-1 expression after LIF 
treatment, primary cortical neurons were treated with either PBS or 200 ng/ml LIF prior to 24 h 
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of OGD. After incubation, neurons were fixed and stained with MZF-1 antibodies. The percentage 
of cells that stained positive for MZF-1 was calculated by dividing by the total number of cells 
imaged. Neurons that were treated with LIF prior to OGD showed a significant increase in MZF-
1-postive cells compared to the cells that were treated with PBS (p = 0.002; t = 5.056, df = 5; 
Fig. 3.2b).  
Neurons that Upregulate MZF-1 also Upregulate SOD3 
Previous studies from this lab show that LIF treatment prior to OGD increases SOD3 
gene expression in neurons. In addition, Moeenrazakhanlou et al. demonstrated that PI3K/Akt 
signaling, which is increased after LIF treatment, controls MZF-1 activity through increased 
protein expression (Moeenrezakhanlou, Shephard et al. 2008, Rowe, Collier et al. 2014). To 
determine whether MZF-1 upregulation in neurons coincided with increased SOD3 expression, 
total RNA was isolated from neurons that were treated with LIF or PBS prior to OGD. Total RNA 
was converted to cDNA, which was used to perform qRT-PCR. The PCR results confirmed the 
upregulation of MZF-1 after LIF treatment that was observed in the immunohistochemical 
analysis (p = 0.0195; t = 3.024, df = 4; Fig. 3.3a). These same samples also showed increased 
expression of SOD3 after LIF treatment, indicating that higher levels of MZF-1 are observed in 
neurons with increased SOD3 expression (p =0.0302; t = 2.595, df = 4; Fig. 3.3b).   
Sp1 Expression is not significantly altered by LIF Treatment  
To determine whether LIF controls Sp1 in a protein expression-dependent manner, 
western blots were performed using samples from rats euthanized 72 h after MCAO or sham 
injury. The protein expression patterns of Sp1 mirrored those of MZF-1; there was an overall 
change in Sp1 expression due to the MCAO and LIF treatment that approached significance (p 
= 0.0505; F4,13 = 3.167). Although there was a trend towards an increase in Sp1 levels between 
sham and PBS ipsilateral (p = 0.2809) as well as between sham and LIF ipsilateral tissue (p = 
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0.0962), these increases were not statistically significant (Fig. 3.4a). Among primary cortical 
neurons subjected to OGD for 24 h, there was no significant change in Sp1 expression between 
neurons treated with PBS and neurons treated with LIF (p = 0.3810; t = 0.3243; df = 4; Fig. 3.4b).  
High Sp1 Levels Correlate with Increased MZF-1 after LIF treatment 
Considering the high degree of similarity between the expression patterns of Sp1 and 
MZF-1 after LIF treatment, Pearson’s r correlation analysis followed by linear regression was 
performed to determine whether increased MZF-1 levels in brain tissue were associated with 
higher Sp1 expression after sham surgery, MCAO + PBS treatment, and MCAO + LIF treatment.  
Among sham samples (p = 0.7931, r = -0.2069) and PBS samples (p = 0.4706, r = 0.2998), there 
was no significant correlation between MZF-1 and Sp1 expression (Figs. 3.5a, 3.5b). However, 
there was a significant positive correlation between MZF-1 levels and Sp1 levels in the brains of 
LIF-treated rats (p = 0.0068, r = 0.8550), demonstrating that higher MZF-1 levels after LIF 
treatment correspond to higher Sp1 levels (Fig. 3.5c).  
Sp1 and MZF-1 Accumulate in Neuronal Nuclei in vivo  
To visualize the expression and localization of Sp1 and MZF-1 in brain tissue after MCAO 
+ LIF treatment, brain tissue sections from rats euthanized at the 72 h time point were double-
labeled with antibodies against Sp1/MZF-1 (red), and NeuN (green). At 72 h after MCAO, Sp1 is 
expressed at high levels in neurons of the cerebral cortex as well as hippocampal neurons of the 
gray matter. Sp1 immunoreactivity was concentrated in the nuclear region of neurons in both 
regions of the brain, and staining was also detected independently of neuronal somata in the 
white matter regions (Fig. 3.6). Tissue sections labeled with MZF-1 and NeuN antibodies showed 
MZF-1 localized in neurons of the cortex and hippocampus. While Sp1 appeared to be localized 
to mainly the nucleus of neuronal somata, MZF-1 showed strong immunoreactivity in the nuclear 
and cytoplasmic regions. However, while Sp1 showed strong nuclear localization within and 
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outside of the hippocampal gray matter, MZF-1 immunoreactivity was strongest in the gray 
matter of the hippocampus. By contrast, little MZF-1 staining was observed in the white matter 
of the hippocampus (Fig 3.7).  
SOD3 co-localizes with MZF-1 and Sp1 after LIF treatment 
Double labeling brain sections with NeuN and MZF-1/Sp1 antibodies showed that these TFs 
accumulate in neuronal nuclei after LIF treatment. Furthermore, LIF treatment led to a positive 
correlation between Sp1 and MZF-1, but this relationship was not observed in samples from 
PBS-treated or sham rats. It has not yet been determined whether SOD3 expression is 
associated with high levels of MZF-1 and Sp1/ MZF-1 after LIF treatment. Considering the high 
levels of Sp1 and MZF-1 in neuronal nuclei of the cortex, which lies within the ischemic core, 
these cells could upregulate SOD3 as a defense mechanism against ischemic damage.  To 
determine whether neurons showing high levels of MZF-1 and Sp1 also express SOD3 in vivo, 
representative brain sections from LIF-treated rats euthanized 72 h after MCAO. At this time 
point, SOD3 (green) was expressed by several cells in the cerebral cortex. MZF-1 and Sp1 (red) 
were expressed by cells of the cortex at this time point. The merged images revealed co-
localization of SOD3 with MZF-1 as well as Sp1 after LIF treatment (Fig 3.8).  
Sp1 and MZF-1 siRNA counteract in vitro neuroprotection by LIF 
 To determine whether silencing Sp1 or MZF-1 decreased the neuroprotective effects of 
LIF in vitro, siRNA was used to knock down expression of these transcription factors immediately 
following isolation. Once transfected neurons were mature, they were treated with PBS or LIF 
and subjected to 24 h of OGD. LDH release in the supernatant was used to measure in vitro 
cytoxicity. LIF treatment and siRNA-mediated silencing of Sp1 and MZF-1 expression 
significantly altered LDH release among treatment groups (p = 0.0017, F5,19 = 5.993). In 
accordance with previous findings from this lab, LIF reduced LDH release among scrambled 
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siRNA-transfected neurons compared to those treated with PBS prior to OGD. Neurons 
transfected with MZF-1 or Sp1 siRNA and treated with PBS were not significantly different from 
their scrambled-transfected counterparts. However, neurons transfected with MZF-1 siRNA and 
treated with LIF released significantly more LDH compared to the scrambled + LIF group (p = 
0.0004), the MZF-1 siRNA + PBS (p = 0.0004), and the scrambled + PBS groups (p = 0.0228). 
Cells transfected with Sp1 siRNA and treated with LIF prior to OGD did not differ significantly in 
their LDH release compared to scrambled + PBS neurons, but the siRNA counteracted the 
protective effect of the LIF seen in the scrambled + LIF neurons (p = 0.0061) and increased LDH 
release compared to the Sp1 siRNA + PBS group (p = 0.0206). However, the LDH release from 
the Sp1 siRNA + LIF group was still significantly lower than that of the MZF-1 siRNA + LIF group 
(p = 0.012; Fig. 3.9).  
Discussion 
 Rowe et al. identified several TFs that regulate the expression of HUCB cell-inducible 
genes in cultured OLs. Prdx4, which is induced by HUCBs and LIF in an Akt-dependent manner, 
contains binding sites for MZF-1 and Sp1 in its promoter region (Rowe, Leonardo et al. 2010, 
Rowe, Leonardo et al. 2012, Rowe, Collier et al. 2014). In addition to its oligoprotective 
properties, this laboratory showed that LIF exerts pro-survival effect on neurons via the Akt-
dependent upregulation of SOD3 (Davis, Collier et al. 2016). Other groups have examined the 
ability of Sp1 and MZF-1 to regulate expression of SOD3 in vitro and in vivo (Zelko and Folz 
2003, Zelko and Folz 2004, Zelko, Mueller et al. 2008. The fact that in vitro LIF protection is 
counteracted by Sp1 and MZF-1 knockdown suggests that both TFs may play a role in the 
upregulation of several antioxidant enzymes. Furthermore, cells in the cerebral cortex that 
expressed high levels of MZF-1 and Sp1 also had high levels of SOD3 after LIF treatment. 
Previously, this lab showed that LIF induces SOD3 in the ipsilateral cerebral cortex at 72 h post-
MCAO. Among these cortical cells that upregulate SOD3 were neurons {Davis, 2016 #363). 
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Therefore, the high levels of MZF-1 and Sp1 in cortical tissue facilitate the increase in SOD3 
expression after MCAO and LIF treatment.  
Previous research shows that MZF-1 activity is regulated by PI3K/Akt signaling at the 
level of protein expression, and the increased MZF-1 mRNA and immunoreactivity in primary 
cortical neurons confirms earlier findings. Although MZF-1 upregulation approached, but did not 
reach, significance in brain tissue after LIF treatment, these could be due to several factors. 
While in vitro cultures contain almost exclusively neurons, tissue samples include neurons, glia, 
endothelial cells, as well as other cell types. The double-staining with NeuN and MZF-1 further 
demonstrated that MZF-1 upregulation and nuclear translocation is more prominent in neurons 
compared to other neural cell types. The majority of hippocampal neurons in the dentate gyrus 
showed co-localization of NeuN and MZF-1, but little MZF-1 was found outside of neuronal 
tissue. The upregulation of MZF-1 in neurons after LIF treatment may be responsible for the 
trend towards increased MZF-1 expression in brain tissue. Immunohistochemical staining and 
qRT-PCR data from purified neuronal cultures showed that LIF induces the expression of MZF-
1 under ischemic conditions. Furthermore, transfection with MZF-1 siRNA prior to LIF treatment 
significantly increased in vitro cytotoxicity compared to the scrambled siRNA + LIF group. These 
results from in vitro experiments demonstrate that MZF-1 is responsible for the neuroprotective 
actions of LIF, and its activation is dependent upon increased gene expression.  
Although transfection with Sp1 siRNA counteracted LIF-mediated neuroprotection in 
vitro, Sp1 was not significantly upregulated by LIF in brain tissue.  Quantitative PCR analysis of 
primary cortical neurons showed no change in Sp1 mRNA transcript between PBS and LIF-
treated neurons. These results indicate that LIF controls the activity of Sp1 independently of its 
expression. In addition, experiments using siRNA-mediated knockdown demonstrated that 
among primary cortical neurons, those transfected with MZF-1 siRNA prior to LIF treatment had 
significantly higher LDH levels than those transfected with Sp1 siRNA prior to LIF treatment.  
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Both sets of neurons that were transfected with siRNA prior to LIF treatment had higher 
LDH release than their PBS-treated counterparts, indicating that LIF may be detrimental to 
neurons under OGD when lacking one or more TFs. Studies from this laboratory show that the 
protective actions that LIF exerts on neurons/glial cells are dependent upon the Akt-dependent 
upregulation of protective genes. Without the necessary TFs, in this case Sp1 and MZF-1, it is 
possible that the pro-survival effect of Akt-dependent gene expression may be overshadowed 
by other signaling pathways. For instance, p38 MAP kinase is activated by LIF signaling, and 
Ghatan et al. demonstrated that p38 initiates apoptosis by facilitating the translocation of Bax to 
the mitochondria (Ghatan, Larner et al. 2000, Kato, Sano et al. 2000). Since knockdown of either 
Sp1 or MZF-1 is sufficient to counteract the in vitro neuroprotection provided by LIF, this data 
suggests that the presence of both TFs is necessary for induction of protective genes in neurons.  
 According to several independent groups, the activity of Sp1 is regulated by multiple 
post-translational modifications. Suzuki et al. demonstrated that p300, a histone 
acetyltransferase, enhances the DNA-binding of Sp1 via protein-protein interaction and 
increasing its acetylation (Suzuki, Kimura et al. 2000). Histone deacetylase inhibitors also 
enhance the activity of Sp1 (Huang, Zhao et al. 2005, Marinova, Ren et al. 2009). The HDAC 
inhibitor valproic acid enhances neuroprotection following transient MCAO by increasing the 
acetylation of Sp1 and the expression of the chaperone Hsp70 (Ren, Leng et al. 2004). 
Moreover, Zelko et al. demonstrated that trichostatin A, another histone deacetylase inhibitor, 
upregulates SOD3 expression in an Sp1-dependent manner (Zelko and Folz 2004). This lab 
demonstrated that inhibition of Akt activity counteracts the protective effects of LIF on cultured o 
p300 via phosphorylation of Ser1834, and inhibition of PI3K/Akt signaling via treatment with 
LY294002 triggers proteolysis of p300. Therefore, it is possible that enhanced Akt activity 
following LIF treatment regulates Sp1 transcriptional activity in a p300-dependent manner (Chen, 
Halappanavar et al. 2004, Huang and Chen 2005).  
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  In addition to acetylation, Sp1 activity is regulated via direct phosphorylation. Multiple 
studies indicate that transcriptional activity of Sp1 is increased by Akt-dependent 
phosphorylation. According to Reisinger et al., hepatocyte growth factor increases serine 
phosphorylation of Sp1 and expression of vascular endothelial growth factor (VEGF). This study 
implicated several kinases, including PI3K, MEK1/2, and PKC-ζ, in the activation of 
Sp1(Reisinger, Kaufmann et al. 2003). Pore et al. demonstrated that the upregulation of VEGF 
is dependent upon Sp1, which is regulated by Akt in a phosphorylation-dependent manner (Pore, 
Liu et al. 2004). Sp1 controls expression of other genes downstream of PI3K/Akt signaling. 
Phosphorylation of Sp1 by Akt and MAPK signaling increases expression of the cancer 
biomarker CD147 (Zhao, Ye et al. 2015). Another study showed that caveolin-1, the main 
component of caveolae, is upregulated following increased phosphorylation of Sp1 by Akt (Roy, 
Upal et al. 2013). However, phosphorylation and acetylation are only two of the many post-
translational modifications that may alter the activity of Sp1. According to these data, LIF protects 
neurons against ischemia via Sp1 but does not significantly increase its expression in vivo. 
Consequently, LIF may activate Sp1 by influencing one or more of its post-translational 
modifications (Chu 2012).  
Although LIF does not directly increase expression of Sp1 in neurons during ischemia, 
the significant correlation between MZF-1 and Sp1 protein levels among brain samples from LIF 
treated rats indicates a possible relationships between the two TFs. According to previous 
studies, the Sp1 promoter region contains binding sites for MZF-1. Higher MZF-1 levels after LIF 
treatment may increase transcription of the Sp1 gene, which may explain the trend towards 
higher Sp1 expression after LIF treatment in brain tissue (Thakur 2007). The correlation between 
MZF-1 and Sp1 levels after LIF treatment may be due to reduced degradation of Sp1. During 
ischemia, there is a reduction in the levels of O-glycosylated Sp1 due to low glucose levels in 
the infarct. Consequently, hypo-glycosylated Sp1 is more susceptible to degradation by the 
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proteasome (Han and Kudlow 1997). PI3K/Akt signaling, a pathway activated by LIF in neural 
cells, has been shown to suppress ubiquitin/proteasome-mediated degradation (Wang, Hu et al. 
2006, Rowe, Collier et al. 2014, Davis, Collier et al. 2016).   Therefore, the higher levels of Sp1 
in the brain and its correlation with MZF-1 may be an artifact of its reduced degradation after LIF 
treatment rather than increased gene expression.  
 Another possible explanation for this relationship may be that Sp1 is upregulated by 
neurons in response to ischemia, but LIF treatment does not contribute to further upregulation. 
As a result, Sp1 levels might be highest in tissue with the most severe ischemic damage. 
Previous studies from our lab showed that the induction of Prdx4 and SOD3 after LIF treatment 
are not observed under normoxia. The upregulation of MZF-1 in neurons after LIF treatment 
appears to follow a similar pattern, where the difference between MZF-1 expression in ipsilateral 
and contralateral brain tissue approaches significance (P=0.055). The MCAO+LIF rats are the 
only treatment group subjected to ischemia and LIF treatment, and they are the only group with 
a significant relationship between levels of MZF-1 and Sp1.  
According to the results of the Genomatix analysis, there is an overlapping region 
between the consensus sequences for MZF-1 and Sp1. In the promoters of other genes, MZF-1 
and Sp1 act as regulators of transcription for similar genes. CD11b and CD14 expression are 
regulated by MZF-1/Sp1 and the binding sites for both TFs overlap with each other in both 
promoter sequences (Moeenrezakhanlou, Shephard et al. 2008). Shiraga et al. demonstrated 
that the promoter for the MUC1 mucin gene also contains overlapping binding sites for MZF-1 
and Sp1. Furthermore, supershift analysis confirmed direct interaction between the two TFs at 
the MUC1 promoter. Direct protein-protein interaction between the MZF-1 and Sp1 shows that 
that they may function as co-activators of transcription for many genes.  
Immunohistochemical analysis of brain sections from LIF-treated rats revealed co-
localization of Sp1 as well as MZF-1 with neuronal nuclei in the cerebral cortex and the 
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hippocampus. The intraluminal model of permanent MCAO utilized by this study produces a 
large volume of damage within the cerebral cortex as well as the striatum. This lab previously 
showed that SOD3 expression was induced specifically in the ipsilateral cortical tissue of LIF-
treated rats. The MZF-1 and Sp1 expression and nuclear localization observed in the ipsilateral 
cortex after LIF treatment agreed with this previous findings. While hippocampal damage is not 
as severe in this MCAO model compared to cortical damage, this laboratory previously showed 
that neuronal degeneration in the hippocampus occurs between 12 h and 7 days after MCAO 
(Butler, Kassed et al. 2002). Popp et al. conducted a study showing ischemic damage in regions 
of the brain following transient and permanent MCAO. According to the findings, the ipsilateral 
hippocampus is within the posterior penumbra, most likely due to manipulation of the internal 
carotid artery during the MCAO procedure (Popp, Jaenisch et al. 2009). As with the cortical 
neurons, hippocampal neurons showed MZF-1 and Sp1 in the nuclear region, thus indicating 
that LIF exerts neuroprotection in the outer penumbra as well.  
. Although transfection with either MZF-1 or Sp1 siRNA was sufficient to counteract LIF-
mediated neuroprotection, one would expect simultaneous silencing to be even more effective 
at abrogating the protective effects of LIF. While simultaneous knockdown of genes in primary 
cortical neurons is difficult to accomplish, the efficacy of single-gene knockdown demonstrates 
that both MZF-1 and Sp1 are important for the neuroprotective properties of LIF in vivo. In 
addition, this study is the first to identify a distinct neuroprotective role for MZF-1, which had not 
yet been implicated in neural cell signaling. Prdx4 and SOD3, which are both induced by LIF, 
contain regulatory sequences for MZF-1 and Sp1 in their promoter regions (Rowe, Leonardo et 
al. 2010, Rowe, Collier et al. 2014, Davis, Collier et al. 2016). The pleiotropic effects of LIF 
suggest that it may upregulate other protective genes that are controlled by MZF-1 and Sp1. 
PI3K/Akt signaling, which is responsible for the protective effects of LIF in neural cells, controls 
survival signaling by activating transcription factors. Therefore, other TFs located downstream of 
95 
 
Akt might mediate the protective effects of LIF. Further studies may help identify other 
mechanisms through which LIF controls protective gene expression during focal cerebral 
ischemia.  
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Table 1. MZF-1 and Sp1 have Binding Sites in the SOD3 Promoter. Genomatix was used to 
identify binding sites for MZF-1 and Specificity Protein-1, another protective transcription factor 
activated by Akt signaling, in the promoter for the superoxide dismutase 3 (SOD3) rat gene. Four 
MZF-1 sites were identified in the promoter. All identified MZF-1 sites were 11 nucleotides long 
and contained four consecutive guanine residues (GGGG) in the anchor position.  Two Sp1 
binding sites containing 14 nucleotides each and a core sequence of three guanines followed by 
another residue (GGGX) were found as well. As noted by the start and ending positions of each 
binding site, the first Sp1 site and the third MZF-1 site contain overlapping resides at positions 
73-80.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Transcription 
Factor 
Start 
Position 
End 
Position 
Strand 
(+/-) 
Sequence 
MZF-1 13 23 + aaGGGGaacta 
MZF-1 46 56 + gtGGGGacaat 
Sp1 64 80 + agcggGGGAggggggaa 
MZF-1 73 83 + ggGGGGaaagg 
Sp1 178 194 + aggagGGGCagggaaag 
MZF-1 368 378 + ggGGGGaggag 
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Figure 3.1. Locations of MZF-1 and Sp1 binding sites in the rat SOD3 promoter. Of the four 
MZF-1 sites that were identified by Genomatix, three were clustered within the first 100 
nucleotides of the promoter sequence while the fourth MZF-1 site was located downstream near 
the middle of the sequence. The first Sp1 site was preceded by the second and overlapped with 
the third MZF-1 binding site, suggesting that the two TFs interact with each other. The second 
Sp1 site was located approximately mid-way between the third and fourth MZF-1 site. All of the 
binding sequences for MZF-1 and Sp1 were located on the positive strand.  
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Figure 3.2. MZF-1 is upregulated by cultured neurons but not brain tissue after LIF 
treatment. (a) Western blotting analysis showed that there was a trend towards increased 
expression of MZF-1 in the ipsilateral tissue of PBS-treated rats after MCAO compared to that of 
sham-operated rats. In addition, the increase between MZF-1 levels in the ipsilateral tissue of 
LIF-treated rats and that of sham/PBS-treated rats approached, but did not quite reach 
significance. n = 4 per group. (b) To determine the neuron-specific expression of MZF-1 after LIF 
treatment, immunohistochemistry was performed on fixed primary neurons that were treated with 
either PBS or 200 ng/ml LIF prior to 24 h OGD. Compared to the PBS-treated cells, there was 
significantly higher levels of MZF-1 immunoreactivity in the cells treated with LIF prior to OGD 
(*p<0.01). n = 5 per group. 
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Figure 3.3. Cells with elevated MZF-1 after LIF treatment upregulate SOD3 mRNA. (a) 
Although immunohistochemical staining revealed higher levels of MZF-1 after LIF treatment, 
quantitative real-time PCR was used to determine whether neurons that express high levels of 
MZF-1 also upregulate SOD3 after LIF treatment. As expected, MZF-1 mRNA was significantly 
upregulated after LIF treatment (*p<0.05). (b) SOD3 mRNA levels were measured in the same 
neuronal samples to determine whether SOD3 upregulation coincided with MZF-1 upregulation 
after LIF treatment. Neurons treated with LIF prior to OGD had significantly higher levels of SOD3 
mRNA compared to LIF treatment. n = 3 per group  
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Figure 3.4. Sp1 is not upregulated in brain tissue or primary neurons after LIF treatment. 
(a) Western blotting was performed to determine protein expression in brain tissue after MCAO 
and LIF treatment. There was an increase in Sp1 expression in the ipsilateral tissue of LIF-
treated rats compared to that of PBS-treated or sham rats, but this increase did not quite reach 
significance. n = 4 per group (b) Real time PCR analysis showed that Sp1 expression was not 
significantly different between neurons that were treated with either PBS or LIF prior to OGD. n 
= 3 per group.   
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Figure 3.5. MZF-1 Upregulation Correlates with Higher Sp1 Levels in LIF-treated Rats. 
Linear regression analysis was performed on the normalized western blot band densities for 
MZF-1 and Sp1 in brain tissue samples to determine whether higher Sp1 levels were associated 
with greater MZF-1 expression. (a) There was no significant correlation between MZF-1 and Sp1 
levels in brain tissue samples from sham operated rats. (b) Samples from PBS-treated rats also 
showed no correlation between MZF-1 and Sp1 levels. (c) There was a significant correlation 
and a positive relationship between MZF-1 and Sp1 protein expression in tissue samples from 
LIF-treated rats (p<0.01). n ≥4 samples per group.  
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Figure 3.6. Sp1 accumulates in neuronal nuclei after LIF treatment. Brain tissue sections 
from rats that were treated with LIF and euthanized 72 h after MCAO were labeled with antibodies 
against Sp1 and neuronal nuclear antigen (NeuN) to determine whether LIF causes translocation 
of Sp1 to the nucleus. Cortical staining revealed strong co-localization of Sp1 (red) and NeuN 
(green). In the dentate gyrus of the hippocampus, Sp1 was localized to neuronal nuclei. In 
addition, Sp1 immunoreactivity was detected in the nuclei of non-neuronal tissue of the 
hippocampus. Sp1 was observed in neuronal nuclei in the cortical and striatal tissue adjacent to 
the external capsule, but levels within the external capsule were very low. Arrows identify 
representative cells. Scale bars = 100 µm. 
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Figure 3.7. MZF-1 is expressed in the nuclei of cortical and hippocampal neurons. 
Antibodies against MZF-1 (red) and NeuN (green) were used to label brain sections from rats 
treated with LIF and euthanized 72 h after MCAO. In the cerebral cortex, neurons staining 
positive for NeuN also expressed MZF-1. In addition, the MZF-1 expressed by cortical neurons 
appeared to be localized to the nuclei. In the hippocampus, MZF-1 immunoreactivity was very 
strong in neuronal nuclei. By contrast, little MZF-1 immunoreactivity was observed in non-
neuronal tissue of the hippocampus. MZF-1 also co-localized with NeuN in neurons adjacent to 
the external capsule. While MZF-1 immunoreactivity was visible within the external capsule, it 
less noticeable than MZF-1 staining in neuronal tissue. Arrows identify representative cells. Scale 
bars = 100 µm. 
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Figure 3.8. SOD3 co-localizes with MZF-1 and Sp1. Cortical tissue from 72 h LIF-treated rats 
was double labeled with antibodies against SOD3 (green), MZF-1 or Sp1 (red). At this time point, 
there was a high degree of co-localization between SOD3 and MZF-1 as well as SOD3 and Sp1. 
Arrows identify representative cells. Scale bars = 100 µm.  
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Figure 3.9. MZF-1 and Sp1 siRNA counteract LIF-mediated neuroprotection in vitro. 
Neurons were transfected with either scrambled, MZF-1, or Sp1 siRNA immediately following 
isolation. Once neurons were mature, they were treated with PBS or 200 ng/ml LIF and subjected 
to OGD for 24 h. Lactate dehydrogenase (LDH) activity was measured using a colorimetric 
assay. To account for variations between batches of neurons, absorbance values were 
normalized to the mean absorbance for the Scr + PBS group prior to analysis. Although LDH 
release was significantly decreased in the Scr + LIF group compared to the Scr + PBS group 
(*p<0.05), this neuroprotective effect was counteracted by previous transfection with MZF-1 
siRNA prior to LIF treatment (#p<0.001).  Transfection with Sp1 siRNA prior to LIF treatment 
also significantly increased LDH release compared to the Scr + LIF group (^p<0.05). n ≥ 4 per 
group.  
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CHAPTER 4: 
LIFR IS UPREGULATED IN A TIME-DEPENDENT MANNER IN THE SPLEEN AND IN THE 
BRAIN AFTER LIF TREATMENT 
Note to Reader 
Stephanie Davis is the main author of this chapter. However, assistance in 
experimentation as well as editing of this section was provided by Lisa A. Collier, Jawad A. 
Fazal, Dr. Christopher C. Leonardo, and Dr. Craig T. Ajmo Jr. All experimentation in this 
chapter was overseen by Dr. Keith R. Pennypacker.  
Abstract  
 Leukemia inhibitory factor (LIF) has previously been shown to activate protective 
PI3K/Akt signaling through binding to its heterodimeric receptor (LIFR/gp130). The goal of this 
study was to determine whether LIFR expression is increased after permanent middle cerebral 
artery occlusion (MCAO) the brain and the spleen. Permanent stroke was induced via middle 
cerebral artery occlusion and animals were administered PBS or 125 µg/kg LIF at 6, 24, and 48 
h after MCAO. Western blotting was used to measure protein expression of LIFR in the spleen 
and the brain. Genomatix software was used to identify binding sites for LIF-dependent TFs in 
the LIFR promoter. Cortical neurons were treated with several concentrations (2, 5, 10, 25, or 50 
nM) of a JAK1-specific inhibitor and subjected to OGD or normoxia for 24 h. Lactate 
dehydrogenase (LDH) was measured to assess in vitro cytotoxicity. LIFR expression was 
significantly increased in the brain at 72 h post-MCAO among LIF-treated rats compared to sham 
and PBS-treated rats. Genomatix identified two binding sites for Sp1 in the LIFR promoter. 
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Although LIFR expression in the spleen decreased after MCAO, it significantly increased from 
24 to 72 h post-MCAO among all stroked rats, with 17% higher levels in LIF-treated rats 
compared to PBS-treated rats at 72 h. LIF significantly increased the spleen weight compared to 
PBS treatment 72 h after MCAO, but did not completely prevent splenic contraction. There were 
significant correlations between LIFR expression in the brain and the spleen and the severity of 
post-stroke neuroinflammation. Finally, JAK1 inhibition using GLPG0634 (5, 10, 25, and 50 nM) 
significantly reduced LDH release under OGD, but the concentration that yielded the largest 
decrease (5 nM) had no effect under normoxia. These results indicate that LIFR upregulation 
may be important for sensitizing neural cells and splenocytes to LIF signaling after stroke, and 
that JAK1 inhibition may be a neuroprotective strategy against ischemic damage.  
Introduction: 
Recently, this laboratory demonstrated that administration of leukemia inhibitory factor 
(LIF) after ischemic stroke promotes the survival of oligodendrocytes and neurons through the 
increased expression of antioxidant genes (Rowe, Collier et al. 2014, Davis, Collier et al. 2016). 
Due to its pleiotropic effects on pro-survival signaling and immunomodulation, LIF has emerged 
as a promising therapeutic for inflammatory diseases of the CNS. For instance, LIF promotes 
white matter survival in animal models of multiple sclerosis (MS) by activating anti-apoptotic 
signaling, countering the effects of interferon gamma (IFNγ), and most recently, by increasing 
populations of regulatory T lymphocytes (Tregs) that limit autoimmune-mediated damage 
(Vartanian, Li et al. 1995, Slaets, Dumont et al. 2008, Janssens, Van den Haute et al. 2015).  
One possible reason behind the efficacy of LIF in treating neuroinflammation is its role as an 
endogenous immunomodulatory cytokine. Certain populations of T lymphocytes, which 
contribute to white matter damage in MS lesions, may limit further damage by secreting LIF 
(Vanderlocht, Hellings et al. 2006). Several leukocyte populations as well as oligodendrocytes 
also upregulate the low-affinity, LIF-specific subunit of the LIF receptor (LIFR)  in animal models 
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of MS (Butzkueven, Zhang et al. 2002, Janssens, Van den Haute et al. 2015). Previously, this 
laboratory showed that cortical neurons express the LIFR subunit in vitro and in vivo (Davis, 
Collier et al. 2016). Although LIFR and the high-affinity converter subunit, glycoprotein 130 
(gp130), mediate the downstream effects of LIF, gp130 participates in the downstream signaling 
of IL-6. IL-6 is a pro-inflammatory cytokine that is implicated in the development of CD4+ IL-17+ 
helper T (Th17) lymphocytes. Therefore, the presence of LIFR may mediate the anti-
inflammatory effects of LIF and similar neurotropic cytokines.  
Although LIFR is expressed by several populations of immune cells, the role of 
LIFR/gp130 signaling in the post-stroke splenic response to stroke has not yet been explored. 
Previous studies from this lab showed that human umbilical cord blood (HUCB) cells ,which exert 
effects on gene expression and white matter survival that are comparable to LIF, counteract the 
decrease in spleen size and reduce the number of CD3+CD8+ splenocytes after stroke 
(Vendrame, Gemma et al. 2006). LIF is among the protective factors expressed by HUCB cells, 
but no studies have determined whether LIF is involved with these effect. A report by Gao et al. 
shows that splenocytes are capable of participating in LIF signaling. In this study, splenocytes 
were isolated from mice that received a heart transplant followed by CD4/CD8 blockade to induce 
tolerance. Upon stimulation, these splenocytes released higher levels of LIF and lower levels of 
IL-6 compared to the group that did not have induced tolerance (Gao, Thompson et al. 2009).  
Since LIF is administered systemically after stroke, it is possible that LIF may exert 
immunomodulatory effects on splenocytes.  
Upon LIF binding, LIFR and gp130 participate in the activation of three main signaling 
pathways: Ras/MAPK, PI3K/Akt, and JAK/STAT (Boulton, Stahl et al. 1994, Stahl, Boulton et al. 
1994, Oh, Fujio et al. 1998). Although this laboratory determined that Akt activity is essential for 
mediating the neuroprotective and oligoprotective effects of LIF against in vitro ischemia, the 
protective signaling mechanisms lying upstream of PI3K/Akt and downstream of LIFR/gp130 
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have not yet been heavily explored. Stahl et al. identified the association of Janus Kinases 1 and 
2 (JAK1/2) associate with both LIF receptor subunits (Stahl, Boulton et al. 1994). The binding of 
LIF to its receptor facilitates the dimerization of LIFR/gp130, as well as the recruitment of 
JAK1/JAK2. The JAKs undergo auto-phosphorylation, and phosphorylate both LIFR subunits as 
well (Cheng, Chen et al. 2001). While JAKs are known for controlling the activity of STAT 
proteins, they are involved with regulating the other two signaling pathways, including PI3K/Akt.  
Although both JAK1 and JAK2 are activated by LIF signaling, studies suggest that JAK1 
is a more integral component of downstream LIF signaling. Rodig et al. showed that Jak -/- mice 
show deficiencies in LIF and IL-6 signaling (Rodig, Meraz et al. 1998). T293 cells lacking 
functional JAK1 are unable to respond to LIF. While cell that lack JAK2 show deficiencies in LIF 
signaling, they only demonstrate a 31% decrease in responsiveness. (Nicholson, Willson et al. 
1999) In fact, Oh et al. demonstrated that the association between p85, the regulatory subunit of 
PI3K, and JAK1 is required for the phosphorylation of PI3K and activation of downstream Akt 
signaling in cardiomyocytes (Oh, Fujio et al. 1998). Other reports show that JAK1 activates PI3K 
via a complex of proteins that also includes SHP-2, Gab-1, and STAT3 downstream of IL-6 
signaling (Hsu, Shi et al. 2004). JAK1 is implicated in facilitating the neuroprotective effects of 
other IL-6 family cytokines. For instance, oncostatin M confers protection for primary cortical 
neurons against 3-nitroproprionic acid, a drug that inhibits complex II of the mitochondrial 
electron transport chain, by upregulating the anti-apoptotic protein myeloid cell leukemia-1. 
However, inhibition of JAK1 reversed these protective effects. (Chang, Hwang et al. 2015).  
While previous studies from this lab have focused on the downstream effects of LIF on 
gene expression in neural cells, the goal of this study is to identify upstream signaling 
mechanisms of LIF in the brain and spleen. The hypotheses to be tested for this study are that 
systemic LIF administration further sensitizes neural cells and splenocytes by upregulation of 
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LIFR after stroke, and that JAK1 activity is necessary for conferring LIF-mediated 
neuroprotection.  
Materials and Methods 
Animal Care 
Animal procedures were pre-approved by the Institutional Animal Care and Use 
Committee at the University of South Florida and performed according to the NIH Guide for the 
Care and Use of Laboratory Animals. Power analysis was used to determine the appropriate 
number of animals for each experiment. Sprague–Dawley rats were purchased from Envigo 
(Indianapolis, IN, USA). Animals were maintained on a 12 h light–dark cycle (07:00–19:00 h) in 
a climate-controlled room, and allowed access to food and water ad libitum. In vivo procedures 
were performed on young, male rats weighing between 300 and 350 g. Cultured neurons were 
isolated from taken from embryonic day 18 (E18) fetal rat pups.  
Middle Cerebral Artery Occlusion  
Permanent focal cerebral ischemia was induced using the intraluminal middle cerebral 
artery occlusion (MCAO) model as previously described (Ajmo, Vernon et al. 2006). A 40 mm 
monofilament was introduced through the ligated external carotid artery and advanced through 
the internal carotid artery. The filament was advanced until it reached the origin of the middle 
cerebral artery. Reduction in cerebral blood flow was confirmed using Laser Doppler (Moore Lab 
Instruments, Farmington, CT). Only animals experiencing ≥ 60% reduction in cerebral perfusion 
were included in the study. Animals subjected to the sham MCAO procedure were anesthetized 
and underwent exposure of the common carotid artery without subsequent occlusion of the 
middle cerebral artery.  
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Drug Treatment  
Recombinant human LIF (ProSpec, Ness Ziona, Israel) (125 μg/kg) or PBS (pH 7.4) was 
administered intravenously at 6, 24, and 48 h post-MCAO as previously described (Rowe, Collier 
et al. 2014, Davis, Collier et al. 2016). Rats were euthanized at 24, 48 and 72 h post-MCAO via 
intraperitoneal injection of ketamine/xylazine solution (75 mg/kg and 7.5 mg/kg) (Seifert, Hall et 
al. 2012). Animals used for immunohistochemical analysis were perfused transcardially with 
normal saline followed by 4% paraformaldehyde in phosphate buffer. Animals used for 
biochemical analysis were perfused with saline but not paraformaldehyde prior to obtaining 
tissue. Fresh tissue was snap frozen and stored at -80°C until further processing. 
Tissue Homogenization  
To obtain whole cell extracts, frozen tissue was homogenized in whole cell lysis buffer 
containing the following: 50 mM Tris pH 8, 150 mM NaCl, 0.1% SDS, 1% IGEPAL, 1 mM PMSF, 
and a Complete Mini protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN). .. An 
electric homogenizer was used to disrupt tissue and lysates were incubated on ice for 20 min. 
Tissue lysates were vortexed and pipetted to break up nuclei. Protein concentrations were 
determined by performing a Bradford Assay according to the manufacturer’s protocol (Bio-Rad, 
Hercules, CA). Briefly, Bradford reagent containing Coomassie blue was added to diluted protein 
samples and absorbance was read at 595 nm using a SmartSpec 3000 spectrophotometer (Bio-
Rad). Concentrations were determined by comparing the absorbance readings against a 
standard curve.  
Primary Neuronal Culture 
Primary cortical neurons were isolated and cultured as described previously(Katnik, 
Guerrero et al. 2006). Briefly, brains were removed from E18 fetal rat pups, cortices were 
separated from the midbrain and hindbrain, and meninges were removed. Cortices were 
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dissociated by a combination of mechanical disruption and incubation in trypsin/EDTA solution 
at 37 °C. Cells were re-suspended in DMEM complete, washed 2x, counted, and plated onto 
glass coverslips pre-coated with poly-L-lysine. At 24 h following isolation, DMEM complete was 
removed and cells were incubated in Neurobasal medium containing L-glutamine and B-27 
serum-free supplement. Cells were treated with 2 µM cytosine-β-D-arabinofuranoside at 5 days 
post-isolation to suppress proliferation of glial cells.  
Oxygen Glucose Deprivation 
In vitro ischemia was achieved via oxygen-glucose deprivation (OGD) as previously 
described (Hall, Guyer et al. 2009). DMEM without D-glucose or sodium pyruvate was added to 
each well. Cells were treated with the following concentrations of the JAK1-specific inhibitor 
GLPG0634 (Medchem Express, Monmouth Junction, NJ): 2.5, 5, 10, 25, and 50 nM. DMSO 
(0.5%) was used as a vehicle control. Cells were placed in a 37°C humidified airtight chamber 
that was flushed with 94% N2, 5% CO2, and 1% O2 (Airgas, Tampa, FL) for 15 min. After 15 min, 
the chamber was sealed.  To control for the effects of in vitro ischemia, cells were incubated in 
fresh Neurobasal Complete medium, treated with either GLPG0634 or DMSO, and incubated for 
24 h in a 37°C humidified incubator containing 75% N2, 20% O2 and 5% CO2. Once cells were 
removed from the chamber, supernatants were collected for assessment of cytotoxicity. Cells 
were washed twice with PBS and either fixed for 10 min in 4% paraformaldehyde in phosphate 
buffer or pelleted via centrifugation and snap-frozen. Cell pellets were stored at -80°C until further 
processing.  
 Lactate Dehydrogenase Assay  
Measurement of lactate dehydrogenase (LDH) in the cellular supernatant was performed 
as previously described using a colorimetric assay (Takara Biosciences, Madison, WI) (Davis, 
Collier et al. 2016). Supernatant samples from cells subjected to OGD were diluted 1:4 in fresh 
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cellular medium prior to assay. A µQuant microplate spectrophotometer (BioTek, Winooski, VT) 
was used to read absorbance at 490 nm. LDH readings from separate experiments were 
normalized to a control group (OGD + PBS) to account for differences in the baseline response 
between batches of cells.  
Promoter Analysis 
Identification of transcription factor binding sites was performed as previously described 
using Genomatix Software (Munich, Germany)(Rowe, Leonardo et al. 2010). The sequences for 
the rat (Rattus norvegicus) LIFR gene was used in the search query and a table was generated 
for all TFs that had consensus sequences in the LIFR promoter.  
Western Blot Analysis 
Western blotting was used for semi-quantitative measurement of protein expression. 
Briefly, whole cell from brain or spleen tissue were run on 10% SDS-PAGE gels and transferred 
to nitrocellulose membranes. Membranes were blocked in 5% milk dissolved in TBST) and 
probed with rabbit α-LIFR antibodies (1:100; Santa Cruz). Membranes were incubated in 
AlexaFluor® 488 goat α-rabbit IgG (1:250; Life Technologies) for visualization of protein bands. 
Membranes were imaged using a Typhoon 9410 Imager (GE Healthcare Life Sciences, 
Marlborough, MA). To normalize for loading, membranes containing whole cell extracts were re-
probed with mouse α-β-actin (1:5000; Novus Biologicals) and AlexaFluor® 488 goat α-mouse 
IgG1 (1:250; Life Technologies).  
Data analysis 
All images were analyzed using ImageJ software (NIH, Bethesda, MD) and all statistical 
tests were performed using GraphPad Prism 5.0 Software (La Jolla, CA). Statistical analysis was 
for experiments containing two groups was performed using an independent student’s t-test. One 
or two-way ANOVAs were used to analyze data sets containing three or more groups. Outliers 
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were identified using the interquartile method or median absolute deviation as previously 
described and omitted prior to analyses (Rousseeuw and Hubert 2011, Leys, Ley et al. 2013). 
Fisher’s Protected Least Significant Difference post hoc test was used to detect individual 
differences between groups. A p value of 0.05 or less was considered significant. All p values 
reported are one-tailed, except for the p values obtained from of Pearson correlation analyses.  
Results  
LIF Increases LIFR in the Brain at 72 h post-MCAO  
Western blotting was used to determine levels of LIFR expression in the brain at 72 h 
post-MCAO. At this time point, there was a significant overall change in the levels of LIFR in 
brain tissue after MCAO and LIF treatment (p = 0.0097; F4,12 = 5.46). LIFR levels were 124% 
higher in the ipsilateral tissue from PBS-treated rats compared to sham tissue, but this increase 
was not statistically significant. However, there was a significant increase in LIFR protein 
expression in the ipsilateral tissue from LIF-treated rats compared to levels in the ipsilateral 
tissue from PBS-treated rats (p = 0.0184) and sham rats (p = 0.0005). There was no significant 
change in LIFR protein expression between tissue from sham rats and contralateral tissue from 
either treatment group (Fig. 4.1).  
Specificity Protein 1 Binding Sites were identified in the LIFR Promoter  
Genomatix software was used as previously described in Chapter 3 to locate transcription 
factor binding sites within the LIFR promoter sequence. Data reported in the previous chapter 
showed that the transcription factors (TFs) myeloid zinc finger-1 (MZF-1) and specificity protein 
1 (Sp1) were responsible for in vitro LIF-mediated neuroprotection. Although no MZF-1 sites 
were found, two Sp1 sites were located in close proximity to each other. The first site spanned 
from nucleotides 414 to 430 on the negative strand and had the following sequence: 
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caaatGGGCtgggccgt. The second site was located from nucleotides 427 to 443 and had the 
sequence tttgtGGGCggtgcca (Fig. 4.2).  
LIF Increases Spleen Weight after MCAO but not Splenic LIFR Expression 
Western blotting was used to determine whether MCAO and LIF treatment altered levels 
of LIFR in the brain at 72 h post-MCAO. At 72 h post-MCAO, there was a significant change in 
splenic LIFR expression among sham, PBS, and LIF-treated rats (p = 0.0472; F2,21 = 3.554). 
LIFR levels were lower in PBS treated rats (p = 0.0176) and LIF-treated rats (p = 0.0389) 
compared to sham rats. There was a trend towards increased LIFR expression in the spleens of 
LIF-treated rats compared to PBS-treated rats at this time point, but the increase was not 
statistically significant (Fig. 4.3a).  
Compared to spleens from sham-operated rats, MCAO and LIF treatment caused a 
significant overall change in the average spleen weight (p < 0.0001, F2,7 0= 10.79). There was a 
significant decrease in spleen weight among rats treated with PBS after MCAO compared to the 
sham-operated rats (p < 0.0001). Rats treated with LIF after MCAO had significantly smaller 
spleen weights compared to sham-operated rats (p = 0.0049). Rats treated with LIF had 
significantly larger spleens compared to rats treated with PBS at 72 h post-MCAO (p = 0.0372). 
(Fig. 4.3b).  
Brain and Splenic LIFR Expression Correlates with Spleen Weight  
Previous studies determined that reduction in spleen weight after stroke contributes to 
the severity of neuroinflammation (Seifert, Hall et al. 2012).  To determine the relationship 
between LIFR expression and the severity of the post-stroke immune response, Pearson r 
correlation analyses were performed to determine the relationship between LIFR expression and 
the reduction in spleen weight. There was a significant negative correlation between protein 
expression of LIFR in the brain and spleen weight at 72 h after MCAO (p = 0.0177; r = -0.6676; 
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Fig. 4.4a). On the other hand, there was a significant positive correlation between splenic LIFR 
expression and spleen weight among rats euthanized at 72 h after MCAO (p = 0.0074, r = 0.5325, 
Fig. 4.4b).  
JAK1 Inhibition is Neuroprotective under OGD  
In order to determine the optimum concentration of the JAK1 inhibitor (GLPG0634) 
necessary to counteract the neuroprotective mechanisms of LIF, a concentration-response 
assay was performed using five concentrations of GLPG0634 (2.5, 5, 10, 25, and 50 nM) in 
addition to a vehicle control (DMSO). Cells were subjected to OGD for 24 h and LDH release 
was measured to detect approximate levels of cell death. Treatment with GLPG034 and 24 h 
OGD yielded a significant difference in LDH release among treatment groups (p < 0.0001; F7,53 
= 9.966). The lowest concentration (2.5 nM) yielded a decrease in LDH release compared to 
DMSO that was very close to significance (p = 0.0507), while the 5 nM concentration yielded the 
greatest drop in LDH release compared to DMSO (p < 0.0001). The other treatments, including 
10 nM (p = 0.0098), 25 nM (p = 0.0019), and 50 nM (p = 0.0182), also significantly reduced LDH 
release after 24 h OGD. Neurons were also incubated for 24 h under normoxic conditions 
following treatment with DMSO or 5 nM GLPG0634. Both treatment groups had significantly 
lower LDH release compared to the OGD + DMSO treatment group (p < 0.0001). However, there 
was only a trend towards reduced LDH release in the neurons treated with 5 nM GLPG0634 
compared to the DMSO + Normoxia group (Fig. 4.5).  
Discussion 
 Previously, this lab showed that LIF controls the expression of protective 
antioxidant genes in the brain (Rowe, Collier et al. 2014, Davis, Collier et al. 2016). By 
maintaining high levels of LIFR, LIF increases expression of these enzymes among vulnerable 
cells.  When LIF binds to its receptor, its tail is phosphorylated by ERK1/2, thus triggering its 
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degradation (Blanchard, Duplomb et al. 2000). However, increasing protein expression of LIFR 
counteracts the degradation that occurs after prolonged LIFR/gp130 stimulation. LIFR 
upregulation has previously been shown to protect oligodendrocytes against injury in a mouse 
model of MS (Butzkueven, Zhang et al. 2002). The in vivo upregulation of LIFR after LIF 
treatment demonstrates that exogenous LIF treatment may help prolong its neuroprotective 
effects via expression of its receptor.  
LIFR levels in the brain are higher among rats with lower spleen weights, which indicate 
that LIFR is induced to counteract damage from invading immune cells.  A smaller spleen 
indicates the release of splenocytes into the peripheral circulation and infiltration of the brain 
(Seifert, Hall et al. 2012). The infiltration of peripheral leukocytes after stroke contributes towards 
this increase in brain LIFR levels, since many of these cell populations express LIFR (Janssens, 
Slaets et al. 2015). In addition, neural cells may upregulate LIFR in response to injury or 
neuroinflammation (Butzkueven, Zhang et al. 2002). Therefore, cells in the brain may increase 
LIFR expression to amplify the antioxidant effects of LIF.  
 The previous chapter of this dissertation showed that Sp1 is one of the TFs that is 
required for conferring its protective effects in neurons. According to Genomatix, Sp1 has two 
binding sites in the LIFR promoter. Although data from the previous chapter implicates Sp1 in 
LIF-mediated neuroprotection against OGD, Sp1 may contribute to neuroprotection against 
ischemic oxidative damage in the absence of LIF (Yeh, Yang et al. 2011).  By controlling levels 
of LIFR, Sp1 would not only sensitize cells to signaling from LIF, but other IL-6 cytokines that 
utilize the LIFR subunit (i.e. ciliary neurotrophic factor, oncostatin M, cardiotrophin-1).  
Splenic LIFR protein expression was significantly lower in both MCAO groups at 72 h 
compared to the sham-operated group. Furthermore, a positive relationship was observed 
between spleen weight and splenic LIFR expression. The migration of LIFR+ leukocytes from 
the spleen to the brain after stroke may contribute to this drop in LIFR expression compared to 
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sham levels Janssens et al. demonstrated that macrophages/microglia and T lymphocytes in the 
lesions of MS patients expressed high levels of LIFR {Janssens, 2015 #145}. By upregulating 
LIFR, leukocytes increase their sensitivity to LIF, which is also found at high levels in active MS 
lesions (Vanderlocht, Hellings et al. 2006).  Although there was a significant increase in spleen 
weight after LIF treatment, LIFR levels in the spleen was not significantly higher after LIF 
treatment compared to the PBS-treated rats.  The small difference in LIFR levels between LIF 
and PBS-treated rats could be explained by populations of splenocytes that increase LIFR after 
CNS injury. For instance, Cao et al. showed that lymphocyte populations of the spleen upregulate 
LIFR after induction of experimental autoimmune encephalomyelitis. Increased LIFR expression 
on splenocytes decreases CNS damage by reducing numbers of pro-inflammatory 
lymphocytes(Cao, Yang et al. 2011).  It is possible that remaining splenocytes that did not enter 
the peripheral circulation may upregulate LIFR as a general protective mechanism after stroke.  
 At 72 h after MCAO, LIF-treated rats had significantly larger spleens than PBS-treated 
rats. However, the spleen weight among LIF-treated rats was still significantly lower than sham 
rats, which shows that LIF lessened but did not block the decrease in spleen weight. The drug 
treatment regimen utilized in these animal studies involves intravenous LIF administration rather 
than direct intracranial or intraventricular administration. While systemic administration allows 
LIF to reach the spleen, this treatment failed to attenuate the decrease in spleen size. In a study 
published by Vendrame et al., HUCB cell therapy, which confers similar pro-survival effects to 
LIF treatment, counteracted the release of splenocytes into the circulation (Vendrame, Gemma 
et al. 2006).  This phenomenon is explained by the release of chemokines from the HUCB cells 
that promote chemotaxis of the splenocytes back to the spleen (Newman, Willing et al. 2006). 
However, the ability to prevent or reverse the splenic response is not necessarily enough to 
reduce brain damage. According to Ajmo et al., systemic injection of the α1-adrenoreceptor 
antagonist prazosin attenuated the decrease in spleen size, but did not significantly reduce 
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infarct size (Ajmo Jr, Collier et al. 2009). Therefore, LIF may modulate the immune response via 
a mechanism independent of the splenic response.  
 Although the hypothesis for this study indicated that JAK1 activity contributed to 
neuroprotection during ischemia by facilitating LIF signaling, the concentration-response 
experiments under normoxia and OGD demonstrated that JAK1 inhibition is neuroprotective 
under OGD but has no effect on cell death under normoxia. Although JAK1 has been implicated 
in LIF-mediated activation of PI3K/Akt signaling, JAK1 activity has also been shown to contribute 
to neurodegeneration. For instance, JAK1 activation contributes to neuronal death after spinal 
cord injury as well as ischemic stroke through tyrosine phosphorylation of STAT1 (Takagi, 
Harada et al. 2002, Osuka, Watanabe et al. 2011).  Therefore, GLPG0634 treatment prior to 
OGD may have a neuroprotective effect through inhibition of STAT1. Several of the in vitro 
studies that implicate JAK1 in neuroprotection involve its role in STAT3 activation. Studies in the 
literature indicate that STAT3 activation serves as a figurative double-edged sword during 
cerebral ischemia. Among neurons, activated STAT3 may upregulate genes that protect against 
ischemia(Jung, Kim et al. 2009). However, STAT3 activation plays a detrimental role during 
stroke by contributing to IL-6 and IL-23-induced development of Th17 cells. According to Yang 
et al., STAT3 upregulates the retinoic acid receptor-related orphan receptor γ-T, a marker for 
Th17 lymphocytes while suppressing expression of Forkhead box transcription factor P3 
(FoxP3), a Treg-specific transcription factor (Yang, Panopoulos et al. 2007). 
 In this study, JAK1 inhibition was only effective at reducing neuronal death under in vitro 
ischemia, and not under normoxia. This finding demonstrates that JAK1 activity increases under 
ischemia, and it favors the activation of signaling pathways that are detrimental to neurons over 
neuroprotective signaling. GLPG0634, an inhibitor that favors JAK1 over other Janus Kinase 
members JAK2/3 and Tyk2, is currently undergoing Phase II clinical trials for use in rheumatoid 
arthritis patients. According to a preclinical study by Van Rompaey et al., GLPG0634 reduces 
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production of interferon gamma (IFNγ), IL-13, and IL-17, which are involved in the development 
of mature CD4+CCR5+ (Th1), CD4+CCR3+ (Th2), and Th17 lymphocytes (Van Rompaey, 
Galien et al. 2013). Considering the detrimental role of Th1 and Th17 cells in the post-stroke 
inflammatory response, GLPG0634 may have potential as stroke therapeutic that could target 
neuroprotection as well as the inflammatory response.  
 This laboratory has published several studies examining the pro-survival effects 
of LIF signaling. However, the regulation of LIFR expression and activity during stroke is less 
understood. LIF treatment did not significantly counteract the splenic contraction after stroke over 
time or compared to PBS treatment. However, this study showed that brain LIFR expression 
increases after LIF treatment, and LIFR expression in splenocytes increases in a time-dependent 
manner after stroke. Since LIFR is responsible for mediating the neuroprotective effects of 
multiple IL-6 family cytokines, targeting its expression in future studies may sensitize neural cells 
to the protective properties of exogenous and endogenous LIF signaling.  
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Figure 4.1. LIF upregulates LIFR in the Brain 72 h after MCAO. Western blotting was used to 
determine levels of LIFR protein expression in brain tissue 72 h after MCAO. Ipsilateral tissue 
from LIF treated rats had significantly higher levels of LIFR compared to sham tissue (*p<0.01) 
and ipsilateral tissue from PBS-treated rats (#p<0.05). n =4 per treatment group.  
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Figure 4.2. The LIFR Promoter contains two Sp1 binding sites. Genomatix was used to 
identify binding sites for MZF-1 and Sp1, which are responsible for LIF-mediated 
neuroprotection, in the LIFR promoter sequence. Although no MZF-1 sites were identified, two 
Sp1 sites were identified on each strand at approximately the same location.  
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Figure 4.3. LIF Significantly Increases Spleen Weight but not Splenic LIFR Expression. (a) 
At 72 h, there was a change in splenic LIFR expression between Sham, PBS, and LIF-treated 
rats that reached statistical significance. At this time point, both PBS and LIF-treated rats had 
significantly lower LIFR expression in the spleen compared to sham rats (*p<0.05). There was a 
small trend towards higher LIFR expression in the spleens of LIF-treated rats compared to PBS-
treated rats, but this increase was not significant. n = 8 animals per group. (b) Compared to 
Sham rats, LIF (*p<0.01) and PBS-treated (**p<0.0001) rats had significantly smaller spleens. 
However, at this time point the LIF-treated rats had significantly larger spleens than PBS-treated 
rats (#p<0.05).  n ≥ 23 animals per group.  
 
 
 
 
 
 
 
 
 
 
 
131 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. LIFR Expression in Brain and Spleen Correlates with Spleen Weight after 
MCAO. (a) There was a significant negative correlation between LIFR and spleen weight 
(*p<0.05), and higher LIFR expression was associated with a smaller spleen at 72 h post-MCAO. 
n = 4 per treatment group.  (b) Splenic LIFR protein levels positively correlated with spleen size 
at 72 h post-MCAO (*p<0.01). n = 8 per treatment group 
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Figure 4.5. JAK1 inhibition reduces neuronal death under OGD. Neurons were treated with 
GLPG034 or DMSO prior to incubation for 24 h under OGD or normoxia. 2.5 nM GLPG034 led 
to a decrease in LDH release that approached significance. However, 5 nM (***p<0.0001), 10 
nM, 25 nM (**p<0.01), and 50 nM (*p<0.05) GLPG0634 yielded significant decreases in LDH 
release compared to DMSO. Cells treated with DMSO and incubated under normoxia showed 
significantly lower LDH release compared to their OGD-subjected counterparts (***p<0.0001). 
Under normoxia, treatment with 5 nM GLPG0634 did not significantly change LDH release 
compared to the DMSO-treated cells incubated under normoxia. n ≥ 7 per treatment group.  
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CHAPTER 5: 
DISCUSSION 
Overview 
As the fifth leading cause of death and a major cause of disability in the United States, 
stroke creates a massive burden on the healthcare system. Although 5-10% of all stroke patients 
benefit from thrombolytic therapy, the overwhelming majority of patients are faced with a stunning 
lack of therapeutic options. While tissue plasminogen activator (tPA) restores perfusion to the 
infarct if administered within 3-4.5 hours, the majority of stroke patients are unable to receive 
treatment within this time window. In addition, the use of tPA in stroke patients also carries 
serious risk for hemorrhage, since tPA often weakens the blood-brain barrier. Several research 
groups, including this group have turned their attention away from thrombolytic agents and have 
chosen to focus on drugs that will improve cellular survival and target both phases of 
pathophysiology.  
During the initial phase of stroke injury, increased calcium signaling activates enzymes 
that produce reactive oxygen species (ROS), such as neuronal nitric oxide (NO) synthase and 
NADPH oxidase. These ROS damage lipid membranes, oxidize proteins, and trigger apoptosis 
via mitochondrial dysfunction. Although ROS contribute to the initial phase of ischemic 
cytotoxicity, oxidative damage to neural cells continues into the delayed phase of 
neuroinflammation.  Respiratory bursts from activated microglia, peripheral 
monocytes/macrophages, and neutrophils weaken surviving cells in the penumbra. Considering 
the integral role that oxidative stress plays during both phases of stroke pathophysiology, 
researchers expected free-radical scavenging drugs such as NXY-059 to perform well in clinical 
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trials. Unfortunately direct administration of antioxidants has not yielded any viable therapeutic 
options for stroke patients.  
Although the failure of exogenous antioxidant drugs is discouraging, these unsuccessful 
trials do not mean that antioxidant enzymes cannot protect neural cells against stroke. While the 
early success of NXY-059 was ultimately undone by its short half -life (2-4 h) and inability to 
cross the blood-brain barrier (BBB) without difficulty, antioxidant enzymes avoid these pitfalls 
(Strid, Borga et al. 2002). As mentioned in Chapter 1 of this dissertation, neurons and glia are 
equipped with basal levels of endogenous antioxidants including glutathione peroxidase, 
catalase, and the superoxide dismutase (SOD) enzymes. Since these enzymes are expressed 
by the brain prior to stroke, the question of whether they can cross the BBB is not an issue. 
Antioxidant enzymes eventually undergo degradation, but degraded enzymes are replenished 
by newly synthesized protein. Finally, the brain’s antioxidant enzymes include some of the most 
efficient enzymes known in nature. At its maximum rate, catalase may break down approximately 
40 million molecules of hydrogen peroxide per second (Ho, Xiong et al. 2004). Considering these 
advantages, this laboratory has focused on identifying novel treatments with a broad therapeutic 
window and the ability to enhance the brain’s antioxidant capacity.  
 Human umbilical cord blood (HUCB) cell therapy showed extremely promising results in 
a rat model of permanent focal cerebral ischemia by enhancing the expression of protective 
genes. Two of these genes, peroxiredoxin IV (Prdx4) and metallothionein III (Mt3), protect white 
matter by scavenging ROS. In vitro studies using cultured oligodendrocytes (OLs) showed that 
HUCB cells exerted oligoprotection against ischemia via PI3K/Akt signaling during oxygen 
glucose deprivation (OGD). HUCB treatment also increased Prdx4 mRNA compared to cells 
subjected to OGD alone. Blocking the activity of Prdx4 during in vitro ischemia counteracted the 
protective effect of the cells, demonstrating the integral role of Prdx4 in HUCB-mediated 
antioxidant protection(Rowe, Leonardo et al. 2010, Rowe, Leonardo et al. 2012). HUCB therapy 
exerted potent antioxidant and pro-survival effects on white matter, but there was a high degree 
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of variability between batches of cells. This laboratory chose leukemia inhibitory factor (LIF), a 
neurokine expressed by HUCB cells, to confer the protective effects of HUCB cell therapy without 
the variability of cellular treatment. 
The Pleiotropic Effects of LIF in the Brain  
So far, this laboratory has focused mainly on the pro-survival and antioxidant-inducing 
properties of LIF in neurons and OLs. Data from other groups shows that the in vivo effects of 
LIF extend beyond pro-survival signaling and enhanced expression of antioxidant genes. By 
acting through multiple cell types, LIF treatment provides synergistic protection for neural cells 
during ischemia (Figure 5.1).  
LIF Differentially Regulates Antioxidants in Neurons and OLs 
 Rowe et al. demonstrated that intravenous treatment with LIF at 6, 24, and 48 h after 
MCAO reduced infarct size, improved sensimotor skills, and lessened white matter damage. 
Similar to the HUCB cells, LIF protected cultured OLs were dependent upon Akt signaling and 
the full activity of Prdx4, since treating OLs with Akt Inhibitor IV or anti-Prdx4 antibodies negated 
the decrease in lactate dehydrogenase (LDH) release seen after LIF treatment. (Rowe, Leonardo 
et al. 2010, Rowe, Leonardo et al. 2012). Mt3 expression was also induced by LIF treatment, 
although this upregulation was not dependent upon Akt activity. Although LIF treatment 
significantly upregulated Prdx4 mRNA among OLs subjected to OGD, total SOD activity was 
significantly decreased compared after LIF treatment. Blocking Prdx4 not only increased LDH 
release, but it returned SOD activity to levels similar to the cells treated with PBS prior to OGD.   
The decrease in SOD activity coincides with increased antioxidant protection from Prdx4, but 
inhibiting Prdx4 did not significantly increase SOD activity compared to the OGD alone treatment 
group. While OLs increase SOD activity in response to oxidative stress, they aren’t able to 
increase activity to compensate for decreased Prdx4. By contrast, neurons treated with LIF had 
significantly higher levels of SOD3 siRNA compared to neurons treated with PBS. Cells 
transfected with SOD3 siRNA and treated with LIF showed no significant decrease in cell death 
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compared to neurons transfected with scrambled siRNA and treated with PBS. Therefore, LIF 
upregulates different antioxidant genes depending upon the cell type. Increased Prdx4 and Mt3 
expression are a hallmark of LIF-mediated oligoprotection, while SOD3 upregulation is a neuron-
specific mechanism of protection (Rowe 2011 , Rowe, Collier et al. 2014, Davis, Collier et al. 
2016).  
Although LIF confers unique neuroprotective properties among neurons, studies from this 
laboratory demonstrate that while LIF significantly decreases neuronal death during ischemia, 
the reduction is not as great compared to oligodendrocyte cultures. OLs are especially vulnerable 
to ROS-mediated damage due to their high lipid content. Currently, there are no studies 
indicating that OLs endogenously produce LIF during injury. By contrast, astrocytes and neurons 
are able to increase LIF expression during ischemia (Suzuki, Tanaka et al. 2000). This difference 
between neurons and LIF might explain why the reduction in cell death was greater in OLs 
compared to neurons. Astrocytic contamination in neuronal cultures might also protect neurons 
from OGD-mediated damage. To prevent this confounding effect, neurons were treated with 
cytosine-β-D-arabinofuranoside to prevent the proliferation of astrocytes. Nevertheless, a small 
number of astrocytes in neuronal cultures may produce enough LIF to provide neuroprotection 
under PBS treatment alone (Banner, Moayeri et al. 1997).  
In Chapter 2, this laboratory showed that rats receiving LIF treatment show significantly 
higher levels of SOD activity in the ipsilateral hemisphere 72 h after MCAO. Although the brain 
homogenates used in these experiments contained lysates from neurons as well as glial cells, 
there are several pieces of evidence indicating that neurons are primarily contributing to the 
increased SOD activity seen after LIF treatment. Several studies in the literature demonstrate 
that SOD3 has low basal expression in the brain, but neurons increase SOD3 mRNA after LIF 
treatment in vitro. Countering this upregulation with SOD3 siRNA treatment reverses the 
protective effect of LIF administration, demonstrating a positive relationship between SOD3 
expression/activity and neuronal survival. In vivo studies confirmed this positive relationship, 
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since rats treated with LIF after MCAO showed smaller infarct volumes, significantly higher SOD 
activity, and increased SOD3 protein expression. Among OLs, there was an inverse relationship 
between cell survival and SOD activity. OLs treated with LIF prior to OGD showed significant 
decreases in SOD activity and LDH release, while administration of the Prdx4 antibody reversed 
these effects.  
Among brain sections from LIF treated rats, SOD3 immunoreactivity increased in the 
cortical tissue of the ischemic core/penumbra, but little SOD3 immunoreactivity was observed in 
the external capsule (unpublished results). SOD3+ cells possessed the triangular morphology of 
pyramidal neurons, which are the primary type of neurons in the cortex. Double-labeling cortical 
tissue with MAP2 and SOD3 antibodies confirmed that cortical neurons express SOD3 after LIF 
treatment. While it is possible that astrocytes and vascular cells of the gray matter also 
upregulated SOD3, these data suggests that SOD3 induction is primarily a neuronal 
phenomenon.   
One common characteristic of antioxidant enzymes induced by LIF treatment, is the 
ability to be secreted into the extracellular environment. SOD3, unlike SOD1 or SOD2, contains 
a signaling peptide that allows for its secretion into the extracellular environment. (Zelko, Mariani 
et al. 2002). Of the Prdx family enzymes, Prdx4 is the only isoform that is localized to the 
endoplasmic reticulum and contains a signaling peptide. Therefore, Prdx4 may also be secreted 
into the extracellular space from OLs. Mt3 does not contain a signal peptide, but El Ghazi et al. 
discovered that astrocytes secrete Mt3 via a multi-protein complex (El Ghazi, Martin et al. 2010).  
Prdx enzymes catalyze the breakdown of hydrogen peroxide to water and oxygen, but cannot 
break down superoxide. Even with increased Prdx4 expression, OLs are still vulnerable to 
superoxide-mediated damage during cerebral ischemia.  Likewise, SOD3 breaks down 
superoxide but is unable to process hydrogen peroxide. Mt3 also reacts with superoxide anions 
in addition to hydroxyl radicals (Thornalley and Vašák 1985). By increasing the expression of 
secreted antioxidant enzymes, LIF is able to protect neural cells against multiple species of ROS.  
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SOD3 Activity Enhances the Protective Effects of NO 
Since superoxide reacts with free NO to form ONOO-, SOD3 indirectly increases NO 
bioavailability in the cerebral vasculature. NO promotes tissue repair via several mechanisms. 
NO production activates protein kinase G (PKG) by increasing cGMP synthesis by guanylate 
cyclase.  PKG increases cerebral blood flow in the ischemic hemisphere by promoting 
vasodilation of large cerebral vessels. In the cerebral microvasculature, endothelial NO synthase 
(eNOS) activity increases synthesis of vascular endothelial growth factor, which promotes 
angiogenesis. The synthesis of new blood vessels improves perfusion of the infarct by diverting 
blood flow around the occluded vessel. In addition to its effects on vascular tone and 
angiogenesis, NO also promotes synthesis of brain-derived neurotrophic factor (BDNF), a 
protective growth factor. In a study by Chen et al., eNOS knockout mice had larger infarct 
volumes at 24 h post-MCAO, decreased neurogenesis in the subventricular zone, and impaired 
angiogenesis compared to their wild-type counterparts (Chen, Zacharek et al. 2005).  
LIF promotes the self-renewal of several pluripotent stem cell populations, including neural stem 
cells (NSCs). According to Bauer et al., LIF decreases neurogenesis in the SVZ and the olfactory 
bulb while promoting NPC proliferation. By maintaining a high population of NSCs, LIF treatment 
ensures that these cells will be available to repair damaged brain tissue and replace dying cells. 
After MCAO, NSCs utilize blood vessels to migrate toward the infarct, BDNF synthesis, which is 
regulated by NO production, increases the rate of neurogenesis.  
 Akt Activity Protects Microvascular Integrity 
During stroke, breakdown of the BBB renders neural cells vulnerable to the peripheral 
immune system and vasogenic edema. Tight junction (TJ) components, which include the 
claudins (Cldns), occludin, and zona occludens, are responsible for maintaining barrier integrity 
in the cerebral microvessels. Downregulation of TJ proteins during cerebral ischemia contributes 
to overall brain damage. Strecker et al. showed that monocyte chemoattractant protein-1 (MCP-
1), which recruits immune cells to the brain during stroke, decreases expression of the TJ protein 
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Cldn5.  MCP-1 knockout mice expressed higher levels of claudin-5 in the cerebral vasculature 
compared to wild-type mice, and they also exhibited smaller infarcts and less protein 
extravasation into the parenchyma (Strecker, Minnerup et al. 2013).  
Factors that increase PI3K/Akt activation can increase expression of several Cldns 
expressed at the BBB. For instance, granulocyte colony stimulating factor, an Akt-activating 
cytokine that protects OLs during OGD, prevents the downregulation of Cldn5 and Cldn3 during 
neonatal hypoxic-ischemic injury and reduced vasogenic edema as measured by Evans blue 
extravasation (Li, Klebe et al. 2015). Akt protects against this downregulation of Cldn5 via 
inactivation of Forkhead Box Transcription Factor O1 (FoxO1) (Beard, Haines et al. 2014). 
PI3K/Akt signaling induced by Pigment Epithelium-Derived Factor Peptide rescues expression 
of zona occludens 1 and occludin in the blood-retinal barrier of Ins2 (Akita) diabetic mice (Liu, 
Leo et al. 2012). LIF is transported through the cerebral vasculature via active transport, and the 
rate of transport has been shown to increase during central nervous system (CNS) injury. 
Endothelial cells of the CNS express LIFR and gp130, and LIFR protein expression increases in 
addition to LIF transport (Pan, Cain et al. 2006). Therefore, LIF could induce PI3K/Akt signaling 
within endothelial cells in addition to crossing the BBB. By activating this signaling pathway, LIF 
could rescue TJ protein expression and protect neural cells from vascular leakage.  
 LIF Enhances Proliferation of NSCs  
According to Laterza et al., induced neural stem cells (NSCs) secrete LIF in response to 
stimulation with interferon gamma (IFNγ) (Laterza, Merlini et al. 2013). Published work from this 
laboratory demonstrated that IFNγ mediates the post-stroke inflammatory response and the 
infiltration of peripheral immune cells in the brain. Although IFNγ does not directly damage 
neurons, it indirectly contributes to neuronal death via activation of pro-inflammatory 
macrophages/microglia (Seifert, Leonardo et al. 2012, Seifert, Collier et al. 2014).  Therefore, 
the release of LIF from NSC populations acts as a protective mechanism against neural cells, 
which are susceptible to immune-mediated damage. Since LIF increases the population of 
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NSCs, this mechanism would perpetuate the protective effects of exogenous LIF administration 
by enhancing endogenous LIF production.  Since NSCs secrete multiple pro-survival factors, 
they have been examined by several groups as a therapeutic option for ischemic stroke. 
Systemic LIF administration maintains NSC populations and increases the brain’s capacity of 
neural regeneration while avoiding some of the pitfalls associated with cellular therapies.  
The Neuroprotective Signaling of LIF 
As demonstrated by these findings, several mechanisms of LIF in neurons overlap with 
its pro-survival signaling in OLs. Some of these common effects of LIF treatment include the 
reduction in cytotoxicity, increased Akt signaling, and upregulation of antioxidant expression at 
the level of transcription. However, several new mechanisms of LIF-mediated neuroprotection 
have been identified from these experiments. These mechanisms, which are displayed in Figure 
5.2, will be discussed below.  
LIF Administration Sensitizes Neural Cells to LIFR signaling  
At 72 h after MCAO, LIF receptor (LIFR) expression is increased significantly in the brains 
of LIF-treated rats compared to the PBS-treated and sham groups. Although qPCR or 
immunohistochemical staining will be needed to confirm whether this effect is specific to neurons, 
this laboratory demonstrated previously that LIFR is localized in neuronal tissue (Davis, Collier 
et al. 2016). However, OLs upregulate LIFR in response to injury, so this further studies are 
necessary to demonstrate whether LIFR is induced in multiple neural cell types after LIF 
treatment. Furthermore, the LIFR promoter contained two Sp1 binding sites. Sp1 contains 
binding sites in genes that are induced in OLs (Prdx4, Mt3) and neurons (SOD3), so it is possible 
that upregulation is occurring in white and gray matter. Since LIFR expression in the brain 
negatively correlates with spleen weight, it is possible that neural cells induce LIFR to protect 
against immune-mediated damage. However, the increase in brain LIFR levels between sham 
rats and PBS rats was not significant. Therefore, LIF treatment is primarily responsible for this 
increase in LIFR treatment.  
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Although LIFR is a component of the LIF-specific receptor, increasing the expression of 
LIFR would sensitize neurons to IL-6 family cytokines that also signal through receptors that 
contain LIFR. Ciliary neurotrophic factor (CNTF), which exerts similar Akt-dependent pro-survival 
effects on neurons, signals through a gp130/CNTFR/LIFR tripartite receptor(Alonzi, Middleton et 
al. 2001). Since CNTF does not have a signal sequence, it cannot undergo ER/Golgi-dependent 
exocytosis in the same manner as LIF. Previous groups claimed that CNTF could only be 
released by dying astrocytes. Lee et al. showed that intact astrocytes can upregulate and release 
CNTF in response to CNS  injury(Lee, Deller et al. 1997). Increased LIFR in the brain would not 
only sensitize the brain to exogenous LIF, but also IL-6 family neurokines that are released from 
astrocytes. According to Pan et al., LIFR is involved with elevated LIF transport across the BBB 
during CNS injury. Therefore, higher levels of LIFR which would increase the bioavailability of 
exogenous LIF to neural cells during stroke(Pan, Cain et al. 2006).  
Akt, but not JAK1 activity protects neurons during OGD  
Previously, this lab demonstrated that LIF-mediated neuroprotection and oligoprotection 
depends upon Akt signaling by showing how Akt inhibitor IV treatment counteracts the reduction 
in LDH release observed after LIF treatment (Rowe, Collier et al. 2014, Davis, Collier et al. 2016). 
Since LIF exerts its protective signaling via control of gene expression, inhibition of Akt signaling 
would prevent the activation of necessary transcription factors (TFs) and upregulation of Akt-
dependent genes. Specificity protein 1 (Sp1) and myeloid zinc finger-1 (MZF-1), the TFs that are 
responsible for LIF-mediated neuroprotection, have previously shown to be controlled by Akt 
signaling. However, the role of PI3K in LIF-mediated neuroprotection during stroke has not been 
examined. Previously, this laboratory showed that inhibition of PI3K counteracted the protective 
effects of HUCB cells, which also regulate antioxidant genes through Akt signaling(Rowe, 
Leonardo et al. 2012). As a result, PI3K almost certainly plays a role in the neuroprotective and 
oligoprotective effects of LIF signaling, but further experiments will be needed to test this 
hypothesis.  
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In Chapter 2 of this dissertation, SOD3 knockdown increased apoptosis among PBS- and 
LIF-treated neurons compared to their scrambled siRNA-transfected counterparts. Laatikeinen 
et al. demonstrated that SOD3 increases cell survival in a rat model of hindlimb ischemia by 
increasing phosphorylation of Akt. This increased Akt activity increased phosphorylation and 
subsequent inactivation of FoxO3, a transcription factor that upregulates genes involved with 
apoptosis (Laatikainen, Incoronato et al. 2011). Furthermore, this lab previously showed that at 
72 h after middle cerebral artery occlusion (MCAO), neurons expressing high levels of SOD3 
also showed high levels of Akt phosphorylation in vivo (Davis, Collier et al. 2016). By maintaining 
Akt activity, SOD3 upregulation helps prolong anti-apoptotic signaling after LIF has been 
degraded.  
The initial hypothesis in Aim 3 stated that JAK1 inhibition would counteract the protective 
effects of LIF. However, JAK1 inhibition alone was shown to be neuroprotective under OGD. 
While it is still possible that JAK1 activation links LIF-LIFR binding with downstream PI3K/Akt 
signaling, these data suggests that JAK1 activity is primarily detrimental during OGD. Further 
studies showing the change in JAK1 phosphorylation between PBS and LIF-treated neurons will 
be needed to determine the exact role of JAK1 in LIF signaling. Previous studies show that JAK1 
activity contributes to the protective actions of LIF, but JAK1 may also play a role in the 
termination of LIF signal transduction (Oh, Fujio et al. 1998). Phosphorylation of LIFR by ERK1/2 
leads to endocytosis and proteasome-mediated degradation of LIFR (Blanchard, Duplomb et al. 
2000). According to Quintás-Cardama et al., treatment with the JAK1/2 inhibitor INCB018424 
decreases phosphorylation of ERK1/2 in a dose-dependent manner. Since JAK1 lies upstream 
of several signaling pathways, it is possible that it plays a dual role in regards to LIF signaling 
(Quintás-Cardama, Vaddi et al. 2010). In the absence of LIF treatment, the neuroprotective 
properties of GLPG0634 are likely due to the inhibition of STAT1 signaling. During focal cerebral 
ischemia, STAT1 phosphorylation contributes to increased caspase proteolysis and apoptotic 
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cell death (Takagi, Harada et al. 2002). Since JAK1 directly phosphorylates STAT1, its inhibition 
could reduce apoptotic death during in vitro ischemia. 
Since the JAK1 inhibition alone significantly reduces LDH release under OGD, it is likely 
that JAK1 inhibition will add to the protective effects of LIF rather than counteract it. Since JAK1 
lies upstream of multiple signaling pathways, it is possible that pharmacological inhibition alone 
is not sufficient to determine whether JAK1 plays a role in LIF-mediated neuroprotection. Future 
studies may require the measurement of active (phosphorylated) JAK1 among cells treated with 
LIF vs cells treated with PBS using immunohistochemistry as well as western blotting to 
determine its involvement in LIF signaling.   
MZF-1 and Sp1 Regulate Genes Induced by LIF  
Several TFs that regulate the expression of Akt-inducible genes were identified by this 
laboratory. Among those TFs were MZF-1 and Sp1, which had binding sites in eight and seven 
out of eight genes total. Analysis of promoter regions using Genomatix software indicated that 
Sp1 and MZF-1 binding sites were present in the promoters of Prdx4 and Mt3. In addition, both 
TFs have binding sites in the promoter sequence of peroxiredoxin V (Prdx5), a mitochondrial 
Prdx isoform that is also induced by Akt signaling (Shahaduzzaman, Mehta et al. 2015). Several 
groups demonstrated that Sp1 and MZF-1 regulated transcription of SOD3, and the SOD3 
promoter sequence contained multiple binding sites for both TFs. Although MZF-1 has been 
shown to regulate gene expression of SOD3, these studies focused on lung tissue and other 
non-neuronal cell types. Luo et al. demonstrated that MZF-1 plays a protective role in astrocytes 
by mediating the upregulation of fibroblast growth factor-2 after apomorphine treatment.(Luo, 
Zhang et al. 2009). In addition, Ahlemeyer et al. demonstrated that retinoic acid, which increases 
expression of MZF-1, protects cells against oxidative damage by maintaining SOD enzyme levels 
(Ahlemeyer, Bauerbach et al. 2001).   However, this laboratory is the first group to implicate 
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MZF-1 as a transcription factor that is not only expressed by neurons, but acts in a 
neuroprotective manner.  
Currently, very little data exists regarding the regulation of MZF-1 activity in vivo and in 
vitro. Moeenrezakhanlou et al. showed that PI3K/Akt signaling controls MZF-1 activity at the level 
of protein expression. This finding was confirmed to be true in neurons via the qPCR and 
immunohistochemical staining in Chapter 3. MZF-1 upregulation after LIF treatment was not 
quite significant in vivo, but the presence of non-neuronal cells in brain tissue could mask the in 
vivo neuronal upregulation of MZF-1. Double-labeling brain sections with antibodies against 
neuronal nuclear antigen (NeuN) and MZF-1 showed a strong degree of co-localization in the 
cortex, but the adjacent white matter in the external capsule showed much lower levels of MZF-
1 expression. MZF-1 upregulation, like SOD3 upregulation, could be exclusive to neurons after 
LIF treatment. Transfecting neurons with MZF-1 siRNA counteracted the neuroprotective effect 
of LIF treatment, showing that the upregulation of MZF-1 is necessary for LIF-mediated 
neuroprotection. 
Sp1 is known as a ubiquitously expressed transcription factor, and its levels were not 
significantly altered by LIF treatment in vivo and in vitro. However, the trend towards increased 
expression in the brains of LIF-treated animals indicates that LIF helps maintain Sp1 against 
proteasome-mediated degradation(Han and Kudlow 1997, Wang, Hu et al. 2006). Moreover, Sp1 
is controlled by multiple post-translational modifications that are regulated by Akt, including 
acetylation and phosphorylation (Suzuki, Kimura et al. 2000, Chen, Halappanavar et al. 2004, 
Bae, Park et al. 2006) Inhibiting Akt counteracted the reduction in cell death observed after LIF 
treatment in both neurons and OLs. Similarly, transfecting cells with Sp1 siRNA counteracted 
the protective effects of LIF in neurons. Unlike MZF-1, Sp1 is not upregulated by LIF at the level 
of transcription, but LIF treatment is ineffective with reduced Sp1 expression. These data show 
that Sp1 is regulated by LIF in a manner independently of gene expression. According to 
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correlation analysis, there is a positive relationship between Sp1 and MZF-1 protein expression 
after LIF treatment, but not PBS treatment or sham injury. High levels of both TFs are beneficial 
since they are both necessary for the protective effects of LIF. In addition, immunohistochemical 
staining demonstrated that cells in the cerebral cortex express high levels of Sp1/MZF-1 and 
SOD3 after LIF treatment. Further investigation will indicate whether Sp1 and MZF-1 act as co-
regulators of SOD3 transcription.  
Through these studies, this laboratory identified several neuroprotective mechanisms of 
LIF treatment, namely the upregulation of SOD3 and MZF-1 and the activation of Sp1. LIF exerts 
its protection through common signaling mechanisms in neurons and OLs, most notably through 
Akt. Prdx4, which is regulated by Akt, contains binding sites for Sp1 and MZF-1 in its promoter. 
Further studies will determine whether these TFs play a role in oligoprotection, or whether LIF 
activates additional TFs in neurons and glia. The neuroprotective pathways utilized by LIF are 
visualized in Figure 1.  
SOD3 Upregulation is Responsible for Higher SOD Activity  
A previous publication from this lab demonstrated that LIF reduces overall tissue damage 
and white matter degradation after stroke. However, the antioxidant-inducing effects of LIF had 
only been identified through in vitro studies(Rowe, Collier et al. 2014). By determining that LIF 
increases total superoxide dismutase activity, this lab showed distinct in vivo antioxidant 
protection conferred by LIF administration after MCAO. Superoxide anions exert profound 
damage to cellular components through direct oxidation and by reacting with NO to form 
peroxynitrite (Bonfoco, Krainc et al. 1995). SOD enzymes, in conjunction with endogenous 
peroxidases, catalyzes the breakdown of superoxide anions to peroxide and ultimately, water 
and molecular oxygen. Therefore,   increasing SOD activity in the brain has profound effects on 
reducing cellular damage and increasing survival during ischemia.  
Through increased Prdx4 expression, LIF treatment confers protection against the 
oxidation of white matter components. However, in vitro studies using cultured OLs 
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demonstrated that these cells have a limited ability to upregulate SOD activity under ischemia, 
and that LIF treatment reduced SOD activity in OLs. This discrepancy between cultured 
oligodendrocyte studies and in vivo SOD activity demonstrated that systemic LIF treatment 
induces SOD activity in other cell types (Rowe, Collier et al. 2014, Davis, Collier et al. 2016).  
It is possible that LIF increases SOD activity through post-translational modification, but 
microarray and qPCR data from previous studies involving LIF and other Akt-inducing therapies 
shows that protective genes are controlled at the level of transcription. Western blotting and 
immunohistochemical analysis on samples used in the SOD inhibition assay confirmed that 
higher levels of SOD3 expression are present when SOD activity is upregulated. According to 
the western blotting analysis, SOD1 was only significantly upregulated in the contralateral tissue 
of LIF-treated rats. An explanation for this phenomenon was discussed in Chapter 2; although 
LIF may induce SOD1, ischemic conditions cause SOD1 to aggregate(Chen, Guan et al. 2012). 
If these SOD1 aggregates precipitate out of the homogenized brain tissue, they may not be 
detected via western blotting. SOD2 was not altered significantly among treatment groups, but it 
was lower in the ipsilateral tissue of LIF-treated rats compared to the tissue from Sham and PBS-
treated rats. The decreased SOD2 expression might be a consequence of decreased oxidative 
damage in the tissue from the LIF rats as well as upregulated Akt activity. Akt inactivates FoxO3 
via phosphorylation, and decreases transcription of the SOD2 gene(Li, Chiu et al. 2006). 
Nonetheless, the upregulation in SOD3 appears sufficient to counteract any minor decreases in 
SOD2 expression, since SOD activity is significantly higher in the brains of LIF-treated rats.  
Using qPCR analysis, this lab demonstrated that neurons increased SOD3 mRNA after 
LIF treatment. Therefore, the in vivo upregulation of SOD3 protein expression is due to LIF 
signaling in neurons. To confirm that SOD3 was responsible for LIF-mediated protection against 
ischemic damage in neurons, SOD3 siRNA was used to silence expression. Using the 
Nucleofector electroporation device and a transfection protocol optimized for primary mammalian 
neurons, an approximately 30% decrease in SOD3 expression was achieved. Although 
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neutralizing antibodies were used in the oligodendrocyte studies, silencing SOD3 expression at 
the level of transcription is a more efficient manner of counteracting the effects of LIF in neurons, 
since the SOD3 siRNA transfection prevented the LIF-mediated increase in SOD3 mRNA. 
According to Laatikainen et al., SOD3 enhances pro-survival signaling by maintaining Akt 
phosphorylation. Since LIF protects neurons and OLs by activating Akt, SOD3 helps prolong the 
pro-survival actions of LIF (Laatikainen, Incoronato et al. 2011). Suppressing the upregulation of 
SOD3 prevents LIF from protecting neurons against apoptotic and necrotic cell death.  
Indirect Mechanisms of Neuroprotection by LIF  
Although these experiments focused mainly on the neuroprotective and antioxidant 
effects of LIF, there is strong evidence to suggest that LIF could act as an immunomodulatory 
agent during stroke. As an anti-inflammatory cytokine, LIF alters the phenotypes of several 
immune cells in vivo. Since pro-inflammatory microglia/peripheral leukocytes exert the majority 
of damage to cells in the penumbra after stroke, LIF could potentially promote survival in this 
region by shifting the immune balance from pro- to anti-inflammatory. The proposed mechanisms 
of LIF-mediated immunomodulation during stroke are detailed in Figure 4.3.  
 Splenic LIFR increases after MCAO  
At 72 h after MCAO, there was a significant decrease in splenic LIFR expression 
compared to the levels of sham rats. This drop in LIFR expression is explained by the migration 
of immune cells from the spleen to the ischemic hemisphere. LIF treatment slightly increased 
splenic LIFR levels compared to PBS treatment at 72 h post-MCAO, although this increase was 
not statistically significant. The drop in LIFR expression from sham to MCAO rats suggests that 
splenocytes expressing LIFR are migrating into the periphery. The increase in LIFR expression 
after LIF treatment could be explained by a decrease in the number of splenocytes leaving the 
spleen. This phenomenon is reflected in the higher spleen weights observed among LIF-treated 
rats. In addition, the higher level of LIFR in the spleen might also be due to upregulation of LIFR 
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on splenocytes.  Future studies will identify whether LIF significantly alters splenic gene 
expression after MCAO, and whether these changes promote neuroprotection or 
neurodegeneration.  It should be noted that western blotting could only be used to measure LIFR 
expression of splenocytes that were not released into the peripheral circulation. Flow cytometry 
will be necessary to confirm LIFR expression on immune cells in the peripheral blood and the 
brain. Although LIF treatment does not significantly change splenic LIFR expression, the 
increase in spleen weight after LIF treatment suggests that systemic LIF acts at the spleen during 
stroke.  
Previously, this laboratory demonstrated that spleen size decreases after MCAO as 
splenocytes migrate to the ischemic brain. Although the spleens of LIF-treated rats were still 
significantly smaller than those of sham rats, there was a significant increase in spleen size from 
PBS to LIF-treated rats at 72 h after MCAO. Therefore, while LIF treatment may decrease the 
migration of splenocytes, it does not completely counteract the decrease in spleen size. 
However, it is likely that LIF exerts more potent immunomodulatory signaling on splenocytes 
within the peripheral circulation and the brain.  
LIF controls Treg/Th17 Development  
Several groups demonstrate that LIF inhibits the development of CD4+IL-17+ Th17 cells 
while favoring the maturation of CD4+CD25+FoxP3+ Tregs. There are conflicting reports as to 
whether or not increased Treg populations are detrimental or beneficial after permanent stroke. 
While Tregs quell the post-stroke immune response by releasing anti-inflammatory cytokines 
such as LIF, IL-10, and TGF-β (Gao, Thompson et al. 2009, Iadecola and Anrather 2011, Tran 
2011), other studies suggest that higher Treg populations increase the risk of infection by 
contributing to post-stroke immunodepression (Offner, Vandenbark et al. 2009). In spite of the 
controversy Tregs, LIF also counteracts IL-6 signaling during T lymphocyte maturation. IL-6 
contributes to the development of CD4+IL-17+ helper T (Th17) lymphocytes via activation of 
JAK1/STAT3 signaling (Dienz and Rincon 2009, Gao, Thompson et al. 2009, Metcalfe 2011). 
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The increase in the number of Th17 cells, which are implicated in several autoimmune diseases, 
play a largely detrimental role during stroke (Hu, Zheng et al. 2014).   Luo et al. demonstrated 
that administration of IL-33 reduced brain damage after stroke by suppressing Th17-mediated 
inflammation (Luo, Zhou et al. 2015). Gelderblom et al. demonstrated that IL-17, which is 
produced by Th17 cells, stimulates the release of the chemokine CXCL1 during cerebral 
ischemia, which increases the extravasation of neutrophils into the parenchyma. Neutralizing IL-
17 using antibodies decreased the infarct volume and reduced deficiencies in sensimotor 
function (Gelderblom, Weymar et al. 2012). Therefore, the increase in Tregs that occurs after 
LIF treatment may be beneficial by preventing the development of Th17 lymphocytes and the 
subsequent release of IL-17.   
LIF induces Anti-Inflammatory Phenotype in Macrophages/Microglia 
Although LIF influences the development of naïve T lymphocytes, it also favors the 
differentiation of monocytes into anti-inflammatory macrophages/microglia. While pro-
inflammatory macrophages worsen tissue damage during stroke via the release of pro-
inflammatory mediators (TNF-α, IL-12, IL-6, IL-1β, NO, etc.) anti-inflammatory cells are primarily 
phagocytic and release anti-inflammatory mediators. In addition, these macrophages/microglia 
recruit other anti-inflammatory cells such as CD4+CCR4+ helper T (Th2) lymphocytes and Tregs 
to the site of injury. Duluc et al. demonstrated that LIF and IL-6, in conjunction with macrophage 
colony stimulating factor (M-CSF), cause monocytes to differentiate into tumor-associated 
macrophages, a specialized class of anti-inflammatory leukocytes that protect cancerous 
growths from natural killer cells (Duluc, Delneste et al. 2007). Although pro-inflammatory 
macrophages/microglia further damage neural cells after stroke by perpetuating inflammation 
and producing reactive oxygen species, macrophages/microglia with an anti-inflammatory 
phenotype contribute to the repair process during ischemia (Merrill, Ignarro et al. 1993, Patel, 
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Ritzel et al. 2013). Therefore, LIF may indirectly reduce the neuroinflammation-associated 
damage during stroke by increasing the population of anti-inflammatory macrophages/microglia.  
Neutrophil Infiltration is reduced by LIF 
Neutrophils are another population of splenic immune cells that are influenced by the 
anti-inflammatory properties of LIF. Although LIF does not reduce neutrophilic ROS production, 
it does inhibit their migration (Klempner and Rocklin 1983). Banner et al. demonstrated that 
neutrophil infiltration of the injured area is significantly reduced in LIF knockout mice after 
intraplanar injection of complete Freud’s adjuvant (CFA). In addition, local LIF administration 
reduced synthesis of IL-1β, which is involved with neutrophil recruitment. (Banner, Patterson et 
al. 1998, Oliveira, Canetti et al. 2008). This laboratory previously demonstrated that splenectomy 
two weeks prior to MCAO reduced myeloperoxidase immunoreactivity in the infarct, indicating a 
reduction in neutrophil-mediated brain damage (Ajmo, Vernon et al. 2008). However, LIF may 
have a dual role in the regulation of neutrophil function. According to a report by Waring et al., 
low expression of LIF is associated with chronic inflammatory conditions such as rheumatoid 
arthritis. However, acute inflammatory conditions such as sepsis were associated with high levels 
of LIF. These data suggest that LIF might contribute to the neutrophil-mediated inflammatory 
response, which is characteristic of acute inflammation. On the other hand, LIF is primarily anti-
inflammatory in regards to monocytes/macrophages and lymphocytes, which are present at sites 
of chronic inflammation (Waring, Wycherley et al. 1992). Flow cytometry may be used in future 
investigations to determine whether LIF treatment alters the populations of neutrophils, 
alternatively-activated monocytes/macrophages and Th17/Tregs. 
Conclusion 
Through these experiments, this laboratory has identified several new mechanisms of 
neuroprotection by LIF. By upregulating neuronal SOD3, LIF increases neuronal survival during 
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in vitro ischemia and increases total SOD activity in vivo. MZF-1 and Sp1, which bind to the 
promoter of the SOD3 gene, are essential for LIF-mediated neuroprotection in vitro. Furthermore, 
LIF increases MZF-1 transcriptional activity by increasing its gene expression during ischemia. 
LIFR was upregulated in the brain tissue of LIF-treated rats, and splenic LIFR increased in a 
time-dependent manner following MCAO. While it is clear that the protective effects of LIF 
extends to neurons in addition to OLs, further studies will be necessary before testing LIF as a 
stroke treatment in humans. Even though full SOD3 expression is required for the full 
neuroprotective effects of LIF, it is possible that it upregulates other Akt-inducible antioxidant 
genes in neurons, such as Prdx5. In addition, the presence of MZF-1 and Sp1 in the promoters 
of all LIF-inducible antioxidants suggests that other genes may be involved.  
Although LIFR did not counteract the splenic response during stroke, the time-dependent 
increase in splenic LIFR expression suggests that LIF is altering gene expression in splenocytes. 
Flow cytometry may be used to determine whether LIFR expression increased on splenocytes 
in the brain or peripheral circulation. In addition, flow cytometry may be used to measure the 
changes in immune cell populations after LIF treatment. A previous study by Butzkueven et al. 
showed that LIF administration during EAE increased oligodendrocyte survival but did not 
increase or decrease CD3+CD4+ T lymphocyte populations(Butzkueven, Zhang et al. 2002). 
This study does not taken into account the differences in markers between T lymphocyte 
subtypes. For instance, antibodies against CD4 as well as FoxP3 would be required to detect 
changes in Treg populations after LIF treatment. Even if LIF does not alter the total number of 
CD4+ T lymphocytes, it could increase the ratio of Tregs/Th17 cells.  
Finally, all studies performed in this laboratory have utilized young, male Sprague-Dawley 
rats for in vivo experiments. Considering that young, male humans do not match the 
demographics of the typical ischemic stroke patient, LIF will need to be tested on aged rats of 
both sexes. Young, female rats have not been used in these studies due to the neuroprotective 
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effect of estrogen. Once female rats cease to have an estrous cycle, they are more vulnerable 
to stroke-related damage. Furthermore, pharmacokinetic changes that occur with age will need 
to be taken into account, and dosing will need to be adjusted as needed. Nevertheless, the 
synergistic effects of LIF on the expression of antioxidant genes in addition to its 
immunomodulatory properties make it a promising candidate for future investigation.  
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Figure 5.1: LIF Exerts Pleiotropic Effects on Cell Populations in the Brain. Research from 
this lab demonstrates that LIF signaling in neurons upregulates levels of SOD3, which dismutates 
superoxide to hydrogen peroxide. Mt3, which is upregulated in oligodendrocytes, also breaks 
down excess superoxide. Prdx4 levels increase in oligodendrocytes after LIF treatment, which 
increases its breakdown into water and molecular oxygen. By decreasing superoxide, SOD3 also 
prevents the reaction of NO with superoxide to form peroxynitrite, which reduces NO 
bioavailability and increases cell damage. NO aids in tissue repair by increasing vasodilation and 
cerebral blood flow within the infarct. In addition, NO release contributes to angiogenesis and 
the growth of new collateral vessels, which also increases tissue repair. LIF also increases the 
proliferation of NSCs in the subventricular zone. During injury, NSCs migrate to the infarct and 
increase neurogenesis/gliogenesis, which aids in the formation of new neural tissue during 
stroke.  
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Figure 5.2: The proposed mechanisms of LIF-mediated neuroprotection during ishcemia. 
By binding to its heterodimeric receptor, LIF increases Akt activation. Akt signaling increases 
transcriptional activity of MZF-1 via increased gene expression and Sp1, possibly through 
increased post-translational modification. MZF-1 and Sp1 bind to the SOD3 promoter, and 
induce its transcription. In addition, Sp1 possibly binds to the LIFR promoter and increases LIFR 
gene expression. Higher SOD3 expression maintains levels of phosphorylated Akt and increases 
total SOD activity. SOD activity increases the antioxidant capacity of the brain, and reduces 
caspase-3-dependent apoptosis. JAK1, which has been shown to associate with several 
cytokine receptors, opposes neuroprotective signaling via the STAT1/caspase-3 pathway. By 
reducing apoptosis in neurons, LIF promotes neuronal survival during ischemia.  
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Figure 5.3: Proposed Mechanisms of Indirect Neuroprotection by LIF during Stroke. 
Although LIF does not completely block the splenic response after stroke, it significantly 
increases spleen weight and splenic LIFR levels compared to PBS treatment after stroke. Since 
LIF is administered systemically, there is the possibility that IT may exert other effects on the 
spleen, but these effects have not yet been determined. After stroke, the spleen releases immune 
cells into the systemic circulation. These cells include monocytes/macrophages, lymphocytes, 
and neutrophils. LIF has been shown to alter the phenotypes of T lymphocytes and 
macrophages/microglia from pro-inflammatory to anti-inflammatory in vivo. LIF treatment also 
has been shown to reduce the infiltration of neutrophils to areas of injury by inhibiting their 
mobility.  
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